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Studies within Fragment-Based Drug Discovery: Library Synthesis and Hit-to-Lead Optimisation 
Attila Sveiczer 
This thesis reports two projects aimed at addressing challenges within fragment-based drug discovery. 
The first project describes efforts towards utilising synthetic methodology to address deficiencies 
within fragment screening collections. This involved the development of a modular, robust and scalable 
route to access α,α-disubstituted amino ester building blocks, which in turn were derivatised to allow 
the rapid assembly of five (a total of eight in collaboration) spirocyclic scaffolds. Importantly, this library 
was structurally diverse, comprising three (a total of six in collaboration) pharmacophore-like 
heterocycles and carbocycles. Moreover, numerous three-dimensional exit vectors were incorporated 
within each core spirocycle, and the ability of these handles to effect a diverse set of chemical 
modifications was exemplified through the generation of 16 (a total of 21 in collaboration) examples. 
Computational studies highlighted the excellent physicochemical and 3D properties of the library, as 
well as the broad coverage of underexplored chemical space that was achieved. This library was also 
screened for antibacterial activity in a phenotypic assay against the clinically relevant bacterial strains, 
Pseudomonas aeruginosa and Staphylococcus aureus. 
 
Generation of a diverse spirocyclic fragment library. 
The second project examined the inhibition of propionate detoxification mechanisms in bacteria as an 
attractive strategy for the development of antibacterial agents. A fragment screening campaign against 
2-methylcitrate synthase (PrpC) from Pseudomonas aeruginosa identified several hit compounds 
based on an indole unit. Synthetic efforts were undertaken to elaborate these fragment hits to increase 
potency. The adopted strategy focused on growing the indole fragment towards the nearby 
oxaloacetate binding pocket and occupying it with a fragment mimicking its natural substrate. This 
approach yielded a compound with an in vitro half maximal inhibitory concentration of 130 µM against 
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1.1 Small Molecules in Drug Discovery 
Global healthcare suffers from a lack of effective treatments and cures for countless 
communicable and non-communicable diseases. Despite the astounding achievements of the 
pharmaceutical industry in developing therapeutics against contagious diseases through 
antibiotic and vaccine development, many challenges remain to be overcome—such as malaria, 
cancer and the growing antibiotic resistance.1–3 
Therapeutics—chemical entities used to treat diseases—can be divided into two main categories: 
small molecules and biopharmaceuticals (also referred to as ‘biologics’).4 Within the fields of 
molecular biology and pharmacology, the term ‘small molecule’ typically refers to organic 
compounds possessing a molecular weight (MW) less than 1500 Da, the potential for oral 
bioavailability, and a structure distinct to those found in biological macromolecules.5,6 On the 
other hand, biologics are large MW substances comprising structures isolated from biological 
systems such as nucleic acids and proteins. In recent years, a number of biologics have proved 
immensely successful in the treatment of several disease classes, including inflammatory and 
cardiovascular disease as well as cancer, mainly due to their excellent specificity.7 Although 
biologics account for a continually increasing proportion of therapeutics approved by the United 
States of America Food and Drug Administration (FDA) year on year (from 10% in the 1990’s to 
23% in the 2010’s),8 it remains the case that the majority of approved therapeutics are small 
molecules.8 This continued success of small molecules can be attributed to several advantages 
over biologics such as: superior chemical stability, are easier to characterise, good homogeneity, 
better (oral) bioavailability, their non-immunogenic nature and often better pharmacokinetic 
profiles. They are also cheaper to develop and produce, and generics are typically approved 
faster providing more cost efficient alternatives after the expiration of the original patents.7,9  
2  
1.2 The Drug Discovery Process 
Small molecule drugs are brought to the market in a well-established pharmaceutical pipeline, 





Figure 1.1 The drug discovery process. The pre-clinical stage involves the development of drug 
candidates and their initial testing. During the clinical stage the drug candidates are tested in humans to 
assess their safety and efficacy in order to gain approval by regulatory agencies.
The innovative pre-clinical stage involves the identification of a target disease with no or 
suboptimal treatment(s) available. This is followed by the development of a potent lead 
compound, which is further optimised to achieve good pharmacokinetic and pharmacodynamic 
properties. Subsequently, optimised leads are assessed by pre-clinical in vitro and in vivo animal 
testing and drug candidates are selected.10,11  
The heavily regulated clinical stage consists of several phases. The drug candidate is first given to 
a few healthy humans (30 – 100) during phase 0 and I to evaluate its safety. Upon successful 
completion of this stage, the drug is introduced to people suffering from the target disease (100 
– 300) in phase II to obtain initial information about the efficacy and acute side effects. Finally, 
in phase III, a much larger cohort of patients (1000 – 3000) are supplied with the drug candidate 
to fully assess its efficacy and possible side effects. The relevant regulatory agencies are then 
presented with the collected data and make decision if the compound can be marketed as a drug 
for the treatment of the specified disease. Marketed drugs are continued to be monitored (phase 
IV), and if deemed necessary they can be withdrawn by the licensing authorities.12 
1.2.1 Duration and cost of drug discovery 
Estimates on the length and cost of this process are varied within the literature, but most studies 
examining drugs that received FDA approval after 1990 agree that on average it takes more than 
10 years and in excess of US$1 billion to develop a single marketed drug.13–16 Furthermore, an 
influential study by Scannell et al. in 2012 showed that the number of new drugs approved by 
FDA per US$1 billion spent on R&D has exponentially decreased (termed ‘Eroom’s law’) since 
1950, and halving approximately every 9 years.17 Moreover, a recent analysis by DiMasi et al. in 
2016 exposed that the costs associated with the pre-clinical stage (including the pre-clinical 
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testing) account for 38%, the clinical stage (Phases 0-III) for 51%, and the post-approval (Phase 
IV) for 11% of the total capitalised expenditure of $2.8 billion per approved new drug.13 This study 
also showed that lead generation and optimisation takes about two and a half years—the same 
as the pre-clinical tests—whereas the clinical stage takes 8 years on average, and the approval 
process an additional 16 months—amounting to more than 14 years for a drug to reach the 
market from inception. Thus, the development of new drugs is more costly both in terms of 
money and time than ever before.  
Analyses have shown that the clinical stage contributes tremendously to both the cost and length 
of the drug development process, partially due to high attrition rates (40% for phase 0-I, 64% for 
phase II, 38% for phase III and 10% for the FDA approval process, yielding an overall success rate 
of 12% for drug candidates reaching the market).13 This is highlighted by the fact that—although 
the direct cost of a single candidate to transition through the clinical phases is estimated to be 
around US$460 million—when the huge expense of failed compounds are considered, the total 
cost of the clinical stage rises to US$1.46 billion for each successful drug candidate.13 
Analysis of clinical success rates by Smietana et al. demonstrated an overall decrease from 16% 
in the late 1990’s to 7.5% around 2010, which can be attributed partially to the increasingly 
demanding requirements of regulatory agencies.18 The decline in clinical success rates 
consequently resulted in a steady decrease in the number of new therapeutics approved for drug 
use by FDA from the late 1990’s until 2007 (Figure 1.2).8 These findings suggest that the major 
scientific and technological advances of the past few decades (combinatorial chemistry, DNA 
sequencing, high-throughput screening, biotechnology, etc.) have failed to deliver the 
anticipated increase in the efficiency of commercial drug research and development (R&D). In 
response, the pharmaceutical and biotechnological industry has been investing an ever-
increasing amount of money into R&D (upwards of US$140 billion worldwide in 2015), producing 
many new drugs over the last decade (Figure 1.2). As a result however, many companies now 
question the sustainability of their R&D programmes.19 
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Figure 1.2 Total number of new therapeutics (small molecules and biologics) approved by FDA. A drastic 
decline can be observed from 1996 to 2007, which is followed by a similarly significant increase from 
2007 to present day. Data obtained from Asher et al.8 
1.2.2 Approaches to improve clinical success rates 
One strategy that has been investigated to improve the efficiency of R&D campaigns is by filtering 
out compounds that are likely to fail expensive clinical trials as early as possible in the 
development process. Several studies have looked at the connections between the success of 
drug candidates throughout the clinical phases and their molecular properties in order to identify 
‘drug-like’ properties. One of the most well-cited pieces of analysis by Lipinski et al. in 1997 
proposed a ‘Rule of Five’, linking a large number of hydrogen-bond donors and acceptors, MW, 
and high lipophilicity to poor absorbance and permeability, ultimately causing insufficient oral 
bioavailability and therefore  a lack of efficacy and candidate attrition (Table 1.1).20 Contrastingly, 
a later study by Veber et al. in 2002 showed that the MW cut off is not a reliable descriptor of 
bioavailability and instead a rotatable bond count of less than 10 and a total polar surface area 
of less than 140 Å2 gives a much better correlation to available research data (Table 1.1).21  
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Table 1.1 Guidelines on physicochemical properties for drug candidates commonly adopted within the 
field. 
Property Rule of Five 
MWa < 500 Da 
HBDa ≤ 5 
HBAa ≤ 10 
clogPa ≤ 5 
RBCb ≤ 10 
TPSAb ≤ 140 Å2 
MW = molecular weight, HBD = number of hydrogen-bond donors, 
HBA = number of hydrogen-bond acceptors, clogP = partition coefficient, 
RBC = rotatable bond count, TPSA = topological polar surface area. 
aOriginal properties by Lipinski et al.20 bProperties added by Veber et al.21 
Whilst the exact definition of ‘drug-like’ properties remains under debate, controlling the 
physicochemical properties of lead candidates continues to be a well-employed strategy within 
the pharmaceutical industry.22 The fact that the upper 90th percentile values of clogP (~5) and 
number of hydrogen-bond donors (4.0) in FDA-approved drugs have not changed significantly 
over the years suggests that these cut offs may indeed be validated criteria for successful drug 
candidates.22 Perhaps most importantly, high lipophilicity has been linked to an increasing 
likelihood of multiple target binding and thus pharmacological toxicity—another major 
contributor to clinical attrition.23,24 Accounting for the long time lag between compound 
synthesis and clinical trial evaluation, the increase in the clinical success rates of drug candidates 
from around 2010 can be rationalised by the beneficial application of such guidelines.18,22 
Another interesting study by Lovering et al. observed a significant increase in the average 
saturation—measured as the fraction of sp3-hybridised carbon atoms (Fsp3)—of drug candidates 
as they transition through the stages of clinical trials. This analysis suggested that saturation 
increases the chance of success; the authors explain this trend partially by the positive correlation 
between saturation and aqueous solubility resulting in increased bioavailability.25 Whilst 
saturation seems to provide some advantages, the extremely broad statistical distribution of Fsp3 
in approved drugs (10th percentile 0.08 and 90th percentile 0.83 for drugs approved between 
1900 and 1997) exposes that saturation is not a requirement for a successful drug candidate.22 
Aside from the control of physicochemical properties of drug candidates, in recent years, 
alternative strategies have been employed to improve clinical success. Advancements within 
information technology and the availability of large data sets have made the use of machine-
learning (ML) methodologies possible for analysing clinical failures and successes in great detail.26 
A recently developed supervised ML model using a random forest approach was able to predict 
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the success of drug candidates during phase II and III clinical trials with accuracies up to 85%.27 
Therefore, such algorithms are demonstrated to be extremely valuable for companies facing 
difficult decisions about whether a certain candidate should enter these high risk and cost trials.  
 7 
1.3 Established Lead Generation Methods 
As discussed earlier, the development of high-quality drug candidates is the principal objective 
of all drug discovery programs, and to that end, the generation of multiple lead series is 
paramount. The lead generation phase includes the whole process of identifying hits and 
developing them into compounds with sufficient in vitro activity alongside the elimination of 
liabilities related to undesirable physicochemical properties or chemical motifs that would likely 
lead to failure during later stage tests such as in vivo trials. Assessment of these lead series should 
provide researchers with enough information for decision making on the future of the project, 
and when high-content lead compounds are identified, they can be further optimised into more 
promising drug candidates.28 
The two, fundamentally different lead generation approaches—target-based and phenotypic 
drug discovery, detailed below—can often be seen as complementary techniques used 
concurrently or sequentially to form integrated methods combining the information and 
productivity from both strategies.29 Furthermore, although computational analyses and ML alone 
are incapable of generating leads, they can substantially increase the efficiency of all stages of 
any drug design program.11,26 
1.3.1 Phenotypic drug discovery 
Phenotypic drug discovery (PDD, also known as phenotypic-based, physiology-based or systems-
based drug discovery) is a paradigm originating from the earliest drug discovery endeavours prior 
to the era of genetics and molecular biology.28,30 A ‘pure’ PDD programme does not require any 
information on the identity or structure of the therapeutic target, or understanding of the biology 
of the disease and mechanism of action—rather it treats the biological system as a ‘black box’. 
Hits, leads and drug candidates are assessed based on their physiological effects in disease-
relevant models such as animal models, isolated organ systems and natural cells. The major 
difficulties with this approach include the development of accurate disease models, the ability to 
measure and analyse complex and often non-trivial outputs, as well as the construction of a high-
quality screening library (further discussed in section 1.4) consisting of diverse ‘lead-like’ 
compounds. Furthermore, structure-activity relationship (SAR) studies are generally much more 
difficult to conduct in the absence of structural information.28–31 
Aside from these challenges, PDD has several significant advantages and accordingly continues 
to gain popularity within pharmaceutical research. Firstly, it has the ability to provide 
instantaneous data on both toxicity and efficacy throughout the whole programme. Another 
benefit of PDD is that the use of living cells allows for genes, proteins, and pathways to interact 
providing a much greater number of possible targets and recognition sites, thus increasing the 
biological space for therapy. As a result, although often technologically difficult, phenotypic 
screening can identify both valuable novel biological targets and hit compounds simultaneously, 
and thus increase the efficiency of R&D campaigns. Therefore it is no surprise that the majority 
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of first-in-class small molecule drugs approved by FDA between 1999 and 2008 were developed 
in PDD programs.28–31 
1.3.2 Target-based drug discovery 
Target-based drug discovery (TDD) can be viewed as a reductionist approach, where it is assumed 
that the cause of a disease is a single gene product, and therefore, the most efficient and least 
ambiguous method for developing a therapeutic is by investigating the isolated gene product 
that is suspected of causing the physiological defect. Although often criticised for its limited set 
of poorly validated targets and high clinical attrition rates due to off-site toxicity of candidates, 
TDD is arguably the most effective approach for developing potent binders of single well-
characterised targets due to gaining full advantage from structural information in SAR studies 
and rational design during hit elaboration. However, the underlying concept renders TDD highly 
susceptible to the quality and physiological relevance of the target.28–30 One area within the 
pharmaceutical industry where targets are sufficiently characterised and validated such that TDD 
can thrive is the generation of follower drugs.28 A recent analysis found that 73% of FDA approved 
small molecule follower drugs originated from TDD methods.30 They are also well suited to 
develop first-in-class therapeutics for diseases caused by the inheritance of a single gene 
mutation such as cystic fibrosis and sickle cell anemia.28 
Unlike in PDD where the overall lead generation process consists of only the hit generation and 
hit-to-lead development stages, within TDD the same process requires four stages: 1) target 
identification and 2) validation, 3) hit generation and 4) hit-to-lead development.10 
1.3.3 Target identification and validation 
The overall success of TDD campaigns is primarily determined by the identity of the target and 
therefore the stages of target identification and validation are critical.28–30 To that end, biological 
systems have been extensively studied to identify target genes responsible for various 
physiological conditions. Forward genetics applies the screening of randomly mutated cells based 
on their phenotypes to identify unusual morphologies and ultimately the gene(s) responsible for 
the phenotype(s) of interest. On the other hand, reverse genetics involves the phenotypic 
characterisation of model organisms with loss of specific gene functions, usually using gene 
knockout animals or small interference ribonucleic acid (siRNA) techniques. If available, chemical 
probes can also be used to modulate the activity of genes either by effecting their expression or 
the coded function. Both approaches are commonly applied to aid the identification of desirable 
biological targets (Scheme 1.1). Typically, reverse genetic studies are employed to validate the 




Scheme 1.1 Forward genetics utilises phenotypic screening to identify the gene responsible, whereas 
reverse genetics uses specific removal of gene functions to identify genes responsible for certain 
phenotypes. 
1.3.4 Hit generation methods 
Following the identification and validation of a suitable biological target, the next crucial 
objective of any TDD programme is to find hit compounds possessing the desired activity against 
the target. In contrast, in PDD programmes hit identification is the first stage following the 
development of a suitable assay. The apparent hits identified during the initial screening must 
first undergo hit disqualification processes to remove compounds with promiscuous binding or 
interference with the assay itself, as well as orthogonal assays to produce validated hits providing 
chemical starting points for further development of drug candidates.11,31,33 
Generally speaking, methods can be divided into two major categories based on the size of the 
compounds within the screening libraries: lead-like molecules (discussed in this section) and 
fragments (discussed in section 1.5). 
1.3.4.1 Screening lead-like compounds 
Conceptually the most straightforward method to generate leads is to screen collections of 
compounds with similar physicochemical properties. Hits are required to be relatively potent, 
usually possessing low or even submicromolar activities, in order to facilitate both their 
identification and development into sufficiently active leads. Approaches for this include 
phenotypic and high-throughput screening.28,33 
1.3.4.2 Phenotypic screening 
Phenotypic screening is analogous to a forward genetic study as it is based on complex model 
organisms, with the exception that the physiology of the cells is altered using random small 
molecules rather than random mutations. Compounds causing a desired phenotype are 
considered to be hits. Although this technique is primarily used in PDD rather than TDD, targets 
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are often identified, validated and characterised following the initial screening, and as a result, 
the hit compounds can then enter target-based rational hit-to-lead designs. In this regard, 
phenotypic screenings can provide both novel targets and hit compounds for TDD programs. It is 
hypothesised that such an integrated drug discovery approach might combine the advantages of 
both PDD and TDD whilst concomitantly overcome some of their weaknesses, overall 
substantially increasing the efficiency of the programme.29 
1.3.4.3 High-throughput screening 
High-throughput screening (HTS) is not a well-defined method, rather it is used collectively within 
the context of drug discovery for technologies that enable rapid assaying.34 Robotics for 
accurately handling small volumes of liquids and imaging such as fluorescence resonance energy 
transfer (FRET) for the rapid and automated reading of the outputs are examples of essential 
techniques that were developed in the period leading up to 1990’s enabling the faster and more 
efficient screening of the rapidly expanding lead-like libraries owned by pharmaceutical 
companies.34,35 Further innovation and miniaturisation yielded ultra-high-throughput screening 
(uHTS) methods capable of screening 100,000 compounds per day using microplates, or 
performing and screening 100 million enzyme reactions in 10 hours using drop-based 
microfluidics.35,36 
Methods can be divided into phenotypic and target-based HTS as the assays used can involve 
either living cells or purified single proteins as targets respectively; therefore, HTS has utility in 
both PDD and TDD programmes. Furthermore, the screening libraries may consist of various 
chemical entities such as nucleic acids and analogues, peptides, natural products and synthetic 
small molecules.34,37 As a result, HTS is one of the most versatile methods available for hit 
generation. The overall success rates of HTS campaigns producing hits that could be developed 
into drug candidates is found to be about 50% for most target classes, and the applicability of 
this approach is demonstrated by the fact that one third of the drugs with known starting leads 
approved by FDA between 1991 and 2008 originated from HTS.37 However, target-based HTS has 
been subject to numerous criticisms, most of which are either related to intrinsic limitations of 
TDD programs or the quality of the commonly used combinatorial libraries.37 
1.3.4.4 Virtual screening 
The field of artificial intelligence has grown exponentially over the past few years due to the 
advances of powerful computer hardware such as graphical processing units making numerically 
intensive parallel processing faster. ML algorithms, such as those designed for deep learning, can 
be used to build valuable models based on available research data, that can be used to predict 
biologically active compounds. Ligand-based approaches use information on known active and 
inactive compounds to screen virtual libraries by similarity searches and pharmacophore 
modelling to identify likely hit molecules. Since this approach does not require any information 
on the target, it can be used in both virtual target-based and phenotypic screenings. Structure-
based methods on the other hand require structural information on the target elicited from 
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techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) and use 
sophisticated and computationally demanding docking algorithms to predict ligand binding 
affinities. As a result, when both ligands and target structure are available, hybrid approaches 
are often employed whereby a huge virtual library is first filtered using a fast ligand-based 
method and then the resultant manageable compound set is docked against the target to further 
narrow it down. Compounds identified in a virtual screen are treated as apparent hits and can be 
experimentally validated.26,31,38 
1.3.4.5 Miscellaneous methods 
The newly emerged DNA-encoded library (DEL) technology can be regarded as a powerful 
alternative to target-based HTS. From hundreds of millions to even trillions of compounds are 
synthesised in a combinatorial fashion and conjugated to unique DNA sequences used as bar 
codes; the library is then screened as a mixture for affinities for immobilised protein targets, and 
conjugates with the desired affinity are decoded to reveal the hit structures.39,40 Another 
alternative is to conjugate compounds to specific locations on the surface of a glass chip forming 
small molecule microarrays. These can then be incubated with protein solutions, either purified 
or complex mixtures (e.g. cell lysates), and the bound target can be detected with a fluorescent-
labelled antibody.41,42 Although both approaches can provide cost efficient HTS technologies, 
there are several major limitations: the conjugation chemistry can interfere with target binding; 
the screens only give information on affinities toward targets, but not on the function; hit 
validation requires the synthesis of new compounds (with no conjugation); and the target must 
be known.31 
On the other hand, chemical biology approaches can take full advantage of identifying both new 
ligands and targets at the same time in living cells, and as such, they are closely related to 
phenotypic screening. However, the use of fully functionalised fragments allows the detection of 
weakly binding fragments by covalently modifying the target using either an electrophilic or a 
photoreactive warhead, and easy identification of the target via introducing a fluorescent label 
using a bioorthogonal ‘click’ reaction on the alkyne moiety.31,43  
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1.4 Screening Libraries 
1.4.1 Library design 
Individual compounds must possess certain properties to be suitable for screening collections, 
but their exact nature is dependent on the applications and subject to debate in the literature.44 
The basic physicochemical properties should roughly adhere to the Ro5 to ensure sufficient water 
solubility, reduce the risk of protein aggregation and promiscuous binding due to excessively high 
lipophilicity, and limit the size of the hit compounds making them acceptable starting points for 
drug development.28 Reactive functional groups such as alkyl halides, peroxides, thiols, epoxides, 
aziridines, aldehydes, reactive Michael acceptors, etc. should be avoided to minimise chemical 
reactions and covalent modifications of the targets often resulting in aspecific binding.45 
Furthermore, several structural motifs have been identified to cause promiscuous binding or 
false positives known as pan assay interference compounds (PAINS), including alkylidene 
barbiturates and heterocycles, hydroxyphenylhydrazones, phenolic Mannich bases, catechols, 
quinones, dialkylanilines and diazo compounds.45,46 Synthetic tractability, or the ability to 
synthesise analogues efficiently, is also an important aspect when considering the hit-to-lead 
optimisation of any potential hit compound.28,47 
The characteristics of the library as a whole is also extremely important and should match the 
requirements of the drug discovery programme in which they are employed. In general we can 
conclude that although screening a larger library creates more data, in terms of identifying 
tractable hits, quality is more important than quantity.28 
1.4.2 Chemical space 
The concept of the whole chemical space describes all the possible chemical entities from single 
atoms through organic and inorganic molecules to polymers and nanostructures. This can be 
further limited to the chemical space of small organic molecules by using the ‘definition’ from 
section 1.1; however, specifying the more relevant ‘drug-like’, ‘lead-like’ or ‘biologically relevant’ 
chemical spaces is a lot more challenging.48 An early estimate by Bohacek et al. hypothesised that 
the ‘universe of organic molecules’ might consist of more than 1060 compounds with no more 
than 30 C, N, O and S atoms.38 The ‘biologically relevant’ chemical space can also be 
approximated by considering chemically stable small molecules made of C, H, N, O, S and halogen 
atoms disregarding any constraints about physicochemical properties. Ruddigkeit et al. 
enumerated a virtual library of 166 billion such molecules comprising up to 17 non-hydrogen 
atoms.49 This computational study also showed that the number of possible molecules is 
exponentially growing with the heavy atom count (HAC), and each added atom increases the 
number almost seven-fold. Therefore, the total number of ‘drug-sized’ molecules (HAC up to 35) 
can be estimated to be in the order of 1027; although significantly smaller than the previous 
estimate, chemical space can still be considered as almost infinite in terms of any practical 
considerations, and no screening library can contain all possible molecules. However, compounds 
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closely related to one another can be assumed to have similar biological activity, and so, areas 
within chemical space containing molecules with a certain activity against a target could be 
expected.38 Having even just a single compound in a screening library that falls into such a desired 
subspace can be enough to identify a hit, and then a focused library of analogues could be 
synthesised and screened to identify more potent compounds and eventually a lead. Therefore, 
the sampling of chemical space, whether the whole space or just an area of interest, is an 
absolutely crucial property of any screening library (Figure 1.3).48 
 
Figure 1.3 Graphical representation of chemical space. Contours show areas of compounds with activities 
against specific (hypothetical) targets. A diverse library gives a broad coverage of chemical space, and 
more likely to feature compounds with activities against different targets. Focused libraries give dense 
coverage of small areas of chemical space. 
1.4.3 Complexity 
The concept of complexity is often regarded as a crucial element for library design; however, it is 
extremely difficult to define or quantify. According to the intuitive notion of molecular 
complexity and assuming complementary protein-ligand binding, a less complex molecule should 
be more likely to ‘match’ any target (potentially in more than one way). Thus, ignoring limitations 
on binding affinities, a lower complexity should result in both higher hit rates and promiscuity. 
A very simple model by Hann et al. treating both ligands and receptors as one-dimensional strings 
of binary data has demonstrated that the probability of binding—defined as a perfect 
complementary match between the ligand and the receptor—decreases dramatically with the 
increasing complexity (in this case, simply the length) of the ligand.50 On the other hand, the 
probability of measuring a binding is highly dependent on its strength, which in this model is 
proportional to the number of matching features and so the size or complexity of the ligand. As 
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a result, the probability of a ‘useful event’—defined as a measured binding—plotted against the 
ligand complexity (or length) goes through a maximum value (Figure 1.4). 
  
Figure 1.4 The probability of useful event (measured binding) has a maximum value depending on the 
sensitivity when using a simple complexity model. Values of ‘probability of matching’ were reproduced 
from Hann et al.50 Probability of measuring binding is calculated by 𝑃 = !"#$%&(()*)
,
, where M is the 
complexity of the ligand and S is the sensitivity of the assay. Probability of useful event is the product of 
the probabilities of matching and measuring binding. The binding site complexity is 12; the sensitivities 
are 3 (left) and 6 (right). 
This further suggests that, depending on the sensitivity of the assay, there should be an optimal 
ligand complexity that maximises the probability of a useful event, which can be correlated to a 
hit in a real compound screening. This idea prompts the general paradigm of drug discovery 
whereby ‘less complex’ molecules should be screened first to produce more hits, that could then 
be developed into ‘more complex’ leads with decreased promiscuity providing high selectivity 
and low off-target toxicity. 
From a mechanistic point of view, the complexity of a compound could be related to the number 
and types of constituent atoms or even the connectivities between them. Therefore, HAC is often 
used to estimate the complexity of molecules – the larger the molecule, the more complex it is. 
This concept is easily related to the arbitrary complexity used by Hann’s model.50 Indeed, whilst 
hit rates of 0.001–0.151% for the identification of lead-like ligands in HTS programs with 
micromolar potency thresholds were observed, hit rates of 3% or more were achieved by 
screening small fragment-sized compounds using more sensitive methods to detect millimolar 
binders.51 A number of studies tested the validity of Hann’s original complexity model by 
collecting promiscuity data from numerous screenings, and, although the result vary 
considerably, there is more evidence suggesting that contrary to the model’s prediction, 
promiscuity increases with MW.52,53 This observation was rationalised by the fact that, unlike as 
was assumed in the original model, a perfect match is not required for observing binding; if 
instead a modified model is used where only a certain minimum number of complementary 
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features is required for a match, then the probability of a match, and therefore of a useful event 
or hit, is actually increasing with the size or complexity of the ligand.53 The true nature of ligand 
bindings is probably somewhere in between these two extremes of the model, and an attempt 
has been made to create a more realistic model with better correlation to experimental data.54 
Apart from its size, other properties of a molecule are also thought to contribute towards its 
complexity. The concepts of shape and stereochemical complexity, defined by Fsp3 and the 
number of chiral centres respectively, are often used to describe the size-independent 
complexity of compounds by arguing that a complicated three-dimensional (3D) object is less 
likely to match different binding pockets resulting in lower promiscuity,55 which might offer an 
alternative explanation for the observed increase of these properties throughout clinical 
trials.25,56 
Even more importantly, it has been observed that interactions between targets and ligands with 
higher information content, such as directionality or charge gradient, are more difficult to 
position correctly compared to low information content interactions such as most hydrophobic 
interactions.57 As a result, compounds displaying several polar groups, especially hydrogen-bond 
donors, acceptors and charged groups, tend to be more selective and therefore can be regarded 
as more complex. This is also in agreement with other studies relating high lipophilicity to 
promiscuity and toxicity.23,24 
1.4.4 Diversity and three-dimensionality 
Structural diversity is used to describe the variation in the 3D shapes of molecules within a library 
and is typically divided into four main components: 1) appendage diversity, 2) functional group 
diversity, 3) stereochemical diversity, and 4) scaffold diversity. The key contributor towards 
structural diversity however, is the scaffold diversity since the scaffold of a molecule determines 
its overall 3D shape.47 
A comprehensive scaffold analysis on more than 2.4 million compounds from 17 different 
commercially available screening collections highlighted that framework-distributions are 
generally extremely uneven. Large combinatorial libraries, generated in industrial settings, 
greatly overrepresent very few and simple scaffolds, many of which overlap between separate 
suppliers. On the contrary, much smaller but more diverse libraries do exist based on more 
complex scaffolds, and often originate from academic laboratories or natural sources.47 A similar 
study of over 24 million different organic compounds in the CAS registry found that only 0.25% 
of all known scaffolds are found in almost half of all molecules in the registry, displaying the very 
low scaffold diversity.58 
Furthermore, it is often found that current screening libraries overrepresent ‘flat’ sp2-rich 
(hetero)aromatic molecules limiting the covered areas of chemical space.25,59 A comparative 
shape analysis demonstrated that whilst most compounds within a commercial collection are 
indeed quite ‘flat’, the majority of possible lead-like molecules show high levels of three-
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dimensionality.49 Therefore, in order to obtain better coverage of the potentially biologically 
relevant chemical space, it is important to develop collections of compounds featuring chiral 
centres and high Fsp3, both of which can increase the 3D nature of small molecules.25,59,60 
1.4.5 Types of libraries 
Libraries can be characterised according to their chemical space coverage. Whilst focused 
libraries give dense coverage of a small area, diverse libraries aim to sample as large an area, and 
ideally as evenly, as possible (Figure 1.3). Furthermore, they can be divided into two categories 
based on the type of small molecules employed: either natural or synthetic. 
1.4.5.1 Focused libraries 
When a chemical starting point for a project is known or assumed (e.g. native substrates for 
enzymes or ligands for receptors, previous hit or lead compounds for the target, binders for 
structurally related targets, hits obtained from virtual screenings or developing follower drugs), 
focused libraries of compounds similar to the starting point are often used. These approaches 
are anticipated to give higher hit rates, and are especially suitable for establishing SAR studies 
during hit-to-lead development.47,60,61 
1.4.5.2 Diverse libraries 
If no reliable structural information is available on the target, binding pocket(s) or ligand(s), or if 
the identification of a novel target, binding mode or compound class is desired, then screening a 
structurally and thus functionally diverse collection increases the chance of finding desired 
hits.6,47,60,62–66 
1.4.5.3 Natural products 
One extremely important source of small molecules is nature itself. Secondary metabolites or 
natural products are produced by all living organisms and generally feature high levels of 
complexity and diversity.67 As a result, natural products show activity against a wide range of 
biological targets and have been used in medicine for many centuries. Modern drug discovery 
still benefits from natural products and around half of all FDA approved drugs are derived from 
natural products.68 However, there are major challenges associated with using natural products 
to generate screening libraries including sourcing, isolation, purification and identification of the 
active compounds as well as often poor synthetic tractability due to the lack of efficient synthetic 
methodologies enabling the construction of such complex molecules.69 
1.4.5.4 Synthetic compounds 
Deliberate chemical synthesis is arguably considered the most efficient approach for the 
generation of small molecule collections.63 In fact, synthetic libraries have been widely used in 
pharmaceutical research for over a century and provided a very important basis for identifying 
hit compounds in biological screenings. It is well established that the quality of the screening 
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collections is crucial for discovering novel biologically active molecules, and yet, the synthesis of 
structurally diverse and biologically relevant small molecule libraries remains a huge challenge 
for synthetic chemists.70 
1.4.6 Synthetic approaches 
1.4.6.1 Biology-oriented synthesis 
Due to the vastness of chemical space, designing individual compounds for screening collections 
that maximises the success rates of identifying tractable hits in any assay is very difficult. Based 
on the success of natural products in drug discovery and the theory that proteins and their 
cognate ligands and substrates have co-evolved, it is assumed that related compounds are more 
likely to fall into areas of chemical space with biological activity. Therefore, biology-oriented 
synthesis (BIOS) aims to generate compounds based on scaffolds found within natural products 
and thus create arguably diverse libraries of molecules with anticipated higher biological 
relevance or hit rates in screens.71,72 
1.4.6.2 Target-oriented synthesis 
Target oriented synthesis (TOS) utilises retrosynthetic analysis to devise synthetic routes to 
access compounds from simple starting materials and reagents. Therefore, it is often the best or 
only available approach for the synthesis of specific complex molecules like late-stage lead-like 
compounds and drug candidates, and it is also well suited for the generation of focused libraries 
of such molecules. However, since most synthetic routes are quite long, and diversity is usually 
only created in the appendages during final steps, this method is often considered to be 
inefficient for generating diverse libraries for initial screening since the resulting compounds 
occupy a small and confined region of chemical space.59,73,74 
1.4.6.3 Combinatorial synthesis 
The application of combinatorial synthesis using highly automated split-and-pool techniques in 
the 1990s enabled the formation of millions of small molecules for biological screenings to 
populate commercially available libraries and pharmaceutical compound collections.75 However, 
as an inherent feature of the synthetic approaches employed, the resulting libraries possessed 
enormous numbers of molecules that were based on limited number of distinct molecular 
scaffolds, resulting in libraries where most compounds cluster in a few small areas of chemical 
space.66 Moreover, as a direct result of most compatible methodologies utilised for combinatorial 
synthesis as well as the available starting materials, the resultant libraries tend to be dominated 
by ‘flat’ (hetero)aromatic scaffolds. These libraries were revealed to be much less successful in 
most biological screenings than initially anticipated, something which is often attributed to the 
lack of structural diversity.76 However, it was later realised that these techniques can indeed be 
very effective for the synthesis of focused libraries.47,60,61 
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1.4.6.4 Diversity-oriented synthesis 
An important approach emerged in the late 1990s which utilised a forward synthetic analysis to 
construct divergent synthetic pathways that generate several small molecules bearing different 
scaffolds from common starting materials. In 2000, Stuart L. Schreiber described this new design 
as diversity-oriented synthesis (DOS), with the aim of producing structurally diverse compound 
collections, to be used especially for identifying biological targets and their modulators 
simultaneously in phenotypic screenings.73 This strategy benefits from synthetic efficiency since 
complex and structurally diverse small molecules are generated in typically 3 to 5 synthetic steps 
and introducing high levels of scaffold diversity yielding powerful screening collections.66,74 
Within DOS, two main methods are commonly adopted to achieve scaffold diversity.74 The 
branching or reagent-based approach uses different reagents to form diverse scaffolds from a 
single multifunctional or pluripotent intermediate in a divergent manner (Scheme 1.2, A).77 
Alternatively, the folding or substrate-based approach utilizes subtle differences in the structures 
of diverse intermediates to form different scaffolds under the same reaction conditions (Scheme 
1.2, B).6 Often, however, DOS strategies use elements of both approaches.66 
 
Scheme 1.2 Reagent-based DOS approaches generate complex and diverse scaffold collections from 
single common intermediates using different reagents (A) and substrate-based approaches achieve 
similarly diverse and complex small molecule libraries from diverse sets of highly functionalised 
intermediates under common reaction conditions (B).  
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1.5 Fragment-Based Drug Discovery 
Fragment-based drug discovery (FBDD) is a well-established target-based lead generation 
strategy used within both industry and academia. Instead of screening lead-like compounds, 
FBDD focuses on identifying low MW hits, that can then be grown into potent drug candidates or 
chemical probes.32,78 
The first report of obtaining SAR and developing a potent nanomolar binder based on fragments 
utilising NMR studies was published by Shuker et al. in 1996.79 Although the approach faced a 
significant amount of internal resistance within most companies, following several other 
successes and major technological advancements in the field, FBDD is now recognised as a 
validated and popular alternative to other lead generation methods within industry with overall 
success rates competitive with those of HTS.80–83 
The success of FBDD is showcased by the development of numerous clinical candidates and four 
FDA-approved drugs: Vemurafenib, Venetoclax, Erdafitinib and Pexidartinib for the treatment of 
late-stage melanoma, chronic lymphocytic leukemia, urothelial carcinoma and tenosynovial giant 
cell tumor respectively (Figure 1.5).81,84–87 Screening fragment libraries has two main advantages 
over other approaches: better chemical space coverage of libraries and more optimal 
interactions with the protein targets (discussed in more detail below). 
 
Figure 1.5 Examples of the first two FBDD-derived FDA-approved drugs: Venetoclax and Vemurafenib. 
1.5.1 Chemical space coverage 
As described in section 1.4.3, the number of possible chemically stable organic molecules grows 
exponentially with size, and the fragment-like chemical space (HAC up to 16) has been evaluated 
to contain about 57 billion compounds.49 Therefore, a relatively small library of a few thousand 
fragments can give exceedingly better coverage of the relevant chemical space (103 vs 1010) than 
HTS libraries (106 vs 1027) or even the largest DELs (1012 vs 1027). As a result, fragment screens 
often yield several hits against targets, even when no hits could be identified using more 
traditional techniques such as HTS. This is especially beneficial when targeting traditionally 
‘undruggable’ targets, such as protein-protein interactions (PPIs) with large and shallow binding 
pockets, where HTS is often unable to produce tractable hits.88,89 Indeed, Venetoclax (Figure 1.5) 
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was developed from fragment hits against the oncogenic B-cell-lymphoma-2 protein inhibiting a 
key PPI that results in the activation of an intrinsic apoptosis pathway.90 
1.5.2 Interactions and hit-to-lead development 
Due to their small size, fragments inherently form very few interactions with the protein targets 
resulting in weak binding with affinities usually in the range of high micromolar to low millimolar. 
As a result, more sensitive techniques such as NMR spectroscopy, X-ray crystallography and 
surface plasmon resonance (SPR) or the recently emerging microscale thermophoresis, thermal 
shift assay and weak affinity chromatography need to be employed when screening fragment 
libraries.81 Whilst the commonly used NMR and X-ray methods provide crucial structural 
information on the binding mode of the initial hits enabling rational design, other methods such 
as SPR or in vitro inhibition assays are also crucial to measure binding affinities or activities in 
order to establish SAR for further development.78 
The Gibbs free energy of binding (ΔG) determines the affinity of a ligand toward its target 
expressed as the dissociation constant (Kd) according to Equation 1.1: 
∆𝐺 = 𝑅𝑇 ln(𝐾!) (1.1) 
where R is the universal gas constant and T is the absolute temperature. Assuming that binding 
results in inhibition, Kd can be equated to the half maximal inhibitory concentration (IC50) 
obtained in vitro. Assuming standard conditions, Equation 1.1 can be reformulated as Equation 
1.2 to give ΔG in kcal mol-1 calculated from IC50 values given in units of M: 
∆𝐺 = 1.37	kcal	mol"# log 6
IC$%
M : = −1.37	kcal	mol
"#	pIC$% (1.2) 
Therefore, it follows that a weakly binding fragment hit with an IC50 of 1 mM would have a free 
energy of -4.1 kcal mol-1, whereas a strongly binding drug candidate with an IC50 of 1 nM would 
have a free energy of -12.3 kcal mol-1 which is three-times greater. 
Using the definition of Gibbs free energy, ΔG can be further divided into entropic (ΔS) and 
enthalpic (ΔH) contributions according to Equation 1.3: 
∆𝐺 = ∆𝐻 − 𝑇∆𝑆 (1.3) 
The rigid-body entropy loss of binding (TΔS) under standard conditions has been estimated to be 
in the range of 3.6 – 4.8 kcal mol-1 for a small molecule.91 Thus, in order for a fragment to off-set 
the entropy loss and give a detectable binding affinity, the sum of interactions must give an 
enthalpy of at least -8 kcal mol-1, while the aforementioned drug candidate needs about -16 kcal 
mol-1. This shows that if a fragment hit can be elaborated to twice its size whilst maintaining the 
average binding enthalpy per size, a highly potent lead compound could be developed. 
Therefore, to help researchers focus on progressing the most appropriate compounds, ligand 
efficiency (LE) has been introduced giving a measure of the average binding free energy 
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contribution of each heavy atom (Equation 1.4); although LE has units of kcal mol-1, it is most 
often reported as a unitless number.92 If the fragment mentioned above had a HAC of e.g. 10, 
this would give a LE of 0.41, keeping LE constant a HAC of 30 would be required to reach the 1 
nM potency, which is a reasonable size for a drug candidate. Since increasing lipophilicity often 
results in promiscuous binding as well as increased potency against the target, the lipophilic LE 
(LLE) can be used instead of IC50 to compare the utilities of compounds with different 








LLE = pIC$% − log P (1.5) 




Lead-like hits, such as those identified by HTS, possess relatively high potency arising from 
multiple suboptimal interactions resulting in much lower LEs making further optimisation rather 
difficult. A high-quality fragment hit, however, forms few optimal interactions with the target in 
order to bind with a sufficient affinity, and these key interactions are often conserved throughout 
the hit-to-lead optimisation. These fragment elaboration strategies usually involve fragment 
growing, merging and linking (Figure 1.6). Fragment growing involves the synthetic expansion of 
the molecule in different direction where further interactions with the target are expected to 
form. These analogues are tested for activity or affinity, and the ones with the highest LEs are 
selected for further optimisation, ensuring that the newly added atoms also form near-optimal 
interactions. If two fragments bind within the same pocket, and there is a significant spatial 
overlap between them, it can be possible to synthesise a hybrid structure displaying features 
from both original molecules and keeping all the favourable interactions. If the two fragments do 
not overlap, there is still a good chance that they can be linked via an additional chemical linker 
region, even if the two fragments bind in different pockets within proximity.91  
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Figure 1.6 Graphical representation of different hit development strategies. HTS hits possess many 
suboptimal interactions and can be difficult to optimise. Fragment hits tend to form few optimal 
interactions and can be elaborated into more potent compounds conserving these interactions by 
growing into nearby areas of the pocket, or if multiple fragments bind to different regions, they can be 
merged or linked. 
In theory, fragment linking can yield compounds with affinities much higher than the sum of the 
original hits. When two fragments (A and B) are linked together (forming compound AB), the 






where KA, KB and KAB are the dissociation constants for molecules A, B and AB respectively.93 
Using the expressions from Equations 1.1 and 1.3, Equation 1.7 can be reformulated as Equation 
1.8: 






where ΔΔG, ΔΔH and ΔΔS are the changes in the binding free energy, enthalpy and entropy 
respectively as fragments A and B are linked to compound AB. An ideal linker allows for both 
fragments A and B to bind in their optimal mode without introducing any strain. Therefore, all 
the binding enthalpies add up resulting in ΔΔH ≈ 0, whereas the rigid body entropy of a small 
molecule is assumed to be independent of size, so TΔSAB ≈ TΔSA ≈ TΔSB ≈ 4.1 kcal mol-1 and TΔΔS 
≈ 4.1 kcal mol-1. Substituting these values into Equation 1.8 gives a theoretical value of E = 10-3. 
In practice, ideal linking of fragments is not often achieved successfully; the difficulty is that a 
suboptimal linker can introduce unfavourable interactions with the target and strain either 
within the linker itself or by forcing fragments in suboptimal binding modes, as well as flexible 
linkers increasing the entropy loss on binding. As a result, linking coefficients in the range of 10-2 
– 102 are often considered to be suitable, although values as low as 4.6 × 10-5 have been 
reported.93 A typical example from the literature is the development of a potent inhibitor of β-
secretase 1 (BACE1) by Jordan et al. via linking two fragments.94 A number of linkers have been 
trialled and although the best linker still has a linking coefficient of 2.5, the resultant compound 
has an IC50 of 0.8 µM and >2000-fold selectivity over the related aspartic protease cathepsin D 








Kd,BACE1 = 140 nM 
IC50,CatD = 510 nM 
 
IC50,BACE1 = 0.8 nM 
IC50,CatD = 1.9 µM 
Figure 1.7 Example of fragment linking resulting in a potent and selective β-secretase 1 (BACE1) 
inhibitor. 
1.5.3 Fragment library design 
Given that fragment libraries form a special category within general screening libraries, all design 
criteria described in section 1.4 are relevant, however, there are several further considerations 
for designing suitable fragment collections. 
linking
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1.5.3.1 Size and physicochemical properties 
In order to take full advantage of the underlying principles of FBDD, the compounds in a screening 
collection must be of small size. Furthermore, due to the weak affinities, these libraries need to 
be screened at high concentrations to measure binding, therefore, fragments must be suitably 
water-soluble. 
The first generally accepted guideline on the physicochemical properties came from an early 
analysis of fragment hits observed by researchers at Astex Pharmaceuticals and found that most 
hits obeyed a so called ‘Rule of Three’ (Ro3) (Table 1.2).95 Later, a study on a much larger set of 
hits observed by X-ray crystallography showed that the highest hit rates were observed for 
fragments with HACs of 10 to 14 and clogP values between 0 and 2,96 therefore, a new guideline 
with slightly narrower ideal ranges has been adapted by Astex with added emphasis on aqueous 
solubility (Table 1.2).97 
Table 1.2 Guidelines on physicochemical properties for fragment libraries set by Astex. 
Property Rule of Three95 Astex Guidelines97 
MW < 300 Da 140 – 230 Da 
HAC – 10 – 16 
HBD ≤ 3 – 
HBA ≤ 3 – 
clogP ≤ 3 0 – 2 
RBC ≤ 3 ≤ 3 
TPSA ≤ 60 Å2 – 
chiral centres – ≤ 2 
aqueous solubility – ≥ 5 mM 
MW = molecular weight, HAC = heavy atom count, HBD = number of hydrogen-bond donors, HBA = 
number of hydrogen-bond acceptors, clogP = partition coefficient, RBC = rotatable bond count, TPSA = 
topological polar surface area. 
1.5.3.2 Synthetic tractability and exit vectors 
Once fragment hits are identified, the ability to obtain meaningful SAR information quickly and 
efficiently is paramount for a successful hit-to-lead optimisation. To that end, it is desirable that 
analogues of all fragments within the library are either commercially available or synthesisable 
in as few steps as possible. This can be facilitated if the scaffolds can be formed using robust 
chemistry that allows for the incorporation of different building blocks and reagents. An 
alternative approach is the utilisation of synthetic exit vectors for the generation of numerous 
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derivatives in short numbers of steps from the initial branching point hit compound, which can 
be synthesised on a larger scale. Such exit vectors can be especially useful for exploring the 
binding pocket further by growing the fragment in different directions.80–83,98 
1.5.3.3 Shape and three-dimensionality 
There is a considerable amount of debate in the literature about the ideal shapes of fragments.81 
The previously mentioned analysis of fragment hits obtained by Astex over a decade showed that 
two-dimensional (2D)  fragments—defined by a mean deviation from planarity (DFP) of less than 
0.05 Å—have an approximately 1.5 times higher hit rate when compared to more 3D ones.96 This 
observation can be interpreted by the differences in molecular complexity, since a more 3D 
shape is expected to have more directional features resulting in higher complexity and a lower 
probability of matching the binding pocket. The higher hit rates and promiscuity associated with 
flat (hetero)aromatic compounds can also be explained by their intrinsic polarisability, which 
results in better adaptation to different environments.57 
While a similar study by AstraZeneca also observed the same trend in the hit rates of 2D versus 
3D fragments, more importantly, a detailed analysis showed that 3D fragments filled a 
significantly larger volume of the binding pockets examined, highlighting the importance of 3D 
fragments.82 3D fragments are also more capable of projecting exit vectors in all directions of 3D 
space allowing for much better exploration of binding pockets. Furthermore, large areas of 
chemical space can only be covered by molecules with 3D shapes. As a result, the consensus of 
the field appears to be that a good balance between 2D and 3D fragments should be maintained 
in screening libraries.98 
Since there are many fewer possible 2D compounds than 3D ones within the same size limit, and 
given that synthetic methodologies for generating flat molecules are much better developed by 
medicinal chemists, a good coverage of 2D fragment space has been achieved early on—whereas 
the coverage of 3D fragment space is sparse in comparison.99 To address this issue, the ‘3D 
Fragment Consortium’ has been established by various academic groups and research 
organisations to create fragment screening libraries with enhanced 3D characteristics and 
encourage the development of new synthetic strategies for accessing 3D fragments with novel 
or underrepresented scaffolds.100 Although synthetic efforts focused on generating such 3D 
fragment collections,101–106 they remain underexplored. 
A library of 38 highly saturated 3D fragments was recently published by Hanby et al. utilising 
diastereomeric α,α-dialkyl β-hydroxy cyclopentatone as a versatile building block (Scheme 
1.3).107 A DOS approach was efficiently used by the authors to afford 20 unique and structurally 
diverse molecular frameworks, each displaying several exit vectors for fragment growth. 
Importantly, the library showed optimal calculated physicochemical properties, a broad coverage 
of 3D chemical space and excellent natural product-likeness score108. However, the utility of 




Scheme 1.3 Synthesis of a natural product inspired fragment library by Hanby et al.107 
1.6 Overview 
FBDD has been proven a powerful tool for developing new drug candidates in TDD campaigns, 
especially against ‘undruggable’ targets where traditional techniques such as HTS fails to provide 
tractable hit compounds. However, most commercially available libraries mainly consist of ‘flat’ 
(hetero)aromatic fragments, therefore, methodologies allowing for the generation of more 
saturated and 3D fragments could improve the chemical space coverage of screening collections 
and thus the overall success rate of FBDD campaigns. Hence, the first project described in this 
thesis (section 2) focuses on the synthesis of highly 3D fragments with spirocyclic scaffolds for 
potential use in FBDD. 
Antibiotic resistance is one of the greatest challenges of modern healthcare. The most 
straightforward strategy to address this crisis is by developing new antibiotics, ideally, against 
novel targets to assure bacterial susceptibility. As such, the bacterial propionate mechanism has 
been studied and its inhibition trialled to attenuate the growth of bacteria in propionate-
containing media. The second project within this thesis (section 3) describes synthetic efforts to 
elaborate simple fragment hits into a more potent chemical probe against a key enzyme involved 
in the propionate metabolism of Pseudomonas aeruginosa. 
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2 Spirocyclic Fragment Library 
2.1 Introduction 
2.1.1 sp3-hybridised quaternary centres 
Within the literature, many different strategies have been developed to introduce 3D character 
within a molecule. Amongst these, the introduction of sp3-hybridised quaternary carbon centres 
into scaffolds has grown in interest. The three-dimensionality of these carbon centres arises from 
the presence of four groups pointing in different directions spanning the 3D space (Figure 2.1).109 
 
Figure 2.1 Introduction of sp3-hybridised carbon centres increases the complexity and 3D shape of the 
molecule, therefore increasing structural diversity of the library. The effect is even more dominant for 
quaternary sp3 centres compared to tertiary ones due to the projection of structural moieties in four 
different directions. 
Indeed, there is strong presence of this structural feature within small molecule FDA-approved 
drugs. Using DrugBank Version 5.0,110 it was shown that a significant proportion of these entities 
contained at least one quaternary sp3-hybridised carbon centre. The most common motif was 
found to be the all-carbon quaternary centre found in almost 14% of all marketed drugs. The 
most prevalent heteroatom-containing quaternary centres were those featuring oxygen (10.6%), 
followed by the less explored, but nonetheless significant class of aza-quaternary centres (3.2%) 
(Table 2.1).  
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Table 2.1 Analysis of quaternary sp3-hybridised carbon centres in FDA approved drugs. 
 
Type of centre R1 R2 R3 R4 Drugs featuring the centre 
All-carbon quaternary C C C C 360 13.6% 
Tertiary alkoxy C C C O 280 10.6% 
Aza-quaternary C C C N 84 3.2% 
Trifluoromethyl (ether) C/O F F F 82 3.1% 
Ketal C C O O 42 1.6% 
Tertiary thio C C C S 31 1.2% 
Tertiary fluoride C C C F 26 1.0% 
R groups show the type of atom attached to the quaternary centre and tabulated above. The number of 
drug molecules containing each type of quaternary centre are given as well as in percentage of the total 
number (2648) of FDA approved drugs in the study.  
Within this sub-section, interesting examples of FDA-approved drugs displaying the aza-
quaternary centre include: Amrubicin, an anthracycline for small cell lung cancer treatment;111 
Alfentanil, a potent short-acting opioid anaesthetic and analgesic; Deflazacort, a glucocorticoid 
anti-inflammatory and immunosuppressant agent;112 Ketamine, a commonly used 
anaesthetic;113 and Methyldopa, for treatment of high blood pressure (Figure 2.2).114 In addition, 
this feature is not only present in chemically synthesised small molecules, but is also found in 
natural products, such as Erythratidine (Figure 2.2).115 
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Figure 2.2 Examples of marketed drugs and an alkaloid with aza-quaternary centres highlighted in red. 
Often, biologically active molecules that contain the aza-quaternary-centre are those directly 
relating to or derived from α,α-disubstituted amino acids. Compared to mono-substituted 
proteogenic amino acids the additional substituent in the α-position sterically constrains the 
motif, resulting in distinct chemical properties. This has been exploited in drug discovery for 
many therapeutic applications including enzyme inhibitors, ion-channel blockers, neuronal 
receptor agonists and antagonists, and antibiotic natural products.116 The interest in these 
moieties within the synthetic community has grown, with examples of incorporation of this 
valuable centre into small molecule libraries being reported. 103,117–123 As a result, a number of 
different strategies have been developed for the construction of such challenging quaternary 
amino acids and derivatives,116 including nucleophilic additions to ketimines (Strecker 
synthesis),124 enolate Claisen rearrengements125 and enolate alkylations.126 However, there is still 
an unmet need for approaches to construct small molecule libraries featuring this motif, and new 
methodologies are urgently required.102 
Recently, a successful reagent-based DOS approach was applied by Mateu et al. to generate 40 
structurally different fragments from a common quaternary amino ester building block in no 
more than five synthetic steps (Scheme 2.1).102 Importantly, the library demonstrated high levels 
of 3D character and a broad coverage of chemical space as well as ideal physicochemical 
properties. The resultant library was screened against three protein targets from different 
protein families—penicillin binding protein 3 (PBP3), cleavage factor 25 kD (CFI25) and Activin A—
by X-ray crystallography identifying hit fragments for each target.127 To validate all hits, a 
minimum of four synthetic exit vectors were utilised to quickly access 10 to 14 analogues of each, 
also providing initial SAR information. 
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Scheme 2.1 Diversity-oriented synthesis of aza-quaternary carbon containing small molecules by Mateu 
et al.102 Following chemoselective functionalisations around the versatile amino ester building block, 
various rings were formed by pairing the a) amino and ester (blue), b) ester and alkyne (green) and c) 
amino and alkyne (red) groups. X-ray crystallography was used to screen the library against penicillin 
binding protein 3 (PBP3), cleavage factor 25 kD (CFI25) and Activin A identifying hits against all targets.127 
Each hit compound displayed a number of exit vectors that were used to quickly build libraries of 10 to 
14 analogues to validate each hit. 
2.1.2 Spirocycles 
In addition to generating 3D features, it is often desirable to rigidify the structures of drug-like 
molecules via the introduction of cyclic systems. This can reduce both the conformational 
entropy penalty of target binding and the number of possible conformations (distinct 3D shapes) 
the molecule can adopt leading to higher potency and selectivity.128 Examples of ring systems 
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employed by nature and chemical synthesis range in size from small rings (3 to 6 atoms) to 
macrocycles (12 or more atoms), and in complexity from simple individual cycles to more 
complex spiro, fused and bridged systems or combinations of these. In particular, spirocyclic 
motifs possess interesting structural features, displaying an inherently 3D character due to the 
presence of a quaternary spiro atom. The conformations adopted by each ring enables the 
projection of different structural elements present on the spirocycle in different directions 
(Figure 2.3).129 Many different classes of spirocycle are known, however, those consisting of two 
small rings have been shown to offer the advantage of being either conformational locked or 
possessing only a small number of well-defined conformations that might contribute towards 
potency and selectivity.130 
 
Figure 2.3 Illustration of a spirocycle projecting appendages in all directions of the 3D space. 
Spirocyclic motifs are present in many bioactive molecules of both natural and synthetic origins. 
The spiroketal antibiotic polyketide Oligomycin131 and Griseofulvin with antifungal activity132 
highlight the relevance of this motif within nature. The first spirocyclic drug to reach the market 
was the competitive mineralocorticoid (aldosterone) receptor antagonist Spironolactone, over 
50 years ago.133 With the development of new methodologies for the introduction of spirocyclic 
scaffolds,134–138 the number of FDA approved drugs containing this motif has increased 
significantly over the last few decades. Amongst these include the selective and extremely potent 
κ-opioid agonist Enadoline139 and Buspirone used to treat generalized anxiety disorder (Figure 
2.4).140 
 
Figure 2.4 Examples of biologically active compounds containing spirocyclic motifs highlighted in red. 
More specifically, an interesting and under-represented class of spirocycles are those which 
incorporate the aza-quaternary centre. Structures of this nature can be found in natural products 
like Histrionicotoxin found in the skin of poison frogs.141 Additionally, four FDA approved drugs 
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display this motif: Irbesartan, a potent angiotensin II receptor antagonist used for the treatment 
of hypertension;142 Fluspirilene, an antipsychotic used to treat schizophrenia;143 Rolapitant used 
for the treatment of chemotherapy-induced nausea and vomiting (CINV);144 and Omacetaxine 
mepesuccinate used for the treatment of chronic myeloid leukemia (CML) (Figure 2.5).145 
Importantly, these molecules exhibit conformational restriction as a result of the spirocyclic 
nature and feature the biorelevant aza-quaternary centre with four different substituents. 
Despite the biological importance of aza-quaternary spirocycles, there remains a need to deliver 
novel scaffolds that feature this particular motif—however, synthesis of compounds containing 
the motif remains challenging due to the inherent steric congestion of the atomic arrangement. 
 
Figure 2.5 Examples of biologically active molecules featuring the aza-quaternary spirocyclic motifs 
highlighted in red. 
The syntheses of spirocyclic α,α-disubstituted amino acid derivatives have previously been 
reported in the literature.146–149 Hung et al. adopted a DOS strategy to generate a fragment library 
containing several spirocycles of this type, among others, from cyclic α,α-disubstituted amino 
acid derivatives.109 This approach utilised a common build/couple/pair DOS algorithm;150 first 
synthesising the multifunctional cyclic allyl amino ester building blocks, followed by 
intermolecular functionalization, finally pairing the terminal alkene functional groups 
intramolecularly to yield structurally diverse and complex cyclic molecules. Alternatively, by 
functionalising the carboxyl group of the quaternary cyclic amino ester building block with an 
additional unsaturated moiety, two spirocyclic scaffolds could be generated using a ring closing 
metathesis (RCM) reaction (Scheme 2.2).109 
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Scheme 2.2 Synthetic strategy to a diverse fragment library including aza-quaternary spirocycles 
(highlighted in red) by Hung et al.109 
Another interesting synthetic approach was established by Stotani et al. for the generation of a 
bis-spirocyclic library.151 This strategy utilised a key condensation between cyclic ketones and 
either a cyclic α-amino amide forming bis-spiro-imidazolinones (Scheme 2.3) or a cyclic α-amino 
alcohol forming bis-spiro-oxazolidines (not shown). Even though interesting and 
underrepresented bis-spirocycles were formed, the majority of the final products did not meet 
the size criterium for a fragment library. 
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Scheme 2.3 Synthetic combinatorial strategy to a bis-spirocyclec library featuring aza-quaternary 
centres (highlighted in red) by Stotani et al.151 
Recently, a visible-light-mediated methodology was reported for the rapid generation of aza-
quaternary spirocyclic fragments from cyclic ketones and alkenyl amines by Flodén et al. (Scheme 
2.4).152 This methodology was used to access 20 different spirocyclic scaffolds, however, the 
fragments only display a very limited number of synthetic exit vectors—most of which are 
secondary amines. Therefore, there is still an unmet need for a strategy that would incorporate 
exit vectors into spirocyclic fragments to allow for rapid analogue synthesis once a hit compound 
is identified. 
 
Scheme 2.4 Photocatalytic synthesis of aza-quaternary spirocycles by Flodén et al.152  
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2.2 Project Outline 
In order to address the lack of sp3-rich fragments in general100 and especially spirocyclic 
scaffolds130 within commercially available screening libraries, a project was devised to develop a 
novel synthetic strategy to access such highly desired fragments, whilst maintaining optimal 
physicochemical properties to be attractive for FBDD purposes. Moreover, modular routes to the 
finalised scaffolds would facilitate introduction of structural diversity and thus a broad coverage 
of underexplored 3D chemical space. In addition, a crucial consideration during the design of the 
library was to incorporate invaluable 3D exit vectors that could be synthetically utilised to access 
analogues once a hit is identified. 
Following the previous success of the use of α,α-disubstituted amino esters in DOS strategies,102 
it was envisaged that this moiety could serve as a suitable building block to access a series of 
fragments containing an aza-quaternary spirocentre (Scheme 2.5). Accordingly, it was 
hypothesised that the incorporation of different alkyl groups bearing terminal alkenes could be 
achieved in either a racemic fashion (Scheme 2.5, step A1) or enantioselectively (Scheme 2.5, 
step A2). Using these motifs, a substrate-based approach was proposed to form carbocyclic rings 
of various sizes in ring-closing metathesis (RCM) reactions (Scheme 2.5, step C). Moreover, it was 
hoped that the presence of a key versatile α-amino ester moiety would facilitate the formation 
of diverse heterocycles (Scheme 2.5, step B) using a reagent-based method. Finally, it was also 
envisioned that strategic 3D exit vectors could be introduced into all fragments at positions on 
both the heterocycles (Scheme 2.5, step D) and the double bond within the carbocycles (Scheme 
2.5, step E). 
 
Scheme 2.5 Synthetic strategy for a diverse spirocyclic fragment library. The α,α-disubstituted amino 
ester building blocks can be synthesised both racemicaly (A1) and enantioselectively (A2) during the build 
phase. The α-amino ester motif highlighted in blue can be used to form numerous heterocycles (B), 
whereas the terminal alkenes highlighted in red can be paired in RCM reactions to form cycloalkene rings 
(C). The different 3D exit vectors can be showcased by various modifications of the heterocycles (D) and 
the double bond (E).  
36  
2.2.1 Scaffold scope 
2.2.1.1 Ring size 
Most of the spirocyclic natural products, FDA approved drugs and other candidates under clinical 
trials feature five- and six-membered rings.153 Cyclopentane- and cyclohexane-containing 
spirocyclic motifs are found in Spironolactone133, Buspirone140, Irbesartan142, Griseofulvin132, 
Enadoline139 and Histrionicotoxin141 amongst others (Figure 2.4, Figure 2.5). Therefore, these 
rings can be regarded as attractive moieties for incorporation into a spirocyclic fragment library. 
Spirocycles containing a 7-membered ring, however, are currently underrepresented in drug 
discovery. As of 2014 there were no approved pharmaceuticals featuring this motif and only four 
compounds were reported with promising bioactivities.153 Two of them are stearoyl-coenzyme A 
desaturase-1 (SCD1) inhibitor candidates for the treatment of metabolic disorders.154 In addition, 
a potent and selective antagonist of the X-linked inhibitor of apoptosis protein (XIAP), a key 
regulator of apoptosis often overexpressed in cancer cells, has been identified by Donnell et al.155 
The last example is an orally available glycogen synthase kinase 3β (GSK-3β) inhibitor for the 
treatment of type 2 diabetes156 (Figure 2.6). The underrepresentation of these moieties may be 
a result of the lack of robust and flexible methodologies to construct these ring systems and 
therefore development of our methodology to facilitate the formation of such scaffolds was 
highly desirable. 
 
Figure 2.6 Examples of biologically active compounds containing spiro[6.n] scaffolds highlighted in red. 
2.2.1.2 Heterocycles 
Heterocycles are extremely important motifs in drug-like small molecules which is well 
demonstrated by the results of the recent analysis by Vitaku et al. that found that more than half 
(59%) of all FDA approved unique small molecule drugs contain at least one nitrogen 
heterocycle.157 Therefore, it was envisaged that incorporation of some of these heterocyclic 
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moieties into our spirocyclic library would significantly increase its biological relevance and 
expand the scaffold diversity. 
Pyrrolidines represent interesting biorelevant motifs and are in fact the most common five-
membered non-aromatic heterocycle unit, present in around one hundred different FDA-
approved drugs.157 One example of a marketed drug featuring this motif is Eletriptan, used to 
treat migraines.158 In addition, the 2-pyrrolidone and succinimide motifs are found in around ten 
and five small molecule drugs respectively,157 and the tetramic acid motif (pyrrolidin-2,4-dione) 
can be found in the natural product, Streptolydigin, with antibacterial properties159 (Figure 2.7). 
 
Figure 2.7 Examples of biologically active compounds containing pyrrolidine and tetramic acid moieties 
highlighted in red. 
Morpholine represents a common motif within drug discovery being one of the five most 
common non-aromatic six-membered heterocycles and found in over thirty different marketed 
drugs.157 The 3-morpholinone motif is present in the important anticoagulant Rivaroxaban160 as 
well as in CP-271485 having interesting anti-inflammatory properties161 (Figure 2.8). 
 
Figure 2.8 Examples of biologically active compounds containing 3-morpholinone moieties highlighted 
in red. 
Oxazolidines are one of the five most common non-aromatic five-membered heterocycles157 and 
can be found in the anti-anxiety drug Cloxazolam162. In contrast, the oxazolidone unit is much 
more commonly used and present in the oxazolidinone class of ‘last resort’ antibiotics, such as 
Linezolid163 (Figure 2.9). 
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Figure 2.9 Examples of biologically active compounds containing oxazolidine and oxazolidone moieties 
highlighted in red. 
Finally, aziridines are found in a variety of natural alkaloids164 such as the FDA-approved antibiotic 
Mitomycin165. Some synthetic therapeutics also feature this important motif like the anticancer 
drug ThioTEPA166 (Figure 2.10). 
 
Figure 2.10 Examples of biologically active compounds containing aziridine moieties highlighted in red.  
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2.3 Results and Discussion 
2.3.1 Building block synthesis 
Initial investigations involved the development of an efficient and robust synthetic route to the 
quaternary amino ester building block 1. It was envisaged that an enolate alkylation approach 
would serve as a reliable method for introducing different alkyl chains, facilitating the formation 
of a variety of building blocks from commercial regents. In the literature both isonitrile167–170 and 
Schiff base169,171,172 derivatives of glycine esters have been used as starting materials for various 
enolate alkylations, recently also extended to ethyl nitroacetate173. However, in general better 
yields, easier purifications and deprotections have been associated with the use of Schiff bases 
(Scheme 2.6). 
 
Scheme 2.6 Retrosynthetic analysis for dialkyl amino ester building blocks 1. 
As such, initial investigations began by forming the diphenylmethylene (DPM)-protected amino 
ester 2 via condensation of the inexpensive and commercially available ethyl glycinate 
hydrochloride and benzophenone as described by Li et al. (Scheme 2.7).174 Pleasingly, this 
proceeded smoothly, yielding 2 in 75% yield. 
 
Scheme 2.7 Synthesis of the protected common starting material 2. 
With 2 in hand, investigations into the alkylation steps were then carried out. Selective step-wise 
double alkylations of substrate 2 have previously been described,169 however, reproduction of 
these results proved to be challenging. Initially, following a literature procedure described by 
Andrei et al.,175 alkylation of 2 with homoallyl bromide in the presence of potassium carbonate 
base proved unsuccessful with no conversion detectable by TLC, despite the use of higher 
temperatures and phase-transfer conditions (Table 2.2, Entry 1). Promisingly, when the more 
reactive allyl bromide was used under similar conditions, the monoallyl intermediate 3a was 
isolated in moderate yield (Table 2.2, Entry 2). 
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Table 2.2 Attempted first alkylation steps. 
 
Entry n (eq.)a Base (eq.) Solvent Temp.b Time Quenchc Yieldd 
1e 2 (1.5) K2CO3 (5.0) MeCN reflux 3 days none 0%f 
2 1 (1.5) K2CO3 (5.0) MeCN reflux 3 days water 47% 
3 2 (3.0) tBuOK (1.1) THF -78 °C to RT 20 h sat. NH4Cl 27% 
4 2 (2.8) tBuOK (1.1) THF 0 °C to RT 20 h sat. NaHCO3 67% 
aAlkylating agent. bReaction temperature. cQuenching conditions. dIsolated yields of products 
contaminated with benzophenone. e0.5 eq. TBAI was also added as phase-transfer catalyst. fOnly 
unreacted starting material was observed by TLC. 
Disappointingly, however, upon subjecting 3a to the conditions described by Ilies et al.126 using 
homoallyl bromide, no desired di-alkylated product was observed, only starting material (Table 
2.3, Entry 1). This was suspected to be a result of the lower reactivity of the homoallyl bromide 
in comparison to that of the allyl bromide. Instead, it was then decided to investigate the reverse 
procedure, first installing the homoallyl and then allyl moieties. Pleasingly, this route led to the 
isolation of the di-alkylated species 4b (Table 2.2, Entry 3 and Table 2.3, Entry 2), but with poor 
to moderate yields for both steps.  
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Table 2.3 Attempted second alkylation steps. 
 
Entry n m (eq.)a tBuOK eq. Temp.b Time Quenchc Yieldd 
1 1 2 (3.0) 1.1 -78 °C to RT 2 days none –e 
2 2 1 (3.0) 1.1 + 0.5 -78 °C to RT 2 days sat. NH4Cl 40%f 
3 2 1 (3.0) 1.5 0 °C to RT 20 h 3M aq HCl 80%g 
aAlkylating agent. bReaction temperature. cQuenching conditions. dIsolated yield of 4b. eOnly unreacted 
starting material was observed by TLC. fContaminated with benzophenone. gPure free amine 1b isolated 
after acidic deprotection. 
Further optimisations at a larger scale were then conducted. One interesting observation 
throughout the alkylation reactions was the increased presence of benzophenone in the reaction 
mixture and purified product, suspected to be a result of in situ hydrolysis of the imine, affecting 
both the overall conversion and yield of each step. To minimise this, the mono-alkylation reaction 
was instead quenched with a basic medium, which significantly improved the yield to 67% (Table 
2.2, Entry 4). Notably, the increase in temperature and use of solid base also resulted in more 
practical reaction conditions. Next, it was decided to directly isolate the free amine 1b from the 
reaction mixture using in situ hydrolysis of 4b once full conversion from 3b was observed. 
Neutralisation by solid sodium carbonate led to the isolation of α,α-disubstituted quaternary 
amino ester 1b with both good yield (80%) and purity, with no further purification. Finally, an 
even more practical ‘one-pot’ route was established, where the first alkylation step was 
permitted to reach completion, followed by the addition of more solid base and allyl bromide. 
The resultant solution of 4b was deprotected under acidic aqueous conditions and the previously 
described aqueous work-up used to yield sufficiently pure 1b, eliminating the need for any 
chromatographic purifications from the building block synthesis (Scheme 2.8). The scalability of 
this synthetic procedure was demonstrated through the multi-gram (4.7 g) preparation of 1b. 
However, it is important to mention, that it was essential to monitor the conversion to 3b as 
premature addition of allyl bromide lead to the formation of  impurity 4a, which resulted in 
inseparable contaminations of cyclopentene containing spirocycles in later steps. 
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Scheme 2.8 ‘One-pot’ synthesis of the building block 1b. 
Due to the substrate-based nature of the carbocycle formation, it was necessary to synthesise 
building blocks with variable chain lengths in their alkenyl groups. To achieve this, it was 
envisaged that synthesis of dialkenyl amino ester 1b would enable the generation of a 
cyclohexene ring, whereas the formation of a cyclopentene ring required a building block with 
one less methylene group. To attain this, the diallyl amino ester 1a was readily synthesised from 
the same DPM-protected amino ester 2. This was achieved using a single one-pot reaction with 
excess allyl bromide and base. Again, the protected intermediate 4a was not isolated, but instead 
directly hydrolysed then neutralised to produce the desired diallyl amino ester 1a in moderate 
yield and sufficient purity without chromatography (Scheme 2.9). 
 
Scheme 2.9 ‘One-pot’ synthesis of the diallyl building block 1a. 
In order to expand the methodology to cycloheptene rings, the synthesis of an additional 
quaternary amino ester bearing one more methylene group was essential. It was envisaged that 
following the successful reaction path to 1b described previously, it would be possible to 
synthesise the desired 1c from DPM-protected starting material 2 in the same manner. In the 
first alkylation step, 5-bromo-1-pentene was used to form intermediate 3c, which led to the 
analogous synthesis of the quaternary amino ester 1c with a low overall yield over the three steps 
resulting from the partial hydrolysis of the DPM group throughout the work-up and 
chromatographic purification steps (Scheme 2.10). However, sufficient quantities of 1c were 
obtained and thus the optimisation of this route was not pursued. 
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Scheme 2.10 Step-wise synthesis of the allyl pentenyl building block 1c. Intermediates 3c and 4c were 
contaminated with benzophenone. 
2.3.2 Different carbocycle and tetramic acid containing spirocycles 
With the amino ester building blocks 1a-c in hand, a suitable heterocycle could be constructed 
pairing the amino and ester functionalities, followed by the RCM reaction, to exemplify the 
different spiro[4.n] ring systems. Tetramic acid was chosen as the default heterocycle due to the 
ease of synthesis and potential for future functionalisations. Introduction of this heterocycle 
began with the direct acylation of amino esters 1a-c by ethyl malonyl chloride in the presence of 
triethylamine in excellent yields (Scheme 2.11). Subjecting 5a-c to basic conditions mediated 
deprotonation of the acidic a-carbonyl protons, followed by intramolecular nucleophilic 
substitutions upon the second ester to generate the tricarbonyl intermediates 6a-c. Due to the 
instability of intermediates 6a-c, they were immediately subjected to hydrolysis and 
decarboxylation by heating in wet solvent under either neutral or acidic conditions to produce 
the quaternary pyrrolidinones 7a-c. Finally, the cycloalkene rings were formed in RCM reactions 
to complete the spirocycle formations. The more stable and versatile second-generation Grubbs 
catalyst was used in higher dilutions to overcome competing oligomerisations and/or 
polymerisation of the starting materials. Under these conditions, the tetramic acid containing 
spirocycles 8a-c were successfully formed in good to excellent yields (Scheme 2.11). However, 
unlike the other RCM reactions, compound 7a was not soluble in CH2Cl2 at reflux; instead toluene 
and heating the reaction to 70 °C was required. The scalability of this route was demonstrated 
with a gram-scale synthesis of 8b with an overall yield of 75% from 1b; and with a low 1% catalyst 
loading in the final RCM reaction with an excellent 99% yield. 
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Scheme 2.11 Synthesis of spirocycles containing tetramic acid and 5-, 6- and 7-membered carbocycles. 
2.3.3 Enantiopure spirocycle synthesis 
A vast number of biologically active compounds and approved drugs contain at least one chiral 
centre and most of the chiral drugs have been approved as single enantiomers during the last 
few decades.176 Additionally, due to the inherently chiral nature of biological targets, often 
different enantiomers of the same compound can have very distinctive bioactivity profiles. 
Examples of the use of racemic entities are known, however often only one enantiomer is 
responsible for the therapeutic effect and the other can also contribute to side-effects or even 
become the main source of them.177 The tragic incidence of Thalidomide shows how important 
it is to evaluate the pharmacokinetic properties of both enantiomers of a drug candidate.178 In 
this manner, demonstration of an enantiopure route to both the amine and one final spirocycle 
was an important objective within the project.  
2.3.3.1 Enantioselective building block synthesis 
The work in this subsection (2.3.3.1) was devised and carried out by Dr. Natalia Mateu as part of 
the Spring group’s collaborative research into spirocyclic fragments.179 
This strategy involved the use of a chiral auxiliary for the formation of chiral iminolactone 
moieties, which are known to give excellent stereocontrol over nucleophilic additions to the 
imine.180–183 Importantly, both enantiomers of the chiral auxiliary are readily available, thus if 
successful this strategy would prove a powerful approach to synthesising the enantiopure 
building blocks. In the first step, the ketoester 9 was synthesised from commercially available 
starting materials using a Grignard reaction.184 The chiral iminolactone 10 was then formed in a 
double condensation reaction between the ketoester 9 and inexpensive commercially available 
(R)-2-(–)-2-phenylglycinol.183 The allyl substituent was introduced in a Barbier-type reaction to 
form the quaternary aminolactone 11 in a good yield. Auxiliary cleavage could then be performed 
via a transesterification induced by thionyl chloride followed by oxidative cleavage of the 
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resultant 1,2-aminoalcohol 12 by lead tetraacetate to produce the desired enantiopure amino 
ester (R)-1d (Scheme 2.12). 
 
Scheme 2.12 Synthesis of the enantiopure amino ester building block (R)-1d. All reactions were carried 
out by Dr. N. Mateu. For full details see reference 179 or Appendix 6.4. 
2.3.3.2 Preparation of the enantiopure tetramic acid containing spirocycle 
With enantiopure amino ester (R)-1d in hand, the optically pure R-enantiomer of 8b was 
synthesised as proof of principle, following the previously developed route with an overall yield 
of 41% over four steps (Scheme 2.13). 
 
Scheme 2.13 Synthesis of the enantiopure spirocycle (R)-8b. 
2.3.4 Different heterocycle and cyclohexene containing spirocycles 
The next stage of the project involved the formation of a range of heterocycles via pairing of the 
amino and ester functional groups within 1b. 
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2.3.4.1 Synthesis of the morpholinone-containing spirocycle 
It was envisaged that installation of a chloroacetyl functionality to the amino group could 
facilitate the formation of a morpholinone-containing spirocycle (Scheme 2.16). Thus, this route 
towards the key N-chloroacetyl alcohol intermediate 13 was next investigated. Initial 
investigations to form 13 began with the direct acylation of the unprotected amino ester 1b to 
give the N-chloroacetal ester 14 (Scheme 2.14). This proceeded successfully yielding 14 in good 
yield. However, suitable conditions for the reduction of 14 to form the N-chloroacetyl alcohol 13, 
could not be identified. It was found that when using lithium borohydride, no product could be 
identified. Instead, a highly polar side product (observed by TLC) was formed but which could not 
be isolated. Alternatively, lithium aluminium hydride was also trialled however the 1H NMR 
spectrum of the crude product suggested that the chloroacetamide had also been reduced. 
 
Scheme 2.14 Attempted first route to the N-chloroacetyl alcohol 13. 
Following the failure of this first route, it was decided to first protect the amino functionality 
within 1b using the tert-butoxy carbonyl (Boc) group and then reduce the ester prior to the N-
acetyl chloride introduction. The Boc protection afforded intermediate 15 in a good yield 
(Scheme 2.15). Unfortunately, the reduction of 15 with lithium borohydride proved sluggish, 
forming the desired alcohol 16 as only a minor product with low yield (Scheme 2.15), potentially 
due to the steric hindrance arising from the neighbouring quaternary centre. Similarly to the 
reduction of 14 with lithium borohydride, the formation of very polar side products was once 
more observed. On the basis of literature reports, this was hypothesised to be the result of 
hydroboration of the terminal alkenes.185 However, sufficient quantities of 16 were isolated, 
allowing progression through the reaction sequence. 
 
Scheme 2.15 Synthesis of the Boc-protected amino alcohol intermediate 16. 
Next, removal of the Boc protecting group using hydrochloric acid followed by selective acylation 
of the amino group led to the isolation of chloroacetamide 13 in a moderate yield over two steps 
(Scheme 2.16). Pleasingly, in the presence of potassium tert-butoxide, the cyclisation between 
the alcohol and the N-chloroacetyl group afforded the quaternary morpholinone 17 in an 
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excellent 98% yield. The cyclohexene ring was successfully formed in the final RCM reaction to 
afford the morpholinone-containing spirocycle 18 with a modest yield (Scheme 2.16). 
 
Scheme 2.16 Synthesis of the morpholinone containing spirocycle 18. 
2.3.4.2 Synthesis of the oxazolidone containing spirocycle 
Previous work in the group found that treatment of quaternary N-Boc amino alcohols with a 
suitable base induced the cyclisation of the alcohol onto the carbamate, replacing the tert-
butoxide to form an oxazolidone ring (Scheme 2.17, A).102 Alternatively, reacting the same 
starting material with potassium hydroxide in the presence of a stoichiometric amount of tosyl 
chloride (TsCl) resulted in the construction of the aziridine moiety via a tosylate intermediate 
(Scheme 2.17, B).102 
 
Scheme 2.17 Formation of oxazolidone (A) and aziridine (B) rings.102 
Firstly, it was decided to synthesise the three-membered aziridine following the procedure 
previously developed in the group. Although a small scale test reaction showed promising results, 
in contrast to expectations, treatment of the N-Boc alcohol 16 with TsCl and KOH on a larger scale 
yielded oxazolidone 19 as the major and the aziridine 20 as the minor products (1.7 : 1 ratio), 
with an overall yield of 76% (Scheme 2.18). A plausible explanation for this observation may be 
due to partial hydrolysis of the TsCl prior to reacting with alcohol 16 to form the tosylate 
intermediate. Alternatively, the sterically hindered alkoxide is more likely to react with the much 
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less electrophilic Boc group intramolecularly than with TsCl intermolecularly. Finally, the 
carbamate could have acted as an oxygen nucleophile rather than a nitrogen nucleophile 
displacing the tosylate as a leaving group to form the oxazolidone instead of the expected 
aziridine. Despite this set back, the two quaternary heterocycles were isolated in sufficient 
quantities to proceed to the final RCM reactions to form the spirocycles. 
 
Scheme 2.18 Synthesis of precursors 19 and 20. 
Oxazolidone 19 was then subjected to the same RCM reaction conditions described previously to 
form the cyclohexene-oxazolidone spirocycle 21 in a good yield (Scheme 2.19). However, the 
cyclisation of the aziridine intermediate 20 proved to be non-trivial. 
 
Scheme 2.19 Synthesis of the oxazolidone containing spirocycle 21. 
Initially, cyclisation of the quaternary aziridine 20 was also attempted under the same conditions 
(Scheme 2.20). Upon subjecting 20 to RCM reaction conditions, total conversion of the starting 
material was observed after 30 minutes. Formation of the desired product was supported by 
both 1H NMR and HRMS spectra of the crude product. However, disappointingly a pure sample 
of 22 could not be isolated after chromatographic purification, potentially due to decomposition 
on the silica gel, a hypothesis that was supported by two-dimensional TLC studies. Whilst 
intermediate 20 was a stable compound under standard conditions used for purification and 
characterisation, it was hypothesised that decreased stability of the spirocycle could have been 
a result of the increased ring strain in 22. 
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Scheme 2.20 Attempted synthesis of the aziridine containing spirocycle 22. 
Further efforts to synthesise 22 were then attempted using an alternative route via first forming 
the cyclohexene ring and then the aziridine spirocycle 22. Indeed, the acyclic N-Boc ester 15 could 
be cyclised to give cyclohexene N-Boc ester 23 in an excellent yield, with a low 0.2 mol% catalyst 
loading (Scheme 2.21). Pleasingly, the reduction of the less hindered ester group in the cyclic 
intermediate 23 proceeded much more smoothly than previously experienced with 15, 
producing the cyclohexene-containing alcohol 24 in very good yield (Scheme 2.21). This provides 
further evidence for the previous hypothesis of hydroboration of the terminal alkenes within 15, 
as this was not observed with 23. 
 
Scheme 2.21 Synthesis of the Boc-protected cyclohexene amino alcohol 24. 
With the cyclohexene N-Boc alcohol 24 acquired, the formation of the aziridine ring was then 
trialled again using TsCl and KOH, but in greater excess to suppress oxazolidone formation 
(Scheme 2.22). Unfortunately, the aziridine spirocycle 22 was not formed, instead only the 
tosylate intermediate 25 was isolated in low yield. It could be hypothesised that the lack of 
intramolecular cyclisation may be a result of the increased ring strain, leading to a very high 
energy transition state as well as reducing the Thorpe-Ingold effect. At this point it was concluded 
that the aziridine spirocycle 22 was most likely not stable enough for any utility in a fragment 
screening library, and therefore further attempts on its synthesis and purification were not 
carried out. 
 
Scheme 2.22 Attempted aziridine formation using the cyclic Boc alcohol intermediate 24. 
Finally, in order to efficiently synthesise larger quantities of the oxazolidone spirocycle 21, an 
improved route was established utilising the N-Boc cyclohexene intermediates. As expected, the 
base mediated cyclisation of 24 afforded spirocycle 21 in excellent yield on 2-gram scale. 
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Scheme 2.23 Improved synthesis of 21. 
2.3.5 Double bond modification 
With a diverse set of core spirocyclic scaffolds in hand, the utility of the alkene as a functional 
handle was then investigated. This double bond was strategically incorporated into the 
carbocycles of each member of the library, to facilitate fragment growth in all directions. 
Modifications to the cycloalkene rings also increases the number of chiral centres resulting in 
greater stereochemical diversity within the library and polar functional groups capable of forming 
hydrogen-bonding interactions with protein targets. Notably, although the objective of this 
project was to exemplify single step reactions for conciseness, many of these transformations 
can create further multifunctional handles. To explore this, the oxazolidone heterocycle was 
selected for its ease of synthesis and chemical stability. The cyclohexene ring was chosen in order 
to observe the diastereo- and regioselectivity of certain reactions.  
Initially, unprotected spirocycle 21 was explored as an appropriate starting material for the 
envisaged chemical modifications ( 
Scheme 2.24). Firstly, hydrogenation of the double bond was investigated and 10% (w/w) 
palladium on charcoal was found to be a suitable catalyst for the reaction under hydrogen 
atmosphere, yielding cyclohexane spirocycle 26 in good yield. More pleasingly, epoxidation of 
unprotected 21 with mCPBA also proved moderately successful, however two chromatographic 
purifications were required before both diastereomers of epoxide 27 could be isolated in a 
modest combined yield of 52% (dr 8:1). Single crystal X-ray crystallography analysis revealed that 
in the major diastereomer, 27a, the epoxide is cis to the carbamate nitrogen (Figure 2.11), 
suggesting that the oxidation by mCPBA is directed by hydrogen bonding, further supported by 
a study on related scaffolds by O’Brien et al.186 However, further synthetic efforts made on the 
non-protected starting material 21 were unsuccessful. The products of these reactions were 
often highly polar rendering the work-up procedures very difficult, and the lack of UV-active or 
easily oxidisable groups made their identification and purification even more challenging. 
Furthermore, it was hypothesised that the unprotected oxazolidone in fact interfered with some 
of the attempted reactions. 
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Scheme 2.24 Attempted double bond modifications on non-protected 21. All products are racemic. 
Crossed arrow: no indication of desired reaction taking place based on TLC and/or crude 1H NMR analysis; 
dashed arrow: formation of desired products is evidenced by both TLC and crude 1H NMR analysis, but 




Figure 2.11 X-ray crystal structure of the major epoxide 27a. 
Following the limited progress made on unprotected 21, the use of a suitable protecting group 
on the amine was considered. The para-methoxy benzyl (PMB) group was identified as the most 
promising candidate due to the ease of incorporation, versatile deprotection conditions and UV-
activity. It was also envisaged that this functionality would render the compounds less polar and 
more soluble in organic solvents. The unprotected spirocycle 21 was thus treated with sodium 
hydride and PMBCl to give the PMB-protected oxazolidone 28 in excellent yield (Scheme 2.25). 
 
Scheme 2.25 PMB-protection of the oxazolidone ring. 
With the PMB-protected cyclohexene 28 in hand, the feasibility of the chemical functionalisation 
of the key alkene exit vector was once more investigated. Dihydroxylation of 28 in the presence 
of 1% OsO4 catalyst proceeded smoothly and yielded two diastereomers of 29 in quantitative 
yield (dr 2.5:1) (Scheme 2.26, step a). Dibromination by phenyltrimethylammonium tribromide 
(PTAB) proved to be similarly successful yielding 30 in 96% (dr 18:1) (Scheme 2.26, step b); 
whereas using the more reactive bromine itself gave partial oxidative deprotection of the PMB 
group and subsequently resulted in lower yields. Formation of the N-tosyl aziridine derivative 31 
was achieved in 70% (dr 1.4:1) following the conditions described by Jeong et al. using 
Chloramine-T as a practical nitrogen source and PTAB as catalyst (Scheme 2.26, step c).187 
Synthesis of the gem-difluorocyclopropane 32 was carried out under the conditions described by 
Wang et al.,188 however, the reaction did not go to completion and the majority of 28 was 
recovered unchanged, whilst products were isolated in a low 26% yield (62% based on recovered 
starting material; dr 20:1) (Scheme 2.26, step d). Following the limited success of the 
difluorocarbene insertion, a more reactive variant of the traditional Simmons-Smith reaction 
described by Yang et al.189 and Bojase et al.190 was attempted, however the desired product could 
not be isolated. Treatment of 28 with chloroform and base did not yield the analogous 
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dichlorocyclopropane either. Finally, the palladium-free Wacker-type oxidation described by Liu 
et al.191 was employed to form regioisomers of ketone 33 in a moderate 43% yield (rr 1.9:1) as 
well as regio- and diastereoisomers of alcohol side products 34 (combined 33%) and unreacted 
28 (8%) (Scheme 2.26, step e).  
 
Scheme 2.26 Double bond modifications on the PMB-protected spirocycle 28. All products are racemic. 
Reactions condition (combined yields (based on recovered 28 where applicable) with ratios a/b are 
given): a) OsO4, NMO, citric acid, H2O/THF, 99%, 2.5:1; b) PhNMe3Br3, CH2Cl2, 96%, 18:1; c) TsNClNa·3H2O, 
PhNMe3Br3, 4 Å MS, 70%, 1.4:1; d) TMSCF3, NaI, THF, 62%, 20:1; e) Fe(acac)2, tBuOH, air, 47%, 1.9:1 (33) 
+ 36% mixture of isomers (34). 
Assignments of the diastereomers are based on single crystal X-ray crystallography analysis 
(Figure 2.12), as NMR studies were not conclusive for these compounds. The regioisomers of 
ketone 33 (and alcohol 34) were easily distinguished by NMR analysis. Diastero- and regioisomers 
of these compounds are numbered in general as Xa, Xb, where Xa corresponds to the major 
isomer, diastereomeric and regioisomeric ratios are given as Xa:Xb. The relative stereochemical 
outcomes of these reactions can be rationalised by assuming that the initial electrophilic attack 
on the double bond is preferred on the sterically less hindered face cis to the PMB-protected 
nitrogen occupying the more favourable pseudo-equatorial position in the half-chair 
conformation of 28. This directly results in the observed major diastereomers of dihydroxy 
derivative 29 and difluorocyclopropane 32. The major diastereomer of the dibromo species 30 
results from the trans-diaxial opening of the bromonium intermediate by bromide. Similarly, the 
bromonium intermediate is attacked by a sulfonamide anion followed by a second intramolecular 
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Figure 2.12 X-ray crystal structures of double-bond-modified spirocycles. 
It was also crucial to demonstrate that the PMB protecting group could easily be removed to 
enable use of the final fragments. The three most common reaction types found in literature for 
the removal of PMB groups from amides and carbamates are: 1) hydrogenation using 
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heterogeneous palladium catalysts and hydrogen gas, 2) oxidative cleavage by 2,3-dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ) or ceric ammonium nitrate (CAN) and 3) acidic cleavage by 
strong acids such as trifluoroacetic acid or hydrochloric acid at elevated temperatures. 
Disappointingly, the attempted hydrogenolysis of the aziridine 31b under hydrogen atmosphere 
in the presence of 10% (w/w) palladium on charcoal returned unchanged starting material. 
Refluxing dibromide 30a in TFA overnight, however, did yield the desired deprotected dibromo-
spirocycle 35 in a good 88% yield, although these conditions are quite harsh and presumably 
incompatible with many desirable functional groups. Unfortunately, the deprotection could not 
be achieved using the milder oxidant DDQ. Pleasingly, however, oxidation of 30a by CAN revealed 
35 in an improved near-quantitative yield of 96% under reasonably mild conditions (Scheme 
2.27). 
 
Scheme 2.27 Removal of the PMB protecting group. 
2.3.6 Further heterocycles and their modifications 
The work in this section (2.3.6) was carried out by Dr. Andrew J. P. North as part of the Spring 
group’s collaborative research into spirocyclic fragments.179 
In order to increase the diversity of the spirocyclic library and incorporate attractive 
pharmacophore-like heterocycles, several further pairing reactions between the amino and 
alcohol groups were also investigated. To achieve this, the more practical route utilising 
cyclohexene intermediate 24 as the branchpoint was employed. This allowed for the large-scale 
synthesis of 24, which was then deprotected by treatment with hydrochloric acid prior to the 
pairing reactions, forming the amine intermediate 36. Spirocycles featuring both the morpholin-
3-one 18 and morpholin-2-one 37 were synthesised using α-halo acid derivatives. Additionally, 
substituted oxazolines 38 and 39 were formed by treating 36 with cyanogen bromide and ethyl 
benzimidate, respectively. 
In addition to the expansion of the core fragment scaffold set, the exploration of alternative 3D 
exit vectors was also expanded to address the heterocyclic component of the compounds. 
56  
Substitution at the N-3 position of the oxazoline ring has been shown by alkylation (incorporating 
the PMB protecting group in 28), whereas at the C-2 position by changing the electrophilic 
reagent used for the heterocycle formation (as shown by 38 and 39). Oxidation of the morpholin-
2-one ring of 37 by lead tetraacetate yielded iminolactone 40, which, similarly to the chiral 
iminolactone 10 (described in section 2.3.3.1), should readily undergo nucleophilic additions at 
the imine centre. The tetramic acid (in 8) proved to be the most versatile heterocycle, allowing 
for several chemical modifications to grow this fragment from the C-4 position. Chemoselective 
O-alkylation yielded dihydropyrrolone ether 41, whereas reacting 8 with triflic anhydride, the 
enol triflate 42 could be isolated. The latter proved to be a suitable substrate for Suzuki-Miyaura 
cross-coupling with para-methoxyphenyl boronic acid affording the aryl functionalised 
dihydropyrrolone 43 in good yield. Furthermore, a simple reduction of the ketone functional 
group by sodium borohydride yielded the more saturated alcohol functionalised pyrrolone 44. 
Treatment of 44 with trifluoroacetic anhydride followed by base mediated elimination and 





Scheme 2.28 Synthesis of further heterocycles and their chemical modifications. All reactions were 
carried out by Dr. A. J. P. North. Reaction conditions: a) HCl, dioxane, quant.; b) BrCN, Et3N, EtOH, 58%; 
c) ethyl benzimidate hydrochloride, Et3N, DCE, 57%; d) (i) chloroacetyl chloride, Et3N, CH2Cl2, 57%; (ii) 
tBuOK, tBuOH, 99%; e) phenyl bromoacetate, iPr2NEt, MeCN, 43%; f) Pb(OAc)4, MeCN, 92%; g) KHMDS, 
EtBr, THF, 54%; h) Tf2O, Et3N, CH2Cl2, 59%; i) PMPB(OH)2, Pd(PPh3)4, Na2CO3, H2O/THF, 73%; j) NaBH4, 
MeOH, 23%; k) TFAA, Et3N, CH2Cl2; then KHCO3, MeOH, 30%. For full details see reference 179 or 
Appendix 6.4. 
2.3.7 Computational analysis 
As discussed in section 1.4, obtaining optimal physicochemical properties is crucial for any 
fragment library and thus was an important aim of this project. Fragments considered in this 
section include 1) the unmodified core spirocycles described in sections 2.3.2 and 2.3.3; 2) the 
non-protected modified spirocycles 27a,b, the synthetically deprotected 35 and the virtual 
collection obtained by removing the protecting groups from the rest of the modified compounds 
described in section 2.3.5; 3) molecules synthesised by Dr. A. J. P. North (section 2.3.6). The 
resultant library of 28 spirocycles was computationally assessed for various physicochemical 
properties and compared to both the commercially available state of the art Maybridge core 
fragment collection192 (further details in Appendix 6.1.2) of 1000 fragments and the widely 
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accepted guidelines set by Astex Pharmaceuticals95,97. The most widely used properties are listed 
in Table 2.4 for both libraries; whereas their distributions are shown as histograms in Figure 6.1 
(see Appendix). 
Table 2.4 Calculated physicochemical properties of fragment libraries compared to the ideal range 
based on the Astex guidelines. 
Propertya Spirocyclesb Maybridgec Ideal Ranged 
MW 186 ± 41 182 ± 42 140 – 230 
HBD 1.3 ± 0.7 1.0 ± 0.8 ≤ 3 
HBA 1.8 ± 0.6 1.8 ± 0.7 ≤ 3 
SlogP 0.9 ± 0.9 1.9 ± 0.8 0 – 2 
RBC 0.2 ± 0.5 2.0 ± 1.5 ≤ 3 
TPSA 48 ± 13 39 ± 14 ≤ 60 
aMW = molecular weight (Da), HBD = number of hydrogen-bond donors, HBA = number of hydrogen-
bond acceptors, SlogP = partition coefficient, RBC = rotatable bond count,  
TPSA = topological polar surface area (Å2). bProtecting groups virtually removed from the library. 
cMaybridge core fragment collection of 1000 fragments. dGuidelines set by Astex Pharmaceuticals.95,97 
All values are presented as the mean value followed by its standard deviation. Green = within ideal range, 
yellow = mean value along with the standard deviation indicates that many fragments fall outside of the 
ideal range. Table reproduced from reference 179; for further details see appendix 6.1. 
The physicochemical properties in Table 2.4 were calculated by the computer program Molecular 
Operating Environment193 (see section 6.1 for further details) and the results analysed by 
Microsoft Excel, which revealed that the spirocyclic library adheres well to the aforementioned 
guidelines. The molecular weight (MW) and the number of hydrogen-bond donors (HBD) and 
acceptors (HBA) are all comparable across both libraries and lie well within the ideal range. The 
slightly higher value of the topological polar surface area (TPSA) shows that the spirocycles 
incorporate more polar functional groups, however, this is still on the optimal spectrum. Whilst 
the calculated lipophilicity (SlogP) of the Maybridge library complies well with the Ro3 (logP ≤ 3), 
it is just on the upper limit of the more stringent guidelines used in this comparison. On the other 
hand, the spirocyclic library shows superior lipophilicity, which could be inferred to impart good 
water solubility. Finally, a noteworthy difference in the number of rotatable bonds (RBC) 
between the two libraries was identified. Importantly, while both values fall within the ideal 
range (RBC ≤ 3), the higher rigidity of the spirocyclic library should in fact be more desirable for 
both fragment screening and elaboration purposes as discussed in section 2.1.2. 
Next, the three-dimensionality and shape diversity of the libraries were assessed by a principal 
moments of inertia (PMI) analysis. First, the lowest energy conformer of each molecule was 
computed using MOE, followed by the corresponding moments of inertia around the 
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perpendicular principal axes (PMI1 ≤ PMI2 ≤ PMI3). Then the normalised PMI ratios (NPR; npr1 = 
PMI1 / PMI3, npr2 = PMI2 / PMI3) were calculated and plotted; the geometrical restrictions on 
the NPR values result in a triangular representation of all possible shapes, the PMI plot. The 
vertices of this triangle correspond to the points (npr1, npr2) of the extremes of rod-like (0,1), 
disk-like (0.5, 0.5) and sphere-like (1,1) features. Objects represented by points alongside the 
rod-disk axis of a PMI plot have all their mass distributed within a single plane, i.e. they are 2D. 
Furthermore, the analysis of commercially available fragments by Morley et al. also showed that 
compounds lying close to the rod-disk axis (npr1 + npr2 ≤ 1.1) are sp2-rich and considered to be 
‘flat’ or 2D by medicinal chemists,100 thus the term ‘flatland’ is often used to describe this area 
within a PMI plot. 
The spirocyclic library (blue diamonds) was first compared to the whole Maybridge core 
collection of 1000 fragments (red dots) (Figure 2.13, left). This comparison shows that the 
conventional fragments aggregate towards the rod-disk axis, while the spirocycles are more 
evenly spread out over the relatively underrepresented area outside of ‘flatland’. However, this 
is visually not necessarily clear when a small set of 28 spirocycles are compared to the much 
larger set of 1000 Maybridge fragments. Therefore, to give a more discernible representation, 
the 147 fragments most closely resembling the spirocyclic library based on the heavy and 
heteroatom counts were selected (Figure 2.13, right). 
 
Figure 2.13 PMI plots representing shape diversity. Each corner corresponds to one of the unique rod-, 
disk- and sphere-like features. The dashed line represents the boundary of ‘flatland’ defined as npr1 + 
npr2 ≤ 1.1.100 The spirocyclic library (blue) is compared to all 1000 fragments of the Maybridge collection 
(red, left) and the best-matched subset of 147 fragments (red, right). Figure reproduced from reference 
179; for further details see appendix 6.1. 
In addition to the qualitative results above, the striking difference between the two libraries in 
term of the 3D properties can be further highlighted by quantitative comparisons. As a direct 
result of the library design, a remarkable level of saturation of the spirocyclic library was achieved 
evidenced by the high fraction of sp3 atoms (Fsp3) and conversely low fraction of aromatic atoms 
(Far). Similarly, the more chiral centres in our library create additional stereochemical diversity. 
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However, the superior 3D nature of the spirocycles is most evident from its much greater sum of 
NPR (npr1 + npr2) and further highlighted by the fact that whereas over 70% of the whole 
Maybridge library and 75% of the best-matched subset falls within ‘flatland’ (Fflat), none of the 
spirocycles do. The 3D properties of the libraries are listed in Table 2.5. 
Table 2.5 Physicochemical properties of fragment libraries describing their 3D properties. 
Propertya Spirocyclesb Maybridgec Best-matchd 
Fsp3 0.60 ± 0.14 0.29 ± 0.22 0.28 ± 0.19 
Far 0.02 ± 0.09 0.52 ± 0.25 0.49 ± 0.22 
chiral 1.6 ± 1.1 0.1 ± 0.5 0.2 ± 0.5 
npr1+npr2 1.25 ± 0.10 1.08 ± 0.09 1.06 ± 0.07 
Fflat 0.00 0.71 0.76 
aFsp3 = fraction of sp3 atoms, Far = fraction of aromatic atoms, chiral = number of chiral centres, npr = 
normalised PMI ratio, Fflat = fraction of molecules lying below the ‘flatland line’100. bProtecting groups 
virtually removed from the library. cMaybridge core fragment collection of 1000 fragments. d147 best-
matched fragments from the Maybridge collection. All values, except Fflat, are presented as the mean 
value followed by its standard deviation. Blue = highly 3D, red = highly 2D. Table reproduced from 
reference 179; for further details see appendix 6.1. 
2.3.8 Assessing the library’s biological activity 
With a diverse collection of 28 spirocycles in hand, a collaboration with Dr. Martin Welch from 
The Department of Biochemistry, University of Cambridge was initiated to evaluate the library 
for antibacterial activity. Although fragment sized molecules often lack the binding strength 
required for a detectable activity in phenotypic assays, many such compounds do exhibit 
outstanding potency—highlighted by the fact that almost 15% of all FDA-approved small 
molecule drugs have a MW less than 230 Da110. With this in mind, the spirocyclic library was 
screened by phenotypic growth inhibition assays—following the guidelines for minimal inhibitory 
concentration testing by the European Committee on Antimicrobial Susceptibility Testing194—
against both the clinically relevant Gram-positive Staphylococcus aureus and Gram-negative 
Pseudomonas aeruginosa. However, no bacterial growth inhibition was observed at 256 mg/mL 
concentration for any of the spirocycles tested against the wild type S. aureus (ATCC 25923) and 
P. aeruginosa (PAO1) cell lines. In a last attempt, the compounds were also screened against the 
efflux pump deficient P. aeruginosa YM64 cell line to identify any potential hit compounds 
rendered inactive by quick transportation from the bacterial cytoplasm and/or periplasm (see 
section 3.1.2 for further details on bacterial resistance to antibiotics), but again, no activity was 
observed. We hypothesise that these results can majorly be attributed to the weak undetectable 
binding of the small fragments to antibacterial targets. 
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Further biological characterisation of these compounds remains underway with the fragment 
collection now incorporated within a fragment screening collection based at XChem at the 
Diamond Light Source Synchrotron, Oxford. The XChem facility represents a world-class high-
throughput method for fragment-based drug discovery using crystallography. Our spirocyclic 
screening collection is offered to all academic users of the facility and thus additional biological 
activities for the described fragments is expected within the near future and will be reported in 
due course.  
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2.4 Conclusions and Future Work 
Herein, this chapter has described the establishment of a novel divergent strategy for the 
formation of an sp3-rich spirocycle-based fragment library. Initially, a robust and modular glycine 
alkylation methodology was developed to access the racemic α,α-disubstituted amino ester 
building blocks 1. The amine and ester functional groups were paired in various reactions to form 
three (a total of six in collaboration) pharmacophore-like heterocycles, whilst the alkene moieties 
were used to generate three different cycloalkenes in RCM reactions, thus allowing for the rapid 
assembly of five (a total of eight in collaboration) spirocyclic scaffolds. Furthermore, the 
enantioselective building block synthesis utilising a commercially available chiral auxiliary by Dr. 
N. Mateu allowed the formation of the optically pure pyrrolidinone containing spirocycle (R)-8b 
as proof-of-concept to show that a single enantiomer of any member of the library could be 
synthesised to be used in SAR studies. Notably, all core scaffolds display a number of exit vectors 
to facilitate library expansion and fragment growth including various functional groups of the 
heterocycles as well as the strategically placed alkene moiety within the carbocycles. 
The subsequent library of 28 diverse fragment-sized spirocycles was computationally assessed 
and showed optimal predicted physicochemical properties with much improved lipophilicity and 
rigidity compared to the commercially available Maybridge core fragment collection. The 
spirocycle library also displayed remarkable 3D properties and shape diversity as evidenced by 
the PMI analysis. 
Finally, the spirocycle collection was screened in phenotypic assays for antibiotic activity against 
S. aureus and P. aeruginosa with limited success. However, future work in the Spring Group will 
focus on establishing new collaborations for identifying broader potential biological applications 
for these interesting fragments as part of the Spring Group Compound Collection. 
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3 Fragment-Based Approaches Towards Inhibiting PrpC 
3.1 Introduction 
3.1.1 Bacterial infections and treatments 
Humanity has struggled against infectious diseases since prehistoric times. Indeed, many of the 
most devastating pandemics such as cholera, typhus, tuberculosis and plague were in fact caused 
by extremely virulent† bacteria. As an example, the most likely causative agent of the Black Death 
in the mid-14th century was found to be Yersinia pestis, killing one third of Europe’s population 
at the time.195,196 Even in the 21st century, opportunistic bacteria, like Streptococcus pneumoniae, 
Pseudomonas aeruginosa and Staphylococcus aureus amongst many others, are responsible for 
numerous severe illnesses. These include the often fatal pneumonia and sepsis for those with 
compromised immune systems including infants, elders, and patients undergoing 
immunosuppression. In addition, numerous viral infections—like human immunodeficiency virus 
(HIV), common cold and influenza— increase the patients’ liability towards these bacteria, posing 
a serious healthcare challenge.197–201 The ‘Spanish flu’ was one of the deadliest pandemics in 
history killing an estimated 50 – 100 million people worldwide between 1918 – 1919, and 
although it was caused by an influenza A virus of the H1N1 subtype, most of the deaths resulted 
from bacterial superinfections leading to pneumonia.202 
Historically, ancient remedies, like the use of mouldy bread for the treatment of open wounds, 
have been shown to possess antimicrobial properties and a number of antiseptics and 
disinfectants, such as alcohols, aldehydes, phenols and halogen-releasing agents have been used 
for centuries. Strikingly, however, mankind had no effective systemic treatment for bacterial 
infections until the 20th century.2,203,204 The isolation of Mycobacterium tuberculosis in 1882 was 
followed by many advancements in microbiology and medicine making the development of 
effective antibacterial therapies possible for the first time in human history.205  
Arguably, conventional antibiotics (discussed further in section 3.1.2) represent the most 
important therapeutics, however, antimicrobial resistance (AMR) becomes more and more 
dominant and threatens to negate our ability to treat these infections. As a result, in addition to 
a drive in the development of novel small molecule antibiotics, several alternative approaches 
have begun to be investigated, with many now undergoing clinical trials.206–218 
3.1.2 Antibiotics and resistance 
Antibiotics were originally defined as secondary metabolites produced by either bacteria or fungi 
with antimicrobial properties, and later extended to synthetic and semi-synthetic small 
 
† Virulence describes the ability of a pathogen to infect and/or damage a host organism. 
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molecules. Nowadays, antibacterial agents are further divided into bacteriostatic—growth 
inhibitory—and bactericidal—killing—entities.205 Although the antibacterial mycophenolic acid 
has been isolated from Penicillium glaucum from as early as 1893,219 the first clinically used 
antibiotic, arsphenamine (Salvarsan, synthesised in 1907), only reached the market in 1910, and 
was mainly used to treat syphilis until replaced by penicillin.220 Following the landmark discovery 
by Alexander Fleming in 1928,221 penicillin was not available to the public until after World War 
II due to its very limited supply. Therefore, sulfamidochrysoidin (Prontosil, developed in 1932 and 
marketed from 1935) became the first truly effective broad-spectrum antibiotic used in the 
clinic.222 The introduction of penicillin to the public in 1945 marked the beginning of the Golden 
Age of antibiotic discovery, with many new classes discovered within two decades, saving the 
lives of millions around the world (Figure 3.1).203,204 
 
Figure 3.1 Timeline of antibiotics. Figure reproduced from Hutchings et al.203 
However, due to the emergence of AMR, the efficacy of most antibiotics has been compromised 
and many rendered essentially ineffective. Worryingly, AMR is currently attributed to the deaths 
of 700 thousand patients every year globally, and this number has been estimated to increase to 
10 million by 2050.223 Thus, the development of new antibiotics is absolutely essential to combat 
this crisis.208 In addition, it is also paramount to develop our understanding of the processes by 
which bacteria obtain resistance in order to develop new drugs and generate protocols to 
minimise casualties or the chance of epidemics breaking out.224 
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It is now known that bacteria have developed a range of resistance mechanisms to reduce drug 
efficacy. Firstly, bacteria can spatially exclude drugs by either preventing their entry to the 
cytoplasm and/or periplasm—by changing the chemical constitution of the cell walls and 
membranes, and thickness of the membrane envelopes, resulting in decreased drug 
permeability—whist efflux pumps serve to actively transport drugs outside the cell.225,226 Small 
molecules can also be chemically modified by specific enzymes to render them inactive, including 
substitutions and degradations or hydrolysis.227 On the other hand, the target itself can also be 
modified to prevent drug binding, including residue substitutions and binding by protective 
factors.228 Alternatively, the expression level of the target can be modified to minimise the effect 
of the drug.229 Finally, the toxicity of the drug can be alleviated by either employing an alternative 
enzyme for the same function that is not susceptible to the drug or altering the metabolic 
pathways to remove the need for the target’s function (metabolic shunt).230 These resistance 
mechanisms can be acquired as a result of several genetic changes including de novo point 
mutations causing single nucleotide polymorphism (SNP) in either the promoter region or the 
open reading frame (ORF) of the gene, structural rearrangements of the genome or horizontal 
gene transfer from other organisms.231,232 Whilst point mutations and genomic shuffling are the 
most frequent causes in laboratory evolution experiments, horizontal gene transfer is often 
responsible for the quick emergence of resistance in natural environments and the clinic (Figure 
3.2).225,227,233,234 Thus, these both varied and complex resistance mechanisms pose a significant 
challenge for the development of novel antibiotic small molecules, making this quest non-trivial. 




Figure 3.2 Antimicrobial resistance mechanisms and acquisitions. Mechanisms (yellow) can prevent the 
entry, accumulation, binding or toxicity of the drug, and can result from single-nucleotide changes 
(green), structural changes within the genome (purple) or horizontal gene transfer (orange) between 
cells. Figure reproduced from Yelin et al.225 with permission. 
3.1.3 Antibacterial targets 
A clinically valuable antibiotic needs to meet two criteria: 1) inhibition or disruption of crucial 
bacterial cell function to efficiently attenuate or kill the pathogen, and 2) low toxicity towards 
the host for safe administration.236 Accordingly, most known antibiotics either target functions 
that are only present in prokaryotes and not in eukaryotes like cell wall synthesis, or biological 
entities that differ significantly between these organisms such as the 70S versus 80S ribosomes. 
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The clinically relevant antibiotic classes are listed according to their target functions in Table 
3.1.203,204 
Table 3.1 Target functions of all antibiotic classes. Most antibiotic classes were first marketed during the 
Golden Age (1940 – 1970), and target one of the four major functions: folate, cell wall, protein and 
nucleic acid synthesis. Data from Hutchings et al.203 
Target Function  Antibiotic Classes 































ATP synthesis  Diarylquinolines 
Multiple  Nitrofurans 
Unknown  Arsphenamines 
Antibiotic classes are coloured according to their source; green: actinomycetes; 
blue: other bacteria; purple: fungi; orange: synthetic. New antibiotic classes 
introduced to the clinic 1970 – 1999 are in italic, 2000 – 2019 are in bold italic. 
Natural products have historically presented an incredibly rich source of antibiotics; however, 
these entities only target a small number of functions limited to enzymes involved with cell wall 
synthesis, protein synthesis (mainly by binding to the 70S ribosome), and RNA polymerase. Even 
though these targets comply with the principles above, these antibiotic classes have been 
employed in the microbial arms race for millions of years and as a result, resistance mechanisms 
have also evolved in nature. Moreover, whilst semi-synthetic analogues can retain activity 
against resistant strains, bacteria usually adopt to these incremental changes quickly, rendering 
these analogues equally ineffective. In contrast, many of the synthetic antibiotics were found to 
target alternative functions such as folate, DNA and adenosine triphosphate (ATP) synthesis. 
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However, resistance was observed soon after their first use in the clinic, proving that bacteria 
can develop resistance even to completely new antibiotic classes. The quickly spreading AMR and 
lacking development of new antibiotics since the end of the Golden Age of antibiotic discovery, 
resulted in an urgent need for finding novel targets. 
The completion of the first bacterial whole genome sequencing from Haemophilus influenzae in 
1995 sparked huge interest in the pharmaceutical community and enabled hundreds of 
prospective genes to be explored as potential antibacterial targets.237 However, sadly this did not 
deliver and since the 1980s no new antibiotics have been developed. This period, termed the 40-
year discovery void, is particularly unnerving. 
Our struggles to develop novel and effective antibiotics are best exemplified with case studies 
from within the pharmaceutical industry. One of the largest scale research efforts was made by 
GlaxoSmithKline (GSK), spanning over 7 years (1995 – 2001).238 This included in-depth study of 
the genomes of several pathogenic bacteria, both Gram-positive and Gram-negative, to identify 
highly conserved genes that occurred as single copies. Then the 358 genes that had no closely 
related human homologues were designated as potential broad-spectrum targets. These genes 
had been evaluated for essentiality using allelic-replacement mutagenesis, and 127 genes were 
identified as in vitro essential in at least one of the bacterial strains tested; almost half of which 
had known and assayable functions. Across this 7-year period, a total of 70 HTS campaigns were 
run against these individual targets as well as whole biosynthetic pathways and living cells, 
screening more than half a million compounds. However, hits were only identified from 16 HTSs 
and only 5 of these were successfully developed into lead compounds with in vivo activity. 
Strikingly, none ultimately reached the clinic. Similar difficulties were faced by many other 
companies investing in similar efforts, with more than 125 HTS campaigns against over 60 novel 
targets by 34 different companies published during 1995 – 2004. Only 2 candidates reached the 
phase I clinical trials.239 These efforts highlight the extreme challenge of developing novel and 
effective broad-spectrum antibiotics, further evidencing why other strategies besides HTS may 
need to be employed, whilst the search for novel antibiotic targets must continue. 
3.1.4 Metabolic pathways 
Most of the clinically used antibiotics target the synthesis of macromolecules, including the cell-
wall, proteins and nucleic acids. The inhibition of crucial metabolic pathways, however, poses an 
important alternative approach achieving lethality or growth attenuation.236 
3.1.4.1 Folate synthesis 
Tetrahydrofolate (THFo) is a key co-factor used by all living organisms for the transfer of methyl 
and formyl groups required for the synthesis of pyrimidines, purines, amino acids, S-
adenosylmethionine and formyl-methionine. Animals are unable to synthesise folate and must 
therefore obtain it from their diet. Plants, fungi and most prokaryotes however synthesise THFo 
de novo and are incapable of its uptake from the environment. Within these organisms, however, 
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variations of the essentially same biosynthetic pathway exist, which renders many of the involved 
enzymes unattractive targets for broad-spectrum antibiotics and also suggest resistance could 
also develop very easily.240–242 
One highly conserved enzyme, and therefore valuable target, is dihydropteroate synthase 
(DHPS), which catalyses the conversion of 6-hydroxymethyl-7,8-dihydropterin pyrophosphate 
(DHPPP) and para-aminobenzoic acid (PABA) into 7,8-dihydropteroate (DHP). The first synthetic 
antibiotics including sulfonamides, sulfones and salicylates bind to the active site by mimicking 
PABA and either inhibit DHPS or get incorporated into DHP analogues and as a result inhibit 
downstream enzymes in the folate biosynthesis (Figure 3.3).243,244  
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Figure 3.3 A) Reactions catalysed by dihydropteroate synthase (DHPS). B) X-ray structures of DHPS in 
complex with substrate analogues (left) and products (right). The overlaid structures show how 
sulfonamides can mimic the natural substrate para-aminobenzoic acid (left) and get incorporated into 
DHP analogues. X-ray images reproduced from Bourne et al.245. 
Another well-established target is the upstream dihydrofolate reductase (DHFR), which directly 
forms THFo. Although DHFR is present in both prokaryotes and eukaryotes, structural differences 
make selective targeting possible; thus, diaminopyrimidines such as trimethoprim can be used as 
safe antibiotics, whilst pyrimethamine is an anti-protozoal and methotrexate is an anti-cancer 







Figure 3.4 A) Reaction catalysed by dihydrofolate reductase (DHFR). B) X-ray structures of DHFR in 
complex with NADPH and dihydrofolate substrates as well as two clinically used inhibitors: Methotrexate 
and Trimethoprim. X-ray images reproduced from Bourne et al.245 
3.1.4.2 Fatty acid synthesis 
Fatty acid biosynthesis is crucial for membrane and cell-wall generation in all bacteria.248 
Accordingly, all genes involved are essential and therefore potential antibacterial targets.249. 
Both the biotin carboxylase and carboxyltransferase domains of the acetyl coenzyme A 
carboxylase—the first dedicated enzyme in fatty acid biosynthesis—have been utilised for 
developing novel small molecules with antibacterial activities.250,251 In particular, enoyl-acyl 
carrier protein reductase (FabI) has been identified as a particularly attractive target.252 Indeed, 
it was found that both the pyridineamides like Isoniazid and diphenyl ethers like Triclosan 
primarily target FabI (Figure 3.4, A).253,254 Isoniazid is a prodrug that gets activated by the 
catalase-peroxidase enzyme KatG forming Isonicotinoyl radical which reacts with nicotinamide 
adenine dinucleotide (NAD+) forming an Isoniazid–NAD adduct that binds to FabI.255 In contrast, 
Triclosan—as well as other inhibitors within this category, including the structurally dissimilar 
CG400549—binds to the FabI–NAD(P) complex (Figure 3.5, B).256,257 Both Isoniazid and Triclosan 
72  
show slow on/off kinetics increasing the likelihood of bacteria acquiring resistance via missense 
mutations.258 Promisingly, high affinity inhibitors with fast on/off kinetics have also been 
developed against the FabI–NAD(P)H complex, including AFN-1252 which has completed phase 







Figure 3.5 Different classes of antibiotics targeting enoyl-acyl carrier protein reductase (FabI). A) 
Isoniazid prodrug gets activated by the catalase-peroxidase enzyme KatG and reacts with NAD+ forming 
the inhibitor isoniazid–NAD adduct. B) Examples of substituted diphenyl ethers and CG400549 as 
inhibitors of the FabI–NAD(P) complex. C) AFN-1252 and CG400462 are inhibitors of the FabI–NAD(P)H 
complex. Figure adapted from Yao et al.258. 
In addition to FabI, other enzymes involved in fatty acid biosynthesis have been investigated such 
as acetyl coenzyme A carboxylase. In this case both the biotin carboxylase and 
carboxyltransferase domains have been utilised for developing novel small molecules with 
antibacterial activities.250,251 However, none of them were tested in clinical trials. 
3.1.4.3 Lipid A synthesis 
Lipopolysaccharides are vital components of the outer membrane in Gram-negative bacteria 
consisting of the O-antigen and core domains, as well as lipid A which anchors the polysaccharide 
domains to the lipid membrane. Since the zinc-dependent metalloamidase uridine-diphosphate-
3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) is a highly conserved 
enzyme crucial for the biosynthesis of lipid A and therefore the generation of the outer 
membrane, it has been identified as a promising potent broad-spectrum antibacterial target. So 
far two inhibitors of LpxC have reached the phase I clinical trials, ACHN-975 (Figure 3.6) and RC-01 
(structure undisclosed), but both failed due to safety reasons.261,262 
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Figure 3.6 Structure of the antibacterial ACHN-975, a potent inhibitor of LpxC. 
3.1.5 Propionate metabolism 
Many bacteria generate substantial amounts of short-chain fatty acids as by-products of 
fermentation and in the mammalian gastrointestinal tract these entities play crucial roles in 
sustaining healthy microbiota.263 Propionic acid can be converted to propionyl coenzyme A (CoA), 
a valuable building block for lipid biosynthesis and carbon source, also produced during the 
degradation of odd- and branched-chain fatty acids, branched-chain amino acids and 
cholesterol.264 However, propionate and its metabolic derivatives have been found to be highly 
toxic if accumulated within cells.265 Although the mechanism is not fully understood, evidence 
shows that there are several ways by which they might cause lethality, including the inhibition of 
pyruvate dehydrogenase and fructose-1,6-bisphosphatase by propionyl-CoA and 2-
methylcitrate, respectively.266,267 Nevertheless, the growth of most microorganisms has been 
shown to be attenuated by the presence of propionate in the growth medium.265 As a result, 
propionic acid and its salts are widely used as preservatives in the food industry, whilst their use 
as feed additives have been shown to reduce the risk of Salmonella infection in farm animals.265 
Several metabolic pathways have evolved to alleviate the toxicity and facilitate the metabolic 
utility of propionate. Whilst mammalian cells mainly rely on the vitamin B12-dependent 
methylmalonyl pathway, most bacteria and fungi use the 2-methylcitrate (2-MC) cycle.268 Since 
propionate is present in adequate concentrations in many infection sites, the 2-MC cycle has 
been identified as an appealing antibacterial target.264 Indeed, deletion of genes involved with 
the 2-MC cycle was shown to inhibit the growth of many bacterial strains on rich growth media 
containing propionate, and Mycobacterium tuberculosis growth and survival in ex vivo infected 
murine bone-marrow-derived macrophages.269 
The tricarboxylic acid (TCA) cycle is used by all aerobic organisms to generate energy by oxidising 
the acetyl group (from acetyl-CoA) completely to CO2, and it is the most important central 
pathway connecting almost all other individual metabolic pathways.270,271 In the glyoxylate cycle 
the oxidative decarboxylation steps of the TCA cycle are bypassed by two alternative enzymes 
(isocitrate lyase and malate synthase) allowing the conversion of acetyl groups into four-carbon 
dicarboxylic acids thus rendering the original catabolic TCA cycle into an anabolic variant.272,273 
The 2-MC cycle is closely related to the TCA and glyoxylate cycles but utilises propionyl-CoA in an 
aldol reaction with oxaloacetic acid (OAA) forming 2-MC rather than citrate from acetyl-CoA 
(Scheme 3.1). This first step is catalysed by a methylcitrate synthase (encoded by prpC) that has 
some sequence analogy to citrate synthases, however, due to the often relaxed substrate 
specificities of the enzymes involved in both the TCA and the 2-MC cycles, citrate synthases can 
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also catalyse this step leading to lethal accumulation of 2-MC in cells with high propionyl-CoA 
levels and non-functional 2-MC cycle. The dehydration of 2-MC to 2-methyl-cis-aconitate can 
either be catalysed by the methylcitrate dehydratase (PrpD) directly, or via the formation of 4-
methyl-cis-aconitate by the alternative aconitase (AcnD) followed by isomerisation mediated by 
a specific isomerase (PrpF). Next, 2-methyl-cis-aconitate is hydrated by the aconitase (AcnB) to 
form 2-methylisocitrate, which undergoes a retro aldol reaction catalysed by 2-methylisocitrate 
lyase (PrpB) generating pyruvate and succinate. The succinate then undergoes the same 
oxidative steps as in the TCA and glyoxylate cycles reforming oxalate, whereas pyruvate is an 
extremely versatile building block for anabolic processes such as amino acid and fatty acid 
synthesis, and it can also undergo decarboxylative oxidation forming acetyl-CoA for energy 
generation. Both propionyl- and acetyl-CoA can be generated from the corresponding acids by 
acyl-CoA synthases such as the propionyl-CoA synthase PrpE, or they can be formed during 
catabolic processes such as the degradation of fatty acids, carbohydrates and amino acids.264,268  
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Scheme 3.1 Bacterial metabolism of acyl coenzyme A (CoA) units. The tricarboxylic acid (TCA) cycle, 
highlighted in blue, is used to oxidise the acetyl group to CO2 and generate energy under aerobic 
condition. The glyoxylate cycle, highlighted in green, is an anabolic modification of the TCA cycle whereby 
two acetyl groups are converted into four-carbon dicarboxylic acids. The 2-methylcitrate (2-MC) cycle, 
highlighted in red, is an analogous process to the glyoxylate cycle adapted to metabolise propionyl-CoA, 
the propionyl group, highlighted in red, is oxidised to pyruvate, a versatile metabolite. Stereochemistry 
is not shown. 
Recently, a whole cell phenotypic HTS campaign identified several hits inhibiting Mycobacterium 
tuberculosis growth in macrophages; compound V-13–009920 was found to be an inhibitor of 
PrpC with an in vitro IC50 of 4.0 µM and in vivo IC50’s of 3.0 µM and 0.3 µM in macrophages and 
cholesterol media respectively (Figure 3.7).274 Even though promising hits have been identified 




Figure 3.7 Structure of V-13–009920, an inhibitor of Mycobacterium tuberculosis 2-methylcitrate 
synthase (PrpC) and growth in macrophages.  
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3.2 Previous Work 
The 2-MC cycle has been studied extensively as part of the ongoing research into developing our 
understanding of the physiology and virulence of Pseudomonas aeruginosa—a common clinical 
pathogen with outstanding resistance to antibiotic treatments due to its ability to form biofilms—
within the Welch Group. Due to the challenges and high costs associated with HTS campaigns as 
well as the need for developing new chemotypes for the inhibition of this promising target 
pathway, a FBDD approach proved an attractive alternative (see section 1.5). Recently, the P. 
aeruginosa PrpC enzyme was successfully crystallised by Andre J. Wijaya in complex with OAA to 
facilitate structural analysis by X-ray crystallography. Furthermore, a screening—by soaking the 
PrpC–OAA co-crystals in 10 mM solutions of 580 fragments according to Collins et al.275—was 
conducted at the Diamond Light Source, identifying 11 hits (Figure 3.8). This revealed that PrpC 
has a dimeric structure with most of the residues forming the OAA binding pocket contributed 
by a single polypeptide chain. On the other hand, most of the fragment hits bind at the interface 




Figure 3.8 X-ray crystal structure of the dimeric P. aeruginosa PrpC enzyme (the two chains are coloured 
in green and cyan) in complex with OAA (co-crystallised, highlighted in magenta); 1.65 Å resolution, 
PDB6S87. A selection of the initial X-ray hits (soaked) is overlaid in orange, with their structures shown. 
Subsequently, two orthogonal assay methods were utilised to validate the binding of these initial 
X-ray hits. Firstly, a thermal shift assay using differential scanning fluorimetry (DSF)‡ was used, 
where a higher melting temperature correlates to a more stable protein–ligand complex. 
 
‡Ligands were screened at a concentration of 1 mM against PrpC at a concentration of 5 µM in a pH 7.5 
buffer solution of 100 mM NaCl, 50 mM Tris·HCl and 5% (v/v) glycerol using 5X SYPRO Orange Fluorescent 
Dye.282 
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Therefore, this analysis identified F-2 as the strongest binder (with a corresponding melting 
temperature of 50.5 °C) followed by F-8 (49.5 °C), both with an increase in melting temperature 
of approximately 7 °C compared to the DMSO control. Conversely, an in vitro enzymatic assay§ 
measuring the release of free CoA—following the PrpC catalysed aldol condensation between 
propionyl-CoA and OAA—by UV-VIS spectroscopy was used. In this assay, fragment F-7 was in 
fact found to be the most active with a 78% inhibition at 1 mM concentration. Importantly, 
however, F-8 and F-9 also displayed good activity, whilst the remaining fragments displayed only 
moderate activity (Figure 3.9). 
Both X-ray crystallography and thermal shift assays are prone to give false positives—compounds 
that bind to the target strongly enough for detection, but without causing significant changes in 
its function or activity. On the other hand, although the enzymatic assay gives a direct measure 
of compound activity, as all techniques, it still suffers from the possibility of identifying false 
positives (see section 1.4.1). Therefore, indole fragment F-8, with good activities in both assays, 
was identified as a validated fragment hit with the highest confidence and thus the most 
promising starting point for the development of more potent inhibitors of PrpC. 
  
Figure 3.9 Hit validation by differential scanning fluorimetry (DSF, left) and in vitro enzyme inhibition 
(right) assays, compounds were used at 1 mM concentration. The most active fragments are highlighted 
in orange. 
To gain insights into potential avenues for fragment elaboration it was crucial to firstly review 
the structural information. Comparison of the X-ray crystal structures of PrpC in complex with 
OAA and F-8 by A. J. Wijaya revealed that the indole fragment inserts into a hidden pocket 
displacing a loop consisting of residues 352 – 358. As a result, the sidechain of Arg356—one of 
the key residues forming ionic and hydrogen-bonding interactions with OAA within the active site 
of PrpC—was moved away from OAA, whereas the rest of the pocket is unchanged (Figure 3.10). 
Therefore, a dual mechanism of PrpC inhibition by F-8 was hypothesised: 1) displacement of 
Arg356 reduces the affinity and specificity of PrpC to OAA; and 2) the induced conformational 
 
§Ligands were screened at a concentration of 1 mM against PrpC at a concentration of 10 µg/mL in a pH 
7.5 buffer solution of 100 mM KCl, 50 mM HEPES and 4% (v/v) glycerol using 0.15 mM DTNB; absorbance 
was read at 420 nm.283 
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change of the protein as well as the presence of F-8 sterically prevents propionyl-CoA from 
binding to the active site. It was also envisaged that the core fragment could be grown in either 
the OAA pocket or the propionyl-CoA channel, with the most promising exit vector being the C-3 
position of the indole core. 
A B 
  
Figure 3.10 A) Structure of the OAA binding pocket, key residues and OAA are highlighted in magenta. 
B) X-ray crystal structure of PrpC in complex with F-8 (2.0 Å resolution), key residues and F-8 are 
highlighted in orange. 
A common initial hit validation strategy within FBDD involves conducting an SAR-by catalogue 
approach using commercially available analogues to explore a binding pocket. Crucially, this 
avoids lengthy and costly synthetic investment during the early stages of a project. Accordingly, 
34 commercially available analogues of F-8—containing either the initial monobromoindole or a 
dibromoindole core and featuring variable groups in the C-3 position—were first obtained and 
screened by DSF, leading to the identification of further potent fragments (Figure 3.11, A and B). 
The binding modes of these fragments were also resolved using X-ray crystallography showing 
consistency with that of F-8—seen from the overlapping bromoindole units—whereas the C-3 
appendages were found to point in different directions (Figure 3.11, C). However, no IC50 values 
could be determined due to lack of sufficient quantities of these compounds. With these results 








Figure 3.11 A) Screening results of F-8 analogues using differential scanning fluorimetry (DSF), OAA is 
highlighted in magenta, the most potent analogues are highlighted in orange. B) The structures for the 
most potent compounds F-18, F-19, F-27 and F-30 are shown with the bromoindole units highlighted in 
orange. C) An overlay of F-8 and the most potent analogues in orange and OAA in magenta, atomic 
coordinates taken from X-ray crystal structures. 
Inspired by these results, a further five additional analogues featuring modifications to the C-3 
appendages were purchased from Enamine in slightly larger quantities enabling the 
determination of IC50’s. An additional analogue was also synthesised by Dr. Elaine Fowler in the 
Spring Group to investigate the hydrophobic pocket further by replacing the bromine with the 4-
hydroxyphenyl group (Table 3.2). The ester-linked isoxazole F-50 was not adequately soluble for 
the assay, whereas the bromotyrosine derivatives F-47 and F-48 showed much lower potency 
compared to the original fragment hit demonstrating that certain C-3 appendages are not 
suitable for binding. On the other hand, the amine-linked morpholine F-46 and the ester-linked 
pyrrole F-49 were found to be thirty and seven times more potent than F-8 respectively, however, 
a decrease in LE can be observed in both cases—most prominent for F-49—indicating that the 
C-3 appendages do not bind to PrpC as strongly as the bromoindole core itself. The relatively high 
potency of F-51 indicates that the hydrophobic pocket is flexible enough to accommodate a 
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larger hydroxyphenyl group resulting in only a slight decrease in LE. These results show that 
optimising both the C-3 appendage and the hydrophobic core can prove to be viable approaches 
for developing more potent inhibitors for PrpC. 
Table 3.2 Half-maximal inhibitory concentrations and ligand efficiencies of compounds assessed by in 
vitro PrpC enzyme inhibition assay. 
Compound ID Structured IC50e HACh LEi 
F-8a 
 
825 ± 370 µM 12 0.35 
F-46b 
 
27 ± 2 µM 20 0.31 
F-47b 
 
>1 mM 19 N/A 
F-48b 
 
>1 mM 17 N/A 
F-49b 
 
118 ± 19 µM 21 0.26 
F-50b 
 
N/Af 20 N/A 
F-51c 
 
97 ± 24 µMg 17 0.32 
aOriginal fragment hit. bPurchased from Enamine. cSynthesised by Dr. E. Fowler. dBromoindole units 
highlighted in orange. eHalf-maximal inhibitory concentration against PrpC enzyme; data given as best-
fit parameter followed by standard error. fCompound was not soluble enough for assay. gPrecipitation 
was observed during the assay, which may have compromised the result. hHeavy atom count. iLigand 
efficiency in units of kcal mol-1. 
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3.3 Project Outline 
Following these promising preliminary results, a synthetic project was proposed in order to 
elaborate the fragment hits into more potent inhibitors for PrpC. As shown in Figure 3.11, C) the 
crystal structure data highlighted that the varying groups from the C-3 position of the indole ring 
were found to project towards the OAA binding pocket. Moreover, as depicted in Figure 3.10, 
the residues interacting with the α-keto acid unit of OAA remain unaffected by the indole 
fragment binding, whereas Arg356, which is capping the other carboxylate group, is displaced, 
allowing for chemical modifications at that position. In light of these findings (Figure 3.12, A), a 
fragment linking approach (see section 1.5.2) was proposed—utilising varied linkages between 
the aforementioned C-3 position of the indole core and an OAA mimicking warhead—as an ideal 
strategy to rapidly grow the initial fragment and develop a small molecule binder for PrpC with 






   
general indole 
fragment  OAA  linked compound 
Figure 3.12 A) An overlay of PrpC in complex with OAA (fragment and key residues highlighted in 
magenta) and F-8 (fragment and key residues highlighted in orange). Atomic coordinates were taken 
from X-ray crystal structures. B) Proposed fragment linking approach to develop a more potent binder 
for PrpC. The indole and α-keto acid fragments are highlighted in orange and magenta respectively, while 
the linker is shown in green.  
linking
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3.4 Results and Discussion 
3.4.1 Bis-amide linked fragments 
In accordance with the project proposal, different linkers to connect the two binding portions 
were firstly considered. Initially, bis-amide linked compounds 46 were identified due to their 
resemblance to known fragment binders—F18 and OAA—and hypothesised synthetic tractability 
as well as chemical stability (Scheme 3.2). The optimal length was assumed to correspond to 
either the ethylenediamine-based linker (n = 1) or its homologue (n = 2) based on X-ray crystal 
structures (Figure 3.12, A). 
 
 
   
F-18  OAA  46a: n = 1 
46b: n = 2 
Scheme 3.2 Fragment linking approach for bis-amide linked compounds 46a,b. 
Initially, to access the Boc-protected intermediates 47a,b, it was proposed to utilise amide 
couplings to attach varied linker units to the commercially available 5-bromo-1H-indole-3-
carboxylic acid 48 (Scheme 3.3, A). Upon subjection of acid 48 to EDC-mediated amide 
formations, 47a,b were isolated in moderate yields (Scheme 3.3, B). It was hypothesised that the 
activated ester formed has a low reactivity due to conjugation to the indole ring resulting in a 
sluggish coupling reaction with the desired amine. On the other hand, the same conjugation 
increases the acidity of the indole NH, making it possible for a weak base to deprotonate and 




Scheme 3.3 Proposed route to (A) and initial synthesis of (B) the Boc-protected bromoindole-coupled 
amines 47a,b. *Product is contaminated with an inseparable impurity. 
Due to the low observed yields of 47a,b, an alternative strategy to access these molecules was 
proposed, instead proceeding via the acyl chloride intermediate 49. Indeed, treatment of 48 with 
thionyl chloride to form  49, followed by amide formation enabled isolation of 47a in an improved 
78% yield from a one-pot reaction (Scheme 3.4). 
 
Scheme 3.4 Improved synthesis of the Boc-protected bromoindole-coupled amine 47a. 
Next, to enable downstream coupling of the warhead portion, the removal of the protecting 
group was first explored. Treatment of the Boc-protected intermediates with hydrochloric acid 
gave the corresponding crude amine hydrochlorides 50a,b in quantitative yields (Scheme 3.5). 
The direct coupling of amine 50a with OAA was first attempted under the previously used 
coupling conditions (Scheme 3.5). However, in this instance a complex mixture was obtained, 
and the mass of the desired product could not be identified by liquid chromatography–mass 
spectrometry (LCMS) analysis. 
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Scheme 3.5 Attempted synthesis of oxaloacetamide 46a. 
Due to the difficulties associated with the use of OAA in the amide coupling reaction, the 
synthesis of a suitably protected OAA derivative was investigated. First, a simple enolate 
alkylation approach was trialled, but once again resulted in complex mixtures (Scheme 3.6, A). In 
analogy to other α-keto acids described by Flores et al.276 the annulation of OAA with oximes 
(derived from cyclohexanone and cyclohexane carboxaldehyde) was next attempted, however, 
in these efforts only protected pyruvic acids were formed in tandem decarboxylations (Scheme 
3.6, B). Formation of the presumably highly unstable enol acetonide also proved unsuccessful 







Scheme 3.6 Attempted syntheses of protected OAA derivatives: A) enolate alkylation, B) nitrone 
formation and C) enol acetonide formation. 
As a result of the apparent challenges associated with the synthesis of oxaloacetamides, 
simplifying the design of the warhead was assumed to be the most viable strategy. Therefore, 
compound 51a with succinamide warhead devoid of the α-keto functionality was next pursued. 
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To access this analogue, the corresponding amine 50a was reacted with succinic anhydride 
forming 51a in good yield. The alternative glutaramide 51b was also formed in an analogues 
fashion using glutaric anhydride as the acylating agent. Finally, analogue 51c was also synthesised 
in a similar fashion from 50b and succinic anhydride, however, following the tedious and often 
low-yielding purifications associated with these highly polar compounds, 51c was isolated and 
tested as a crude mixture (Scheme 3.7). 
 
Scheme 3.7 Synthesis of bis-amide-linked fragments 51a-c with simplified warheads. Either Et3N or DIPEA 
was used as base (R3N). The structures of 51b,c were tentatively assigned based on HPLC and LCMS data 
and analogy to 51a. *Crude mixture was tested without further purification. 
Bis-amides 51a-c were then tested by both X-ray crystallography for binding and in vitro enzyme 
inhibition assay by A. J. Wijaya to investigate their activity and binding towards PrpC. These 
results showed that compound 51a (with a shorter linker) bound to PrpC in X-ray studies (Figure 
3.13), and additionally demonstrated inhibitory activity (130 µM). However, analogues 51b,c 
(with longer linkers) were found to not bind and also showed no inhibitory activity (Error! 
Reference source not found.). Intermediates 47a,b, 50a,b were also tested and found to be 
inactive in both instances (data not shown). 
Table 3.3 In vitro biological activity of bis-amide linked fragments 51a-c. 
Compound Linker-warhead length (number of atoms) X-ray result IC50 
51a 9 good e- density 130 ± 20 µM 
51b 10 no e- density >1 mM 







Figure 3.13 A) X-ray structure of PrpC in complex with succinamide 51a, the key residues are highlighted 
in orange. B) Fo-Fc map (displated at 3σ) shown in green around 51a without the ligand being placed. 
With these results in hand, compound 51a was additionally tested by A. J. Wijaya in P. aeruginosa 
growth inhibition assay at a concentration of 1 mM to observe in vivo potency. However, no 
activity was observed against the wild type PAO1 cell line. Next, the efflux pump deficient YM64 
cell line was used to inspect if the lack of potency resulted from the quick export of the compound 
from cytoplasm, but still no activity was detected. 
In light of these findings, it was hypothesised that the negatively charged 51a was unable to 
penetrate the cell membranes. To mitigate this issue, it was proposed that the neutral ethyl ester 
prodrug 52 could be in fact readily synthesised and tested in the cellular assay. Accordingly, 
compound 52 was obtained via a HATU-mediated amide coupling reaction between amine 50a 
and the commercially available mono-ethyl succinate in a moderate yield (Scheme 3.8). 
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Scheme 3.8 Synthesis of ethyl ester prodrug 52. 
Once again, however, compound 52 was found to have no effect on the growth of either PAO1 
or YM64 cells. Whilst cell permeability could still be attributed as the cause, there is no evidence 
suggesting that the hypothesised hydrolytic release of the active parent compound 51a took 
place in vivo. Furthermore, another limiting factor was postulated to be the low in vitro potency 
associated with compound 51a. Accordingly, focus was put on optimising the binding interactions 
and developing a more potent inhibitor for PrpC. 
3.4.2 Studies towards optimising the linker 
The X-ray crystallographic data of compound 51a revealed that the succinamide warhead bound 
to the OAA pocket, whilst the indole portion bound in a novel mode to the previous indole 
fragments (Figure 3.14). 
 
Figure 3.14 X-ray structure of PrpC in complex with succinamide 51a (orange), overlaid with OAA 
(magenta) and F-18 (cyan). The key residues are also highlighted in orange. 
This data indicated that the ethylenediamine-based bis-amide linker, in fact was not flexible 
enough to allow for the warhead to reach into the OAA pocket from the original binding mode, 
instead forcing the indole fragment in a suboptimal position. In order to optimise the binding 
mode, strategies for introducing more flexible linkers of varied lengths were proposed (Scheme 
3.9). 
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optimal warhead binding 
suboptimal core binding 
 
flexible linker 
optimal warhead binding 
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Scheme 3.9 Proposed linker optimisation strategy: a suitable flexible linker would allow for the optimal 
binding of both the warhead and the indole core fragments. 
Following the success of the succinamide warhead strategy utilised previously in the formation 
of 51a, it was envisioned that alternative amines could be employed to generate analogues to 
provide further insight to the effect of linker length on binding as well as identify novel 
interactions. In the absence of suitable commercially available indole-containing amines, 
homologues 53a-c with varied alkyl chain length between the succinamide warhead and the 
hydrophobic phenyl ring were designed to enable systematic investigations into the ideal linker 
length. On the other hand, 53d was designed to incorporate the indole unit—although without 
the bromine moiety—of 51a but featured a shorter linker-warhead length of 7 atoms. Following 
the previously used strategy, compounds 53a-d were synthesised in a single step from 
commercially available amines and succinic anhydride (Scheme 3.10). To enable rapid binding 
readout, the crude products were tested by X-ray crystallography without further purification,277 
and their structures were tentatively assigned based on crude 1H NMR data and analogy to 
known compounds. 
 
Scheme 3.10 Synthesis of succinamides 53a-d. Products are tentatively assigned based on crude 1H 
NMR data, and were tested without further purification. 
However, no electron density was observed for any of these fragments, suggesting that the 
presence of a bromoindole core is crucial. Therefore, synthetic efforts were returned to 
compounds based on this bromoindole core but having a more flexible linker. Compounds of type 
54 with fully saturated ether linkers of variable lengths were hypothesised to be both chemically 
stable and synthetically tractable as they could be formed by alkylating the commercially 




Scheme 3.11 Retrosynthetic analysis for flexible ethers 54. 
To access these compounds, firstly, the N-Boc alcohol 56 was synthesised according to conditions 
described by Liu et al.278 This procedure involved the chemoselective silylation of tryptophol 55 
forming the O-TBS derivative 57. Crude 57 was then reacted with Boc2O to form the doubly 
protected intermediate 58 in an excellent yield over two steps. Finally, removal of the TBS group 
by TBAF afforded N-Boc tryptophol 56 in good yield (Scheme 3.12). 
 
Scheme 3.12 Synthesis of N-Boc bromotryptophol 56. 
However, when N-Boc alcohol 56 was subjected to strongly basic alkylation conditions, the 
desired N-Boc tert-butyl ester 59 was not obtained, instead, the isomer 60 was formed in an 
intriguing protecting group shift followed by alkylation on the nitrogen (evidenced by 2D NMR 
analysis, Scheme 3.13). Therefore, the use of weaker bases and higher temperatures was 
attempted, however, despite our efforts, no product could be observed by TLC analysis under 
these conditions. 
 
Scheme 3.13 Synthesis of N-alkyl O-Boc tryptophol 60. 
Following the unsuccessful Boc-protection strategy, it was envisaged that the same approach 
could be employed successfully by utilising a more suitable protecting group that is stable under 
basic conditions. Accordingly, the N-PMB O-TBS tryptophol 61 was obtained in good yield by 
treating crude intermediate 57 with sodium hydride and PMBCl (Scheme 3.14). This route should 
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in principle allow for the successful synthesis of analogues with various flexible linkers, like those 
of type 54, in order to further explore the binding site and ultimately develop more potent 
binders for PrpC. However, due to lack of time the work was not continued. 
 
Scheme 3.14 Synthesis of N-PMB O-TBS tryptophol 61.  
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3.5 Conclusions and Future Work 
Following the interest in identifying novel binders for P. aeruginosa 2-methylcitrate synthase 
using FBDD, succinamide 51a was successfully designed, synthesised and confirmed as a novel 
binder of PrpC with an in vitro IC50 of 130 µM. Unfortunately, no in vivo activity was attained, 
even when the neutral ester prodrug was trialled, suggesting that higher potency and better cell 
permeability are key to biological utility. Since X-ray crystallography revealed a suboptimal 
binding mode of the indole portion, the synthesis of further analogues with more flexible linkers 
were pursued in order to improve potency. Although the initial Boc-protection strategy proved 
fruitless, the alternative PMB-protection should provide a functioning route to such analogues. 
Future work will focus on further exploring the synthesis of several compounds with flexible ether 
linkers, including compound 54. Development of further analogues such as bis-ether linked 62, 
sulfonamide 63 and benzimidazolinone 64 could also be considered for their potentially 
improved water-solubility, polar interactions with the target and chemical stability (Figure 3.15). 
Once the length and conformation of the linker is optimised, it will be also crucial to rigidify it 
(reduce the rotatable bond count) by introducing further rings and unsaturated moieties in order 
to obtain drug-like lead structures. 
 
Figure 3.15 Structures of proposed compounds with flexible ether linkers. 
Further strategies, such as the incorporation of the α-keto acid warhead could also be explored 
to investigate how this region of the molecules affect activity. Based on the number of hydrogen-
bonding interactions directed at the α-carbonyl group (Figure 3.10, A), the presence of a 
hydrogen-bond acceptor at this position should increase the potency of the compounds 
considerably. Possible approaches include the formation of (thio)ether linked pyruvic acids. 
Alternatively, bioisosteric replacements of the ketone and/or acid functional groups of the 
warhead could be employed to form chemically and metabolically more stable analogues, such 
as those shown in Figure 3.16. 
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Figure 3.16 Proposed warheads for improving the binding within the OAA pocket. The R group represents 
an optimised indole fragment attached via a suitable linker to the warhead. The intact α-keto acid unit 
is highlighted in magenta, bioisosteres are highlighted in red. 
This work described the exploration of the C-3 indole position. However, SAR studies on the 
effects of substituents on the C-5 and C-6 positions of the indole ring could also be conducted. 
To that end, the bromine can serve as a multifunctional exit vector facilitating Suzuki cross-
couplings as well as Sonogashira couplings and substitution to azide allowing for potential azide-
alkyne cycloadditions (AAC), thus forming a variety of different (hetero)aromatic groups at this 
position (Scheme 3.15). 
 
Scheme 3.15 Proposed modifications of the indole ring to further explore the binding pocket. R1 
resembles an appropriate construct of a linker and a warhead, whereas R2 and R3 denote general groups 
introduced. 
Finally, given that the target organism is a Gram-negative bacterium, it could be desirable to 
modify any lead compounds with suitable in vitro potency according to the ‘eNTRy rules’—stating 
that compounds with sterically non-hindered basic amines, low three-dimensionality and high 
rigidity are most likely to accumulate inside Gram-negative bacteria.279 Assuming that the 
hypothetical lead compound has a rigidified linker, the 2D and rigid nature are easily attainable, 
leaving the presence of a negatively charged carboxylate (or bioisostere) instead of a positively 
charged amine the likely cause for poor cell permeability. Therefore, the introduction of amine 
functionalities and the use of ester prodrugs to mask the negative charge would be attractive 
strategies to improve the pharmacokinetic properties of potential lead series (Scheme 3.16). 
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4.1 General Remarks 
All reactions were carried out under argon or nitrogen atmosphere using oven-dried glassware 
at room temperature unless otherwise stated. Temperatures of -78 °C were maintained using a 
dry ice acetone bath. Temperatures of 0 °C were maintained using an ice-water bath. Room 
temperature (rt) refers to ambient temperatures. All reagents were used as received from 
commercial sources or prepared as described in the literature unless otherwise stated. 
Acetonitrile (MeCN), dichloromethane (CH2Cl2), methanol (MeOH) and toluene were distilled 
from calcium hydride. Tetrahydrofuran (THF) was dried using sodium wire and distilled from a 
mixture of calcium hydride and lithium aluminium hydride with triphenylmethane as indicator. 
Diethyl ether (Et2O) was distilled from a mixture of calcium hydride and lithium aluminium 
hydride. Ethyl acetate (EtOAc) was distilled before use; petroleum ether (PE) was distilled before 
use and refers to the fraction between 40-60 °C. Anhydrous dimethylformamide (DMF), 1,2-
dichloroethane (DCE), tert-butyl alcohol (tBuOH) and pentane were purchased from commercial 
sources and used without further purification. Reactions were monitored by thin layer 
chromatography (TLC) using pre-coated Merck glass backed silica gel 60 F254 plates and visualised 
by quenching of UV fluorescence (λMax = 254 nm) or by staining with potassium permanganate. 
Retention factors (Rf) are quoted to 0.01. Flash column chromatography was carried out using 
Merck 9385 Kieselgel 60 SiO2 (230-400 mesh) under a positive pressure of dry nitrogen. Yields 
refer to chromatographically and spectroscopically pure compounds unless otherwise stated. 
Melting points (m.p.) were obtained using a Büchi Melting Point B-545 or Gallenkamp MPD350. 
BM2. 5 melting point apparatus and are uncorrected. Optical rotations were measured on an 
Anton Paar MCP 100 Modular Compact Polarimeter. Infrared (IR) spectra were recorded neat on 
a Perkin-Elmer Spectrum One spectrometer using an ATR sampling accessory either as solids or 
liquid films. Selected absorptions (νMax) are reported in wavenumbers (cm-1) with the following 
abbreviations: w, weak; m, medium; s, strong; br, broad. 
Proton magnetic resonance spectra were recorded using an internal deuterium lock at ambient 
temperatures on Bruker Avance III HD (400 MHz; Smart probe), Bruker Avance III (400 MHz; QNP 
Cryoprobe) or Bruker Avance III (500 MHz, DUL Cryoprobe) spectrometers. Chemical shifts (δ) 
are quoted in ppm to the nearest 0.01 ppm and are referenced to the residual non-deuterated 
solvent peak (CDCl3: 7.26, MeOD: 3.31, DMSO-d6: 2.50, acetone-d6: 2.05). Discernible coupling 
constants (J) are reported as measured values in Hertz, rounded to the nearest 0.1 Hz. Data are 
reported as: chemical shift, number of nuclei, multiplicity, coupling constant(s) and assignment. 
Carbon magnetic resonance spectra were recorded using an internal deuterium lock at ambient 
temperatures on Bruker Avance III HD (101 MHz), Bruker Avance III (101 MHz) or Bruker Avance 
98  
500 (126 MHz) spectrometers with broadband proton decoupling. Chemical shifts (δ) are quoted 
in ppm to the nearest 0.1 ppm and are referenced to the deuterated solvent peak (CDCl3: 77.16, 
MeOD: 49.00, DMSO-d6: 39.52, acetone-d6: 29.84). Discernible coupling constants (J) to 19F nuclei 
are reported as measured values in Hertz, rounded to the nearest 0.1 Hz. Data are reported as: 
chemical shift, multiplicity (if not singlet), coupling constant(s) (if any) and assignment. 
Fluorine magnetic resonance spectra were recorded using an internal deuterium lock at ambient 
temperatures on Bruker Avance Neo Prodigy (376 MHz, Cryoprobe) spectrometer. Chemical 
shifts (δ) are quoted in ppm to the nearest 0.1 ppm. Data are reported as: chemical shift, number 
of nuclei, multiplicity and coupling constant(s). 
High resolution mass spectrometry (HRMS) measurements were recorded with a Micromass Q-
TOF, Waters Vion IMS Qtof or a Waters LCT Premier TOF mass spectrometer using Electrospray 
ionisation (ESI) techniques. Mass values are reported within the ±5 ppm error limit.  
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4.2 Procedures and Analytical Data 
4.2.1 Building block synthesis 
Ethyl 2-allyl-2-aminopent-4-enoate 1a 
 
To a solution of 2 (500 mg, 1.87 mmol) in THF (20 mL) at 0 °C was added tBuOK (629 mg, 
5.61 mmol) and the reaction stirred for 10 min, followed by the dropwise addition of allyl 
bromide (970 µL, 11.2 mmol) at 0 °C. The reaction mixture was warmed to rt and stirred 
overnight. Upon completion, HCl (3 M aq, 10 mL) was added and the reaction stirred for 10 min 
before diluting with H2O (20 mL). The reaction mixture was extracted with CH2Cl2 (3 × 20 mL). 
The aqueous phase was basified with Na2CO3 (pH ≈ 12). The basic aqueous layer was then 
extracted with EtOAc (3 × 30 mL), and the combined organic layers were dried over MgSO4, 
filtered and concentrated in vacuo to yield the crude product 1a (229 mg, 1.25 mmol, 67%) as a 
colourless oil. The crude product 1a was taken on to the next step without further purification.  
Rf = 0.41 (EtOAc). IR (ATR) νMax 3379 (w, N-H), 3078 (w, C-H), 2980 (w, C-H), 1729 (s, C=O), 1640 
(m, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 5.75 – 5.64 (2H, m, H4), 5.16 – 5.10 (4H, m, H5), 4.17 
(2H, q, J = 7.1 Hz, H6), 2.55 (2H, br dd, J = 13.5, 6.5 Hz, H3a), 2.26 (2H, br dd, J = 13.5, 8.3 Hz, H3b), 
1.67 (2H, br s, NH2), 1.27 (3H, t, J = 7.1 Hz, H7) ppm. 13C NMR (101 MHz, CDCl3) δ 176.4 (C1), 132.7 
(C4), 119.6 (C5), 61.2 (C6), 60.4 (C2), 44.2 (C3), 14.5 (C7) ppm. HRMS (ESI) calcd for 
[C10H17NO2Na]+: 206.1151, found 206.1147. 
Ethyl 2-allyl-2-aminohex-5-enoate 1b 
 
To a solution of 2 (10.35 g, 38.7 mmol) in THF (250 mL) was added tBuOK (10.9 g, 96.7 mmol) and 
4-bromo-1-butene (11.8 mL, 116 mmol) in three batches over a period of 64 h. Upon completion, 
the reaction was cooled to 0 °C, tBuOK (6.52 g, 58.1 mmol) was added and stirred for 10 min, 
followed by the dropwise addition of allyl bromide (5.03 mL, 58.1 mmol). The reaction mixture 
was warmed to rt and stirred for 5 h. A further amount of tBuOK (2.17 g, 19.3 mmol) and allyl 
bromide (1.68 mL, 19.3 mmol) were added and the mixture stirred for 1 h. Upon completion HCl 
(3 M aq, 50 mL) was added and the reaction stirred for 10 min before removing the organic 
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solvent in vacuo. The aqueous residue was washed with Et2O (3 × 50 mL). The aqueous phase 
was basified with Na2CO3 (pH ≈ 12). The basic aqueous layer was then extracted with EtOAc (3 × 
50 mL), and the combined organic layers were dried over MgSO4, filtered and concentrated in 
vacuo to yield the crude product 1b (4.67 g, 23.8 mmol, 61%) as a pale orange oil. The crude 
product 1b was taken on to the following steps without further purification.  
Rf = 0.10 (PE/EtOAc, 4:1). IR (ATR) νMax 3374 (w, N-H), 3077 (w, C-H), 2979 (w, C-H), 2925 (w, C-
H), 1726 (s, C=O), 1640 (m, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 5.83 – 5.61 (2H, m, H4, H10), 
5.15 – 5.09 (2H, m, H5), 5.00 (1H, dq, J = 17.0, 1.6 Hz, H11t), 4.93 (1H, dq, J = 10.1, 1.6 Hz, H11c), 
4.16 (2H, q, J = 7.1 Hz, H6), 2.55 (1H, br dd, J = 13.5, 6.4 Hz, H3a), 2.24 (1H, br dd, J = 13.5, 8.5 Hz, 
H3b), 2.17 – 2.06 (1H, m, H9a), 1.99 – 1.88 (1H, m, H9b), 1.88 – 1.80 (1H, m, H8a), 1.67 – 1.58 
(3H, m, H8b, NH2), 1.27 (3H, t, J = 7.1 Hz, H7) ppm. 13C NMR (101 MHz, CDCl3) δ 176.7 (C1), 138.0 
(C10), 132.8 (C4), 119.6 (C5), 115.0 (C11), 61.1 (C6), 60.5 (C2), 44.5 (C3), 39.2 (C8), 28.5 (C9), 14.4 
(C7) ppm. HRMS (ESI) calcd for [C11H19NO2Na]+: 220.1313, found 220.1309. 
Ethyl 2-allyl-2-aminohept-6-enoate 1c 
 
To a solution of 2 (1.00 g, 3.74 mmol) in THF (40 mL) at 0 °C was added tBuOK (629 mg, 
5.61 mmol) and the reaction stirred for 10 min, followed by the dropwise addition of 5-bromo-
1-pentene (1.33 mL, 11.2 mmol). The reaction mixture was warmed to rt and stirred overnight. 
Upon completion, the reaction was diluted with NH4Cl (sat. aq, 50 mL) and extracted with EtOAc 
(3 × 50 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The residue was purified by flash column chromatography 
(silica gel, PE/EtOAc, 9:1) to give crude 3c (825 mg) as a colourless oil. To a solution of crude 3c 
(550 mg) in THF (20 mL) at 0 °C was added tBuOK (276 mg, 2.46 mmol) and the reaction stirred 
for 10 min, followed by the dropwise addition of allyl bromide (426 µL, 4.92 mmol). The reaction 
mixture was warmed to rt and stirred overnight. Upon completion, the reaction was diluted with 
NH4Cl (sat. aq, 25 mL) and extracted with EtOAc (3 × 25 mL). The combined organic layers were 
washed with brine (25 mL), dried over MgSO4, filtered and concentrated in vacuo. The residue 
was purified by flash column chromatography (silica gel, PE/Et2O, 9:1) to give a crude 
intermediate (343 mg) as a colourless oil. To a solution of the crude intermediate (300 mg) in THF 
(8.0 mL) was added HCl (3 M aq, 1.0 mL) and the reaction stirred for 10 min before diluting with 
H2O (25 mL). The reaction mixture was extracted with CH2Cl2 (3 × 25 mL). The aqueous phase was 
basified with Na2CO3 (pH ≈ 12). The basic aqueous layer was then extracted with EtOAc (3 × 
25 mL), and the combined organic layers were dried over MgSO4, filtered and concentrated in 
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vacuo to yield the crude product 1c (144 mg, 0.681 mmol, 31%) as a colourless oil. The crude 
product 1c was taken on to the next step without further purification.  
Rf = 0.10 (PE/EtOAc, 4:1). IR (ATR) νMax 3376 (w, N-H), 2981 (w, C-H), 2932 (w, C-H), 1728 (s, C=O), 
1640 (m, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 5.80 – 5.60 (2H, m, H4, H11), 5.14 – 5.07 (2H, m, 
H5), 5.00 – 4.90 (2H, m, H12), 4.15 (2H, q, J = 7.2 Hz, H6), 2.53 (1H, br dd, J = 13.5, 6.5 Hz, H3a), 
2.21 (1H, br dd, J = 13.5, 8.4 Hz, H3b), 2.01 (1H, br q, J = 7.2 Hz, H10), 1.78 – 1.38 (5H, m, H8, H9a, 
NH2), 1.28 – 1.15 (4H, m, H9b, H7) ppm. 13C NMR (101 MHz, CDCl3) δ 176.8 (C1), 138.3 (C11), 
132.9 (C4), 119.5 (C5), 114.9 (C12), 61.1 (C6), 60.6 (C2), 44.4 (C3), 39.6 (C8), 33.9 (C10), 23.3 (C9), 
14.4 (C7) ppm. HRMS (ESI) calcd for [C12H22NO2]+: 212.1644, found 212.1642. 
Ethyl ((diphenylmethylene)amino)acetate 2 
 
Following a slightly modified version of a reported procedure,174 ethyl glycinate hydrochloride 
(33.6 g, 240 mmol), benzophenone (43.8 g, 240 mmol) and DIPEA (42.0 mL, 240 mmol) were 
added to toluene (150 mL) and the resultant suspension was refluxed for 2 days using Dean-Stark 
apparatus. The mixture was cooled to room temperature, diluted with EtOAc (300 mL), washed 
with NaHCO3 (sat. aq, 300 + 4 × 100 mL), brine (100 mL), dried over MgSO4 then filtered through 
a short silica gel plug eluted with EtOAc and concentrated in vacuo. The crude product was 
recrystallised from Et2O/PE three times to yield pure 2 (10.4 g, 38.9 mmol, 16%) as transparent 
crystals.  
Rf = 0.15 (PE/EtOAc, 9:1). m.p. 52.1 – 52.9 °C(Et2O/PE). IR (ATR) νMax 3049 (w, C-H), 2980 (w, C-
H), 2911 (w, C-H), 1748 (s, C=O), 1619 (m, C=N), 1574 (w, C=C), 1491 (w, C=C), 1476 (w, C=C), 
1444 (m, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.68 – 7.63 (2H, m, H8-13), 7.50 – 7.31 (6H, m, 
H8-13), 7.21 – 7.16 (2H, m, H8-13), 4.21 (2H, q, J = 7.1 Hz, H3), 4.20 (2H, s, H2), 1.27 (3H, t, J = 
7.1 Hz, H4) ppm. 13C NMR (101 MHz, CDCl3) δ 172.0 (C5), 170.8 (C1), 139.4 (C6/7), 136.2 (C6/7), 
130.6 (C12/13), 129.0 (C12/13), 128.9 (C8/9/10/11), 128.8 (C8/9/10/11), 128.2 (C8/9/10/11), 
127.8 (C8/9/10/11), 61.0 (C3), 55.9 (C2), 14.3 (C4) ppm. HRMS (ESI) calcd for [C17H17NO2Na]+: 
290.1157, found 290.1170. 
These characterization data are in accordance with that previously reported in the literature.174  
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4.2.2 Syntheses of different carbocycles 
Ethyl 2-allyl-2-(3-ethoxy-3-oxopropanamido)pent-4-enoate 5a 
 
To a solution of 1a (200 mg, 1.09 mmol) in CH2Cl2 (10 mL) was added Et3N (304 µL, 2.18 mmol) 
followed by ethyl malonyl chloride (210 µL, 1.64 mmol) at 0 °C and stirred for 20 min. The 
reaction mixture was diluted with NH4Cl (sat. aq, 10 mL) and H2O (5 mL) and stirred for 10 min 
then extracted with CH2Cl2 (4 × 10 mL). The combined organic layers were dried over MgSO4, 
filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (silica gel, PE/EtOAc, 4:1) to yield 5a (264 mg, 0.888 mmol, 81%) as a 
transparent viscous oil.  
Rf = 0.17 (PE/EtOAc, 4:1). IR (ATR) νMax 3310 (w, br, N-H), 3074 (w, C-H), 2981 (w, C-H), 1733 (s, 
C=O), 1656 (s, C=O and C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.58 (1H, br s, NH), 5.65 – 5.53 (2H, 
m, H4), 5.09 – 5.02 (4H, m, H5), 4.24 – 4.15 (4H, m, H6, H11), 3.26 (2H, s, H9), 3.15 (2H, br dd, J = 
13.9, 7.2 Hz, H3a), 2.52 (2H, br dd, J = 13.9, 7.4 Hz, H3b), 1.29 – 1.24 (6H, m, H7, H12) ppm. 13C 
NMR (101 MHz, CDCl3) δ 172.6 (C1), 168.8 (C10), 164.0 (C8), 132.2 (C4), 119.1 (C5), 64.4 (C2), 
62.0 (C6/11), 61.6 (C6/11), 42.6 (C9), 39.1 (C3), 14.3 (C7/12), 14.1 (C7/12) ppm. HRMS (ESI) calcd 
for [C15H24NO5]+: 298.1654, found 298.1644. 
Ethyl 2-allyl-2-(3-ethoxy-3-oxopropanamido)hex-5-enoate 5b 
 
To a solution of 1b (1.0 g, 5.07 mmol) in CH2Cl2 (50 mL) at 0 °C was added Et3N (1.52 mL, 
10.9 mmol), followed by the dropwise addition of ethyl malonyl chloride (1.04 mL, 8.11 mmol) 
and the reaction stirred for 30 min. The reaction mixture was diluted with NH4Cl (sat. aq, 25 mL) 
and stirred for 10 min then extracted with CH2Cl2 (3 × 20 mL). The combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (silica gel, PE/EtOAc, 4:1) to yield 5b (1.27 g, 4.27 mmol, 84%) as a pale 
yellow viscous oil.  
Rf = 0.23 (PE/EtOAc, 4:1). IR (ATR) νMax 3337 (w, br, N-H), 2980 (w, C-H), 1732 (s, C=O), 1681 (m, 
C=O), 1650 (m, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.67 (1H, br s, NH), 5.79 – 5.67 (1H, m, 
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H15), 5.65 – 5.51 (1H, m, H4), 5.10 – 5.02 (2H, m, H5), 5.02 – 4.94 (2H, m, H16), 4.27 – 4.18 (4H, 
m, H6, H11), 3.29 (2H, s, H9), 3.26 – 3.18 (1H, m, H3a), 2.61 – 2.47 (2H, m, H3b, H13a), 2.10 – 
1.97 (1H, m, H14a), 1.92 – 1.74 (2H, m, H13b, H14b), 1.32 – 1.26 (6H, m, H7, H12), ppm. 13C NMR 
(101 MHz, CDCl3) δ 173.2 (C1), 168.9 (C10), 163.9 (C8), 137.5 (C15), 132.3 (C4), 119.0 (C5), 115.3 
(C16), 64.7 (C2), 62.1 (C6), 61.7 (C11), 42.8 (C9), 39.5 (C3), 34.1 (C13), 28.7 (C14), 14.3 (C7/12), 
14.2 (C7/12) ppm. HRMS (ESI) calcd for [C16H26NO5]+: 312.1811, found 312.1820. 
Ethyl 2-allyl-2-(3-ethoxy-3-oxopropanamido)hept-6-enoate 5c 
 
To a solution of 1c (100 mg, 0.473 mmol) in CH2Cl2 (5.0 mL) at 0 °C was added Et3N (132 µL, 
0.946 mmol) followed by ethyl malonyl chloride (91 µL, 0.710 mmol) and the reaction stirred for 
20 min. The reaction mixture was diluted with NH4Cl (sat. aq, 10 mL) and H2O (5 mL) and stirred 
for 10 min then extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (silica gel, PE/EtOAc, 4:1) to yield 5c (113 mg, 0.347 mmol, 73%) as a 
transparent viscous oil.  
Rf = 0.19 (PE/EtOAc, 4:1). IR (ATR) νMax 3326 (w, br, N-H), 3081 (w, C-H), 2982 (w, C-H), 2939 (w, 
C-H), 1734 (s, C=O), 1682 (s, C=O and C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.63 (1H, br s, NH), 
5.78 – 5.66 (1H, m, H16), 5.63 – 5.52 (1H, m, H4), 5.07 – 5.00 (2H, m, H5), 5.00 – 4.90 (2H, m, 
H17), 4.26 – 4.16 (4H, m, H6, H11), 3.27 (2H, s, H9), 3.18 (1H, br dd, J = 14.0, 7.2 Hz, H3a), 2.50 
(1H, br dd, J = 14.0, 7.5 Hz, H3b), 2.41 (1H, br td, J = 13.0, 4.6 Hz, H13a), 2.08 – 1.92 (2H, m, H15), 
1.82 – 1.71 (1H, m, H13b), 1.44 – 1.32 (1H, m, H14a), 1.32 – 1.24 (6H, m, H7, H12), 1.14 – 1.01 
(1H, m, H14b) ppm. 13C NMR (101 MHz, CDCl3) δ 173.4 (C1), 169.0 (C10), 163.9 (C8), 138.3 (C16), 
132.4 (C4), 119.0 (C5), 115.0 (C17), 64.9 (C2), 62.0 (C6/11), 61.7 (C6/11), 42.8 (C9), 39.4 (C3), 34.5 
(C13), 33.5 (C15), 23.5 (C14), 14.4 (C7/12), 14.2 (C7/12) ppm. HRMS (ESI) calcd for 
[C17H27NO5Na]+: 348.1781, found 348.1770.  
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5,5-Diallylpyrrolidine-2,4-dione (10a) 7a 
 
To a solution of 5a (200 mg, 0.673 mmol) in THF (10 mL) was added tBuOK (113 mg, 1.01 mmol) 
and the reaction heated under reflux for 2 h. The reaction mixture was diluted with EtOAc 
(20 mL), HCl (3 M aq, 10 mL) and brine (20 mL) and stirred for 10 min. The organic layer was then 
separated and the aqueous layer was extracted with EtOAc (2 × 20 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated in vacuo. The residue was dissolved in 
MeCN/H2O (9:1, 10 mL) and heated under reflux for 1 h, then concentrated in vacuo. The crude 
product was purified by flash column chromatography (silica gel, PE/EtOAc, 1:1) to yield 7a 
(104 mg, 0.580 mmol, 86%) as a white amorphous solid.  
Rf = 0.13 (PE/EtOAc, 1:1). IR (ATR) νMax 3212 (w, br, N-H), 2981 (w, C-H), 1768 (m, C=O, ketone), 
1698 (s, C=O, amide), 1640 (m, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.64 (H, br s, NH), 5.77 – 
5.64 (2H, m, H6), 5.23 – 5.12 (4H, m, H7), 2.89 (2H, s, H2), 2.50 – 2.35 (4H, m, H5) ppm. 13C NMR 
(101 MHz, CDCl3) δ 209.1 (C3), 170.5 (C1), 130.5 (C6), 121.5 (C7), 71.5 (C4), 41.7 (C2), 41.3 
(C5) ppm. HRMS (ESI) calcd for [C10H14NO2]+: 180.1025, found 180.1021. 
5-Allyl-5-(but-3-en-1-yl)pyrrolidine-2,4-dione (10b) 7b 
 
To a solution of 5b (2.03 g, 6.81 mmol) in THF (70 mL) was added tBuOK (1.15 g, 10.2 mmol) and 
the reaction heated under reflux for 1 h. Upon completion, the reaction was diluted with HCl (3 
M aq, 50 mL) and heated under reflux for 30 min. The organic solvent was removed in vacuo and 
the aqueous layer was extracted with CH2Cl2 (3 × 50 mL). The combined organic layers were dried 
over MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (silica gel, PE/EtOAc, 1:1) to yield 7b (1.24 g, 6.42 mmol, 94%) as a white 
amorphous solid.  
Rf = 0.10 (PE/EtOAc, 4:1). IR (ATR) νMax 3282 (w, br, N-H), 3081 (w, C-H), 2921 (w, C-H), 2848 (w, 
C-H), 1639 (s, C=O and C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.90 – 7.62 (1H, m, NH), 5.74 – 5.62 
(2H, m, H6, H10), 5.17 (1H, d, J = 10.4 Hz, H7c), 5.13 (1H, d, J = 17.4 Hz, H7t), 5.00 (1H, d, J = 
17.4 Hz, H11t), 4.95 (1H, d, J = 10.4 Hz, H11c), 2.91 (1H, d J = 22.3 Hz, H2a), 2.88 (1H, d J = 22.3 Hz, 
H2b), 2.46 – 2.31 (2H, m, H5), 2.22 – 2.11 (1H, m, H9a), 2.03 – 1.87 (2H, m, H8a, H9b), 1.77 – 1.67 
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(1H, m, H8b) ppm. 13C NMR (101 MHz, CDCl3) δ 209.9 (C3), 171.6 (C1), 137.0 (C10), 130.5 (C6), 
121.3 (C7), 116.1 (C11), 71.6 (C4), 42.8 (C5), 41.8 (C2), 35.8 (C8), 28.4 (C9) ppm. HRMS (ESI) calcd 
for [C11H16NO2]+: 194.1181, found 194.1184. 
5-Allyl-5-(pent-4-en-1-yl)pyrrolidine-2,4-dione (10c) 7c 
 
To a solution of 5c (72 mg, 0.221 mmol) in THF (4.0 mL) was added tBuOK (37 mg, 0.332 mmol) 
and the reaction heated under reflux for 2 h. The reaction mixture was diluted with HCl (3 M aq, 
4.0 mL) and brine (10 mL) and stirred for 10 min. The organic layer was then removed and the 
aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were dried 
over MgSO4, filtered and concentrated in vacuo. The residue was dissolved in MeCN/H2O (9:1, 
4.0 mL) and heated under reflux for 1 h, then concentrated in vacuo. The crude product was 
purified by flash column chromatography (silica gel, PE/EtOAc, 1:1) to yield 7c (40 mg, 
0.193 mmol, 87%) as a transparent viscous oil.  
Rf = 0.22 (PE/EtOAc, 1:1). IR (ATR) νMax 3196 (w, br, N-H), 2943 (w, C-H), 1641 (s, C=O and C=C) 
cm-1. 1H NMR (400 MHz, CDCl3) δ 7.68 – 7.58 (1H, m, NH), 5.77 – 5.62 (2H, m, H6, H11), 5.19 – 
5.09 (2H, m, H7), 5.01 – 4.93 (2H, m, H12), 2.91 (1H, d, J = 22.4 Hz, H2a), 2.89 (1H, d, J = 22.4 Hz, 
H2b), 2.46 – 2.31 (2H, m, H5), 2.06 – 1.98 (2H, m, H10), 1.82 – 1.72 (1H, m, H8a), 1.65 – 1.55 (1H, 
m, H8b), 1.55 – 1.43 (1H, m, H9a), 1.27 – 1.14 (1H, m, H9b) ppm. 13C NMR (101 MHz, CDCl3) δ 
210.0 (C3), 171.4 (C1), 137.6 (C11), 130.7 (C6), 121.2 (C7), 115.6 (C12), 71.9 (C4), 41.8 (C5), 41.7 
(C2), 36.4 (C8), 33.6 (C10), 23.0 (C9) ppm.  
HRMS (ESI) calcd for [C12H17NO2Na]+: 230.1152, found 230.1146. 
1-Azaspiro[4.4]non-7-ene-2,4-dione 8a 
 
A solution of 7a (95 mg, 0.530 mmol) in toluene (25 mL) was degassed with argon and heated to 
70 °C, followed by the addition of Grubbs II catalyst (17 mg, 20 µmol) and the reaction stirred for 
90 min, then concentrated in vacuo. The residue was purified by flash column chromatography 
(silica gel, CH2Cl2 then EtOAc) to yield 8a (55.0 mg, 0.364 mmol, 69%) as a brown amorphous 
solid.  
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Rf = 0.23 (EtOAc). m.p. 154 – 155 °C (Et2O). IR (ATR) νMax 3180 (w, br, N-H), 3083 (w, C-H), 2949 
(w, C-H), 2846 (w, C-H), 1764, (s, C=O, ketone), 1702 (s, C=O, amide), 1673 (s, C=C) cm-1. 1H NMR 
(400 MHz, CDCl3) δ 6.89 (1H, bs, NH), 5.69 (2H, s, H6), 3.08 (2H, s, H2), 2.97 (2H, d, J = 15.9 Hz, 
H5a), 2.53 (2H, d, J = 15.9 Hz, H5b) ppm. 13C NMR (101 MHz, CDCl3) δ 210.1 (C3), 169.9 (C1), 127.6 




A solution of 7b (1.12 g, 5.78 mmol) in CH2Cl2 (250 mL) was degassed with argon, followed by the 
addition of Grubbs II catalyst (49.1 mg, 58 µmol) and the reaction heated under reflux for 1 h, 
then concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 
CH2Cl2 then EtOAc) to yield 8b (950 mg, 5.75 mmol, 99%) as a pale brown amorphous solid.  
Rf = 0.23 (EtOAc). IR (ATR) νMax 3177 (w, br, N-H), 3033 (w, C-H), 2921 (w, C-H), 2845 (w, C-H), 
1650 (s, C=O and C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.65 (1H, bs, NH), 5.85 – 5.79 (1H, m, 
H7), 5.72 – 5.66 (1H, m, H6), 3.12 (1H, d, J = 22.1 Hz, H2a), 3.06 (1H, d, J = 22.1 Hz, H2b), 2.46 – 
2.31 (2H, m, H5), 2.22 – 2.11 (1H, m, H9a), 2.03 – 1.87 (2H, m, H8a, H9b), 1.77 – 1.67 (1H, m, 
H8b) ppm. 13C NMR (101 MHz, CDCl3) δ 209.5 (C3), 170.7 (C1), 126.8 (C7), 123.1 (C6), 66.3 (C4), 




A solution of 7c (38 mg, 0.183 mmol) in CH2Cl2 (10 mL) was degassed with argon, followed by the 
addition of Grubbs II catalyst (15 mg, 18 µmol) and the reaction heated under reflux for 30 min, 
then concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 
CH2Cl2 then PE/EtOAc, 1:1) to yield 8c (25.5 mg, 0.142 mmol, 78%) as a pale brown amorphous 
solid.  
Rf = 0.15 (PE/EtOAc, 1:1). IR (ATR) νMax 3199 (w, br, N-H), 2929 (w, C-H), 2836 (w, C-H), 1630 (s, 
C=O and C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.68 (1H, b s, NH), 6.11 – 6.03 (1H, m, H7), 5.67 
– 5.58 (1H, m, H6), 3.08 (2H, s, H2), 2.66 – 2.59 (1H, m, H5a), 2.35 – 2.25 (1H, m, H8a), 2.22 – 2.11 
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(2H, m, H5b, H8b), 2.06 – 1.95 (1H, m, H10a), 1.95 – 1.85 (1H, m, H10b), 1.85 – 1.74 (1H, m, H9a), 
1.41 – 1.29 (1H, m, H9b) ppm. 13C NMR (101 MHz, CDCl3) δ 209.0 (C3), 169.5 (C1), 136.2 (C7), 
125.2 (C6), 67.4 (C4), 39.7 (C2), 39.0 (C10), 34.5 (C5), 28.1 (C8), 20.7 (C9) ppm. HRMS (ESI) calcd 
for [C10H13NO2Na]+: 202.0839, found 202.0832. 
4.2.3 Synthesis of enantiopure (R)-8b 
Methyl (R)-2-allyl-2-(3-ethoxy-3-oxopropanamido)hex-5-enoate (R)-5d 
 
To a solution of (R)-1d (140 mg, 0.764 mmol) in CH2Cl2 (6.0 mL) at 0 °C was added a solution of 
Et3N (213 µL, 1.53 mmol) in CH2Cl2 (1.0 mL), followed by the dropwise addition of a solution of 
ethyl malonyl chloride (147 µL, 1.15 mmol) in CH2Cl2 (1.0 mL) and the reaction stirred for 30 min. 
The reaction mixture was diluted with NH4Cl (sat. aq, 10 mL) and stirred for 10 min then extracted 
with CH2Cl2 (3 × 10 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by flash column chromatography (silica 
gel, PE/EtOAc, 4:1) to yield (R)-5d (105 mg, 0.353 mmol, 46%) as a transparent viscous oil.  
Rf = 0.33 (PE/EtOAc, 2:1). IR (ATR) νMax 3327 (w, br, N-H), 3080 (w, C-H), 2980 (w, C-H), 1735 (s, 
C=O), 1656 (s, C=O and C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.65 (1H, br s, NH), 5.78 – 5.67 (1H, 
m, H14), 5.65 – 5.53 (1H, m, H4), 5.10 – 5.03 (2H, m, H5), 4.98 (1H, dq, J = 17.2, 1.5 Hz, H15t), 
4.93 (1H, br d, J = 10.1 Hz, H15c), 4.22 (2H, q, J = 7.2 Hz, H10), 3.77 (3H, s, H6), 3.29 (2H, s, H8), 
3.20 (1H, br dd, J = 13.9, 7.3 Hz, H3a), 2.59 – 2.48 (2H, m, H3b, H12a), 2.09 – 1.99 (1H, m, H13b), 
1.93 – 1.75 (2H, m, H12b, H13b), 1.29 (3H, t, J = 7.2 Hz, H11) ppm. 13C NMR (101 MHz, CDCl3) δ 
173.7 (C1), 169.0 (C9), 164.0 (C7), 137.4 (C14), 132.3 (C4), 119.1 (C5), 115.3 (C15), 64.8 (C2), 61.8 
(C10), 52.9 (C6), 42.7 (C8), 39.5 (C3), 34.1 (C12), 28.7 (C13), 14.2 (C11) ppm. HRMS (ESI) calcd for 
[C15H23NO5Na]+: 320.1474, found 320.1473. [α]D20 +13.3° (c = 0.120, MeOH). 
(R)-5-Allyl-5-(but-3-en-1-yl)pyrrolidine-2,4-dione (R)-7b 
 
To a solution of (R)-5d (95 mg, 0.319 mmol) in THF (2.5 mL) was added a solution of tBuOK 
(54 mg, 0.479 mmol) in THF (1.0 mL), and the reaction heated under reflux for 2 h. The reaction 
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mixture was diluted with EtOAc (10 mL) and HCl (1 M aq, 10 mL) and stirred for 10 min. The 
organic layer was then separated and the aqueous layer was extracted with EtOAc (3 × 10 mL). 
The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo to give 
a colourless oil (78 mg). A solution of the oil (70 mg) in MeCN/H2O (9:1, 3.5 mL) was heated under 
reflux for 1 h, then concentrated in vacuo. The crude product was purified by flash column 
chromatography (silica gel, PE/EtOAc, 1:1) to yield (R)-7b (51 mg, 0.264 mmol, 92%) as a 
transparent viscous oil. 
Analytical data matched that of 7b. [α]D20 +111.9° (c = 0.176, MeOH). 
(R)-1-Azaspiro[4.5]dec-7-ene-2,4-dione (R)-8b 
 
A solution of (R)-7b (39 mg, 0.202 mmol) in CH2Cl2 (10 mL) was degassed with argon, followed by 
the addition of Grubbs II catalyst (17 mg, 20 µmol) and the reaction heated under reflux for 1 h, 
then concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 
CH2Cl2 then EtOAc) to yield (R)-8b (32.5 mg, 0.197 mmol, 97%) as a brown amorphous solid. 
Analytical data matched that of 8b. [α]D20 +45.4° (c = 0.410, MeOH). 
4.2.4 Syntheses of different core heterocycles 
2-Chloro-N-(4-(hydroxymethyl)octa-1,7-dien-4-yl)acetamide 13 
 
To a solution of 16 (71 mg, 0.278 mmol) in THF (6.0 mL) was added hydrochloric acid (conc. aq, 
1.0 mL) and heated under reflux for 3 h, then concentrated in vacuo. To a solution of the residue 
in CH2Cl2 (3.0 mL) was added Et3N (116 µL, 0.834 mmol) followed by chloroacetyl chloride 
(21.6 µL, 0.278 mmol) at 0 °C and stirred for 90 minutes. The reaction mixture was diluted with 
NH4Cl (sat. aq, 10 mL) and stirred for 10 minutes then extracted with CH2Cl2 (3 × 10 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The crude 
product was purified by flash column chromatography (silica gel, CH2Cl2 to CH2Cl2/Et2O, 9:1) to 
yield 13 (37.0 mg, 0.160 mmol, 57%) as a colourless oil. 
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Rf = 0.38 (PE/EtOAc, 1:1). IR (ATR) νMax 3285 (m, br, O-H and N-H), 3078 (w, C-H), 2936 (w, C-H), 
1656 (s, C=O), 1640 (w, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.73 (1H, m, NH), 5.86 – 5.74 (2H, 
m, H4, H8), 5.24 –5.17 (2H, m, H5), 5.05 (1H, dq, J = 17.1, 1.6 Hz, H9t), 4.97 (1H, dq, J = 10.3, 
1.2 Hz, H9c), 4.33 (1H, t, J = 6.3 Hz, OH), 4.02 (2H, s, H11), 3.75 – 3.65 (2H, m, H1), 2.46 (1H, br 
dd, J = 14.0, 6.8 Hz, H3a), 2.33 (1H, br dd, J = 13.9, 8.2 Hz, H3b), 2.20 – 1.99 (2H, m, H7), 1.91 – 
1.79 (1H, m, H6a), 1.74 – 1.65 (1H, m, H6b) ppm. 13C NMR (101 MHz, CDCl3) δ 166.6 (C10), 137.8 
(C8), 132.1 (C4), 120.5 (C5), 115.3 (C9), 67.1 (C1), 61.0 (C2), 43.1 (C11), 39.1 (C3), 33.3 (C6), 27.8 
(C7) ppm. HRMS (ESI) calcd for [C11H18NO2NaCl]+: 254.0918, found 254.0914. 
Ethyl 2-allyl-2-(2-chloroacetamido)hex-5-enoate 14 
 
To a solution of 1b (197 mg, 1.00 mmol) in CH2Cl2 (10 mL) was added Et3N (279 µL, 2.00 mmol) 
followed by chloroacetyl chloride (117 µL, 1.50 mmol) at 0 °C and stirred for 20 minutes. The 
reaction mixture was diluted with NH4Cl (sat. aq, 10 mL) and water (5 mL) and stirred for 10 
minutes then extracted with CH2Cl2 (4 × 10 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (silica gel, PE/EtOAc, 9:1) to yield 14 (241 mg, 0.880 mmol, 88%) as a pale yellow 
oil. 
Rf = 0.21 (PE/EtOAc, 9:1). IR (ATR) νMax 3378 (m, br, N-H), 3079 (w, C-H), 2980 (w, C-H), 1731 (s, 
C=O, ester), 1677 (s, C=O, amide), 1641 (w, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 5.54 (1H, m, 
NH), 5.78 – 5.67 (1H, m, H10), 5.61 – 5.50 (1H, m, H4), 5.10 –5.04 (2H, m, H5), 4.97 (1H, dq, J = 
17.2, 1.6 Hz, H11t), 4.94 (1H, dq, J = 10.2, 1.3 Hz, H11c), 4.29 – 4.22 (2H, m, H6), 3.99 (2H, s, H13), 
3.23 (1H, br dd, J = 14.1, 7.3 Hz, H3a), 2.63 – 2.49 (2H, m, H3b, H8a), 2.07 – 1.95 (1H, m, H9a), 
1.95 – 1.76 (2H, m, H8b, H9b), 1.31 (3H, t, J = 7.2 Hz, H7) ppm. 13C NMR (101 MHz, CDCl3) δ 173.1 
(C1), 165.0 (C12), 137.2 (C10), 131.9 (C4), 119.4 (C5), 115.5 (C11), 64.7 (C2), 62.3 (C6), 42.9 (C13), 
39.5 (C3), 33.9 (C8), 28.7 (C9), 14.3 (C7) ppm. HRMS (ESI) calcd for [C13H21NO3Cl]+: 274.1210, 
found 274.1205.  
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Ethyl 2-allyl-2-((tert-butoxycarbonyl)amino)hex-5-enoate 15 
 
To a solution of 1b (1.00 g, 5.07 mmol) in THF (35 mL) was added Boc2O (1.66 g, 7.60 mmol) and 
the reaction heated to 50 °C in a sealed tube overnight. The reaction mixture was concentrated 
in vacuo and the residue purified by flash column chromatography (silica gel, CH2Cl2) to yield 15 
(1.28 g, 4.31 mmol, 85%) as a transparent viscous oil.  
Rf = 0.37 (PE/EtOAc, 9:1). IR (ATR) νMax 3426 (w, br, N-H), 3080 (w, C-H), 2979 (w, C-H), 1714 (s, 
C=O), 1641 (w, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 5.79 – 5.67 (1H, m, H10), 5.67 – 5.53 (1H, 
m, H4), 5.49 (1H, br s, NH), 5.08 – 5.01 (2H, m, H5), 4.96 (1H, dq, J = 17.1, 1.5 Hz, H11t), 4.91 (1H, 
d, J = 10.1 Hz, H11c), 4.18 (2H, q, J = 7.1 Hz, H6), 3.04 (1H, br s, H3a), 2.46 (1H, dd, J = 13.9, 7.4 Hz, 
H3b), 2.42 – 2.28 (1H, m, H8a), 2.11 – 1.96 (1H, m, H9a), 1.90 – 1.72 (2H, m, H8b, H9b), 1.41 (9H, 
s, H14), 1.26 (3H, t, J = 7.1 Hz, H7) ppm. 13C NMR (101 MHz, CDCl3) δ 173.4 (C1), 153.9 (C12), 
137.7 (C10), 132.6 (C4), 118.9 (C5), 115.1 (C11), 79.2 (C13), 63.3 (C2), 61.8 (C6), 40.0 (C3), 34.6 
(C8), 28.6 (C9), 28.5 (C14), 14.4 (C7) ppm. HRMS (ESI) calcd for [C16H27NO4Na]+: 320.1832, found 
320.1822. 
tert-Butyl (4-(hydroxymethyl)octa-1,7-dien-4-yl)carbamate 16 
 
To a solution of 15 (1.00 g, 3.36 mmol) in THF (35 mL) 0 °C was added lithium borohydride 
(366 mg, 16.8 mmol) and the reaction mixture warmed to room temperature and stirred 
overnight. A further portion of lithium borohydride (366 mg, 16.8 mmol) was added and stirred 
for 24 h, followed by heating to 45 °C for 7 h. The reaction mixture was cooled and diluted with 
NH4Cl (sat. aq, 20 mL) and water (5 mL) and stirred for 10 minutes. The reaction mixture was 
extracted with EtOAc (4 × 20 mL) and the combined organic layers washed with NaHCO3 (sat. aq, 
25 mL), brine (25 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude product 
was purified by flash column chromatography (silica gel, PE/EtOAc, 4:1) to yield 16 (223 mg, 
0.873 mmol, 26%) as a white solid. 
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Rf = 0.20 (PE/EtOAc, 4:1). IR (ATR) νMax 3286 (m, br, O-H and N-H), 3076 (w, C-H), 2979 (w, C-H), 
2920 (w, C-H), 2867 (w, C-H), 1678 (s, C=O), 1642 (w, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 5.85 
– 5.74 (2H, m, H4, H8), 5.18 – 5.12 (2H, m, H5), 5.03 (1H, dq, J = 17.1, 1.6 Hz, H9t), 4.96 (1H, dq, J 
= 10.1, 1.5 Hz, H9c), 4.64 (1H, br s, NH), 4.16 (1H, br s, OH), 3.72 – 3.61 (2H, m, H1), 2.40 – 2.28 
(2H, m, H3), 2.17 – 1.97 (2H, m, H7), 1.76 – 1.56 (2H, m, H6), 1.43 (9H, s, H12) ppm. 13C NMR 
(101 MHz, CDCl3) δ 156.4 (C10), 138.3 (C8), 132.9 (C4), 119.6 (C5), 115.0 (C9), 80.1 (C11), 68.0 
(C1), 58.9 (C2), 39.2 (C3), 33.8 (C6), 28.5 (C12), 27.8 (C7) ppm. HRMS (ESI) calcd for 
[C14H25NO3Na]+: 278.1727, found 278.1717. 
5-Allyl-5-(but-3-en-1-yl)morpholin-3-one 17 
 
A solution of 13 (35 mg, 0.151 mmol) in tert-butanol (3.0 mL) was heated to 30 °C, followed by 
the addition of potassium tert-butoxide (19 mg, 0.166 mmol) and the reaction stirred for 6 h. The 
reaction mixture was diluted with NH4Cl (sat. aq, 10 mL), stirred for 10 minutes and then 
extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were dried over MgSO4, filtered 
and concentrated in vacuo to yield 17 (29 mg, 0.149 mmol, 98%) as a pale yellow oil. The crude 
product 17 was taken on to the following step without further purification. 
Rf = 0.26 (PE/EtOAc, 1:1). IR (ATR) νMax 3211 (m, br, N-H), 3074 (w, C-H), 2976 (w, C-H), 2920 (w, 
C-H), 2867 (w, C-H), 1667 (s, C=O), 1640 (w, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.82 (1H, m, 
NH), 5.83 – 5.68 (2H, m, H4, H8), 5.22 –5.13 (2H, m, H5), 5.04 (1H, dq, J = 17.1, 1.6 Hz, H9t), 4.98 
(1H, dq, J = 10.3, 1.2 Hz, H9c), 4.10 (2H, s, H11), 3.62 (1H, d, J = 11.9 Hz, H1a), 3.58 (1H, d, J = 
11.9 Hz, H1b), 2.38 – 2.26 (2H, m, H3), 2.15 – 2.07 (2H, m, H7), 1.68 – 1.60 (2H, m, H6) ppm. 13C 
NMR (101 MHz, CDCl3) δ 169.2 (C10), 137.6 (C8), 131.5 (C4), 120.5 (C5), 115.4 (C9), 70.8 (C1), 
67.6 (C11), 56.3 (C2), 41.4 (C3), 36.1 (C6), 27.7 (C7) ppm. HRMS (ESI) calcd for [C11H18NO2]+: 
196.1338, found 196.1338. 
4-Oxa-1-azaspiro[5.5]undec-8-en-2-one 18 
 
A solution of 17 (26.0 mg, 0.133 mmol) in CH2Cl2 (10 mL) was degassed with argon, followed by 
the addition of Grubbs II catalyst (11.3 mg, 13 µmol) and the reaction heated under reflux for 30 
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minutes, then concentrated in vacuo. The residue was purified by flash column chromatography 
(silica gel, PE/EtOAc, 1:1) to yield 18 (14.0 mg, 83.7 µmol, 63%) as a white amorphous solid. 
Rf = 0.12 (PE/EtOAc, 1:1). IR (ATR) νMax 3165 (m, br, N-H), 3072 (w, C-H), 2920 (w, C-H), 1664 (s, 
C=O), 1641 (w, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 5.76 – 5.70 (1H, m, H5), 5.64 – 5.57 (1H, 
m, H4), 4.20 (1H, d, J = 11.1 Hz, H1a), 4.14 (1H, d, J = 11.1 Hz, H1b), 3.69 (2H, s, H9), 2.21 – 1.95 
(4H, m, H3, H6), 1.82 – 1.74 (1H, m, H7a), 1.69 – 1.61 (1H, m, H7b) ppm. 13C NMR (101 MHz, 
CDCl3) δ 169.1 (C8), 126.8 (C5), 123.4 (C4), 76.3 (C1), 48.3 (C2), 44.1 (C9), 33.3 (C3), 28.6 (C7), 
22.1 (C6) ppm. HRMS (ESI) calcd for [C9H13NO2Na]+: 190.0839, found 190.0833. 
4-Allyl-4-(but-3-en-1-yl)oxazolidin-2-one 19 and tert-butyl 2-allyl-2-(but-3-en-1-yl)aziridine-1-
carboxylate 20 
 
To a solution of 16 (128 mg, 0.500 mmol) in Et2O (10 mL) was added p-toluenesulfonyl chloride 
(114 mg, 0.600 mmol) followed by potassium hydroxide (168 mg, 3.00 mmol), then the reaction 
was heated under reflux for 20 h. The reaction mixture was stirred for further 2 days at room 
temperature, then diluted with NaHCO3 (sat. aq, 10 mL) and stirred for 10 minutes. The layers 
were then separated, and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography (silica gel, CH2Cl2 to CH2Cl2/EtOAc, 4:1) to yield 19 
(43.5 mg, 0.240 mmol, 48%) and 20 (33.7 mg, 0.142 mmol, 28%) both as colourless oils. 
Analytical data for 19: 
Rf = 0.29 (PE/EtOAc, 4:1). IR (ATR) νMax 3255 (w, br, N-H), 3080 (w, C-H), 2978 (w, C-H), 2920 (w, 
C-H), 1738 (s, C=O), 1641 (w, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 6.70 (1H, br s, NH), 5.83 – 
5.68 (2H, m, H4, H8), 5.22 – 5.14 (2H, m, H5), 5.04 (1H, dq, J = 17.1, 1.6 Hz, H9t), 4.98 (1H, dq, J = 
10.1, 1.6 Hz, H9c), 4.14 (1H, d, J = 8.7 Hz, H1a), 4.08 (1H, d, J = 8.7 Hz, H1b), 2.40 – 2.27 (2H, m, 
H3), 2.15 – 2.07 (2H, m, H7), 1.75 – 1.60 (2H, m, H6) ppm. 13C NMR (101 MHz, CDCl3) δ 159.7 
(C10), 137.3 (C8), 131.4 (C4), 120.5 (C5), 115.6 (C9), 73.5 (C1), 60.0 (C2), 43.1 (C3), 37.6 (C6), 27.9 
(C7) ppm. HRMS (ESI) calcd for [C10H15NO2Na]+: 204.0995, found 204.0989. 
Analytical data for 20: 
Rf = 0.84 (PE/EtOAc, 4:1). IR (ATR) νMax 3365 (w, br, N-H), 3080 (w, C-H), 2977 (w, C-H), 2932 (w, 
C-H), 1693 (s, C=O), 1641 (w, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 5.88 – 5.74 (2H, m, H4, H8), 
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5.17 – 5.09 (2H, m, H5), 5.02 (1H, dq, J = 17.1, 1.6 Hz, H9t), 4.96 (1H, dq, J = 10.2, 1.4 Hz, H9c), 
2.37 (1H, dd, J = 14.7, 7.0 Hz, H3a), 2.27 – 2.04 (5H, m, H1, H3b, H7), 1.70 – 1.61 (1H, m, H6a), 
1.51 – 1.42 (10H, m, H6b, H12) ppm. 13C NMR (101 MHz, CDCl3) δ 161.1 (C10), 137.9 (C8), 133.9 
(C4), 118.2 (C5), 115.0 (C9), 80.9 (C11), 45,5 (C2), 38.4 (C3), 36.0 (C1), 33.2 (C6), 29.7 (C7), 28.2 
(C12) ppm. HRMS (ESI) calcd for [C14H23NO2Na]+: 260.1621, found 260.1617. 
3-Oxa-1-azaspiro[4.5]dec-7-ene-2-one 21 
 
Initial RCM route from 19: 
A solution of 19 (41 mg, 0.226 mmol) in CH2Cl2 (15 mL) was degassed with argon, followed by the 
addition of Grubbs II catalyst (19 mg, 23 µmol) and the reaction heated under reflux for 30 
minutes, then concentrated in vacuo. The residue was purified by flash column chromatography 
(silica gel, CH2Cl2 to CH2Cl2/EtOAc, 9:1) to yield 21 (31.1 mg, 0.203 mmol, 90%) as an off-white 
solid. 
Improved route from cyclohexene 24: 
To a solution of crude 24 (3.28 g, 14.4 mmol) in THF (150 mL) was added tBuOK (1.62g, 
14.4 mmol) and the reaction stirred for 1 h. The reaction mixture was diluted with NaHCO3 (sat. 
aq, 150 mL), stirred for 10 min and then extracted with EtOAc (3 × 100 mL). The combined organic 
layers were washed with brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo 
to yield crude 21 (2.05 g, 13.4 mmol, 93% yield) as a white amorphous solid. The crude product 
was further purified by recrystallization from Et2O/pentane 1:1 to yield pure 21 (718 mg, 
4.69 mmol, 33%) as a white crystalline solid. 
Analytical data for 21 (recrystallised product obtained from the improved route): 
Rf = 0.21 (PE/EtOAc, 1:1). m.p. 84 – 85 °C (Et2O/Pentane). IR (ATR) νMax 3235 (m, br, N-H), 3039 
(w, C-H), 2922 (w, C-H), 2904 (w, C-H), 2845 (w, C-H), 1731 (s, C=O and C=C) cm-1. 1H NMR 
(400 MHz, CDCl3) δ 5.77 – 5.70 (1H, m, H5), 5.66 – 5.59 (1H, m, H4), 5.46 (1H, br s, NH), 4.14 (1H, 
d, J = 8.5 Hz, H1a), 4.11 (1H, d, J = 8.5 Hz, H1b), 2.34 – 2.15 (4H, m, H3, H6), 1.90 – 1.82 (1H, m, 
H7a), 1.80 – 1.72 (1H, m, H7b) ppm. 13C NMR (101 MHz, CDCl3) δ 159.4 (C8), 127.1 (C5), 123.6 
(C4), 75.6 (C1), 56.2 (C2), 36.9 (C3), 32.3 (C7), 22.7 (C6) ppm. HRMS (ESI) calcd for [C8H11NO2Na]+: 
176.0682, found 176.0676.  
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Ethyl 1-((tert-butoxycarbonyl)amino)cyclohex-3-ene-1-carboxylate 23 
 
A solution of crude 15 (6.25 g, 21.0 mmol) in CH2Cl2 (300 mL) was degassed with argon, followed 
by the addition of Grubbs II catalyst (18 mg, 21 µmol). The reaction was heated under reflux for 
1 h followed by the addition of another portion of Grubbs II catalyst (18 mg, 21 µmol) and the 
reaction was heated under reflux for further 1 h before being concentrated in vacuo. The residue 
was purified by flash column chromatography (silica gel, PE/EtOAc, 9:1) to yield 23 (3.86 g, 
14.3 mmol, 69%) as a transparent viscous oil.  
Rf = 0.12 (PE/EtOAc, 9:1). IR (ATR) νMax 3368 (m, br, N-H), 2977 (w, C-H), 1706 (s, C=O and C=C) 
cm-1. 1H NMR (400 MHz, CDCl3) δ 5.76 – 5.70 (1H, m, H5), 5.61 – 5.55 (1H, m, H4), 4.78 (1H, br s, 
NH), 4.26 – 4.13 (2H, m, H8), 2.62 – 2.53 (1H, m, H3a), 2.29 – 2.01 (4H, m, H3b, H6, H7a), 1.95 – 
1.86 (1H, m, H7b), 1.43 (9H, s, H12), 1.26 (3H, t, J = 7.1 Hz, H7) ppm. 13C NMR (101 MHz, CDCl3) δ 
174.2 (C1), 155.0 (C10), 127.2 (C5), 122.6 (C4), 79.9 (C11), 61.2 (C8), 57.0 (C2), 34.2 (C3), 28.4 
(C12), 27.7 (C7), 21.9 (C6), 14.3 (C9) ppm. HRMS (ESI) calcd for [C14H24NO4]+: 270.1705, found 
270.1718. 
tert-Butyl (1-(hydroxymethyl)cyclohex-3-en-1-yl)carbamate 24 
 
To a solution of 23 (3.86 g, 14.4 mmol) in THF (150 mL) was added LiBH4 (2 M in THF, 14.4 mL, 
28.8 mmol), and the reaction stirred overnight. The reaction mixture was diluted with NH4Cl (sat. 
aq, 150 mL), stirred for 10 min and then extracted with EtOAc (3 × 100 mL). The combined organic 
layers were washed with NaHCO3 (sat. aq, 100 mL), brine (100 mL), dried over MgSO4, filtered 
and concentrated in vacuo to yield the crude product 24 (3.28 g, 14.4 mmol, 100%) as a white 
amorphous solid. The crude product 24 was taken on to the following steps without further 
purification.  
Rf = 0.26 (PE/EtOAc, 4:1). IR (ATR) νMax 3265 (m, br, O-H and N-H), 3076 (w, C-H), 3020 (w, C-H), 
2968 (w, C-H), 2933 (w, C-H), 1676 (s, C=O and C=C) cm-1. 1H NMR (400 MHz, DMSO-d6) δ 5.59 
(1H, br d, J = 10.0 Hz, H5), 5.50 (1H, br d, J = 10.0 Hz, H4), 4.62 (1H, t, J = 5.6 Hz, OH), 4.41 (1H, br 
s, NH), 3.45 – 3.36 (2H, m, H1), 2.27 – 1.86 (5H, m, H3, H6, H7a), 1.57 – 1.47 (1H, m, H7b), 1.36 
(9H, s, H10) ppm. 13C NMR (101 MHz, CDCl3) δ 156.7 (C8), 127.6 (C5), 123.3 (C4), 80.1 (C9), 69.3 
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(C1), 55.2 (C2), 34.1 (C3), 28.5 (C10), 27.4 (C7), 22.2 (C6) ppm. HRMS (ESI) calcd for [C12H22NO3]+: 
228.1600, found 228.1595. 
(1-((tert-Butoxycarbonyl)amino)cyclohex-3-en-1-yl)methyl 4-methylbenzenesulfonate 25 
 
To a solution of 24 (58.0 mg, 0.255 mmol) in Et2O (4.0 mL) was added p-toluenesulfonyl chloride 
(174 mg, 0.918 mmol) followed by potassium hydroxide (129 mg, 2.30 mmol), and the reaction 
then heated under reflux for 10 h. The reaction mixture was diluted with water (10 mL), stirred 
for 10 minutes and then extracted with EtOAc (3 × 10 mL). The combined organic layers were 
washed with brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
product was purified by flash column chromatography (silica gel, PE/EtOAc, 9:1) to yield 25 
(16.0 mg, 41.9 µmol, 16%) as a white solid. 
Rf = 0.26 (PE/EtOAc, 4:1). IR (ATR) νMax 3369 (m, N-H), 3030 (w, C-H), 2973 (w, C-H), 2929 (w, C-
H), 1697 (s, C=O and C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.77 (2H, d, J = 8.2 Hz, H12), 7.32 (2H, 
d, J = 8.2 Hz, H13), 5.71 – 5.64 (1H, m, H5), 5.53 – 5.47 (1H, m, H4), 4.42 (1H, br s, NH), 4.25 (1H, 
d, J = 9.3 Hz, H1a), 4.12 (1H, d, J = 9.3 Hz, H1b), 2.43 (3H, s, H15), 2.31 – 1.97 (5H, m, H3, H6, H7a), 
1.63 – 1.53 (1H, m, H7b), 1.37 (9H, s, H10) ppm. 13C NMR (101 MHz, CDCl3) δ 154.6 (C8), 144.9 
(C11), 133.0 (C14), 130.0 (C13), 128.1 (C12), 127.1 (C5), 122.8 (C4), 71.8 (C1), 52.8 (C2), 33.5 (C3), 
28.4 (C10), 27.0 (C7), 21.8 (C15), 21.7 (C6) ppm. HRMS (ESI) calcd for [C19H27NO5NaS]+: 404.1502, 
found 404.1494. 
4.2.5 Double bond modification 
3-Oxa-1-azaspiro[4.5]decan-2-one 26 
 
To a solution of pure 21 (15.3 mg, 0.100 mmol) in MeOH (1.0 mL) was added Pd (10 w/w % on 
charcoal, 10.6 mg, 10 µmol), degassed using hydrogen gas and the reaction was stirred under an 
atmosphere of hydrogen for 8 h at rt. The reaction mixture was filtered through Celite and 
concentrated in vacuo to yield crude 26 (14.6 mg, 94 µmol, 94%) as a white amorphous solid. 
116  
Rf = 0.21 (PE/EtOAc, 1:1). 1H NMR (400 MHz, CDCl3) δ 6.59 (1H, br s, NH), 4.09 (2H, s, H1), 1.80 – 
1.30 (10H, m, H3-5) ppm. 
These characterization data are in accordance with that previously reported in the literature.280 
(1R*,3R*,6S*)-7-Oxaspiro[bicyclo[4.1.0]heptane-3,4'-oxazolidin]-2'-one 27a and (1R*,3S*,6S*)-
7-oxaspiro[bicyclo[4.1.0]heptane-3,4'-oxazolidin]-2'-one 27b 
 
To a solution of 21 (30.6 mg, 0.200 mmol) in CH2Cl2 (2.0 mL) was added mCPBA (69.0 mg, 
0.400 mmol) and NaHCO3 (50.4 mg, 0.600 mmol) and the reaction stirred at rt overnight. The 
reaction mixture was quenched by a mixture of NaHCO3 (sat. aq, 8.0 mL) and Na2SO3 (sat. aq, 
2.0 mL), stirred for 10 min then extracted with CH2Cl2 (3 × 10 mL). The combined organic layers 
were washed with the same aqueous mixture as above (2 × 10 mL), NaCl (sat. aq, 10 mL), dried 
over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (silica gel, 1 to 2% MeOH in CH2Cl2) to yield 27b (1.9 mg, 11 µmol, 6%) and crude 
27a, both as a white amorphous solids. Crude 27a was purified by flash column chromatography 
(silica gel, PE/EtOAc, 1:1 to 0:1) to yield 27a (15.5 mg, 92 µmol, 46%) as a white solid. 27a was 
crystallised from Et2O for the single crystal X-ray crystallography analysis.  
Analytical data for 27a:  
Rf = 0.25 (5% MeOH in CH2Cl2). m.p. 110 – 111 °C (crystal decomposition), 116 – 117 °C (Et2O). IR 
(ATR) νMax 3299 (m, N-H), 3008 (w, C-H), 2910 (w, C-H), 1734 (s, C=O) cm-1. 1H NMR (500 MHz, 
CDCl3) δ 5.74 (1H, br s, NH), 4.03 (1H, d, J = 9.3 Hz, H1a), 4.02 (1H, d, J = 9.3 Hz, H1b), 3.29 (1H, 
br s, H4), 3.23 – 3.20 (1H, m, H5), 2.29 (1H, br d, J = 15.0 Hz, H3a), 2.14 – 2.09 (2H, m, H6), 1.94 
(1H, br d, J = 15.0 Hz, H3b), 1.78 – 1.72 (1H, m, H7a), 1.45 – 1.37 (1H, m, H7b) ppm. 13C NMR 
(126 MHz, CDCl3) δ 158.0 (C8), 75.9 (C1), 55.6 (C2), 53.1 (C4), 51.0 (C5), 35.5 (C3), 30.7 (C7), 20.7 
(C6) ppm. HRMS (ESI) calcd for [C8H12NO3]+: 170.0812, found 170.0810. 
Analytical data for 27b:  
Rf = 0.27 (5% MeOH in CH2Cl2). IR (ATR) νMax 3289 (m, N-H), 3000 (w, C-H), 2919 (w, C-H), 2851 
(w, C-H), 1737 (s, C=O), 1708 (s, C=O) cm-1. 1H NMR (500 MHz, CDCl3) δ 6.01 (1H, br s, NH), 4.14 
(1H, d, J = 9.1 Hz, H1a), 4.09 (1H, d, J = 9.1 Hz, H1b), 3.26 – 3.23 (1H, m, H4), 3.20 – 3.17 (1H, m, 
H5), 2.22 (1H, br d, J = 15.3 Hz, H3a), 2.18 – 2.02 (3H, m, H3b, H6), 1.69 (1H, dtd, J = 13.1, 6.6, 
0.9 Hz, H7a), 1.53 (1H, br dt, J = 13.8, 6.9 Hz, H7b) ppm. 13C NMR (126 MHz, CDCl3) δ 158.9 (C8), 
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75.1 (C1), 55.6 (C2), 51.8 (C4), 50.7 (C5), 36.6 (C3), 30.1 (C7), 21.1 (C6) ppm. HRMS (ESI) calcd for 
[C8H12NO3]+: 170.0812, found 170.0808. 
1-(4-Methoxybenzyl)-3-oxa-1-azaspiro[4.5]dec-7-ene-2-one 28 
 
To a solution of pure 21 (718 mg, 4.69 mmol) in DMF (50 mL) was added NaH (60 w/w % 
dispersion in mineral oil, 281 mg, 7.03 mmol) and the reaction stirred for 1.5 h at 50 °C, followed 
by the addition of 4-methoxybenzyl chloride (953 µL, 7.03 mmol) and stirred overnight at 50 °C. 
The reaction mixture was quenched by NaHCO3 (sat. aq, 50 mL), stirred for 10 min, and then 
diluted with H2O (50 mL), brine (100 mL) and extracted with Et2O (3 × 200 mL). The combined 
organic layers were concentrated in vacuo, the residue dissolved in Et2O (20 mL), washed with 
LiCl (10% aq, 3 × 25 mL), dried over MgSO4, filtered and concentrated in vacuo. The residue was 
purified by flash column chromatography (silica gel, PE/Et2O, 1:1 to 0:1) to yield 28 (1.23 g, 
4.50 mmol, 96%) as a white amorphous solid.  
Rf = 0.43 (Et2O). IR (ATR) νMax 3033 (w, C-H), 2926 (w, C-H), 2902 (w, C-H), 2835 (w, C-H), 1736 (s, 
C=O), 1613 (w, C=C), 1514 (s, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.28 – 7.22 (2H, m, H11), 
6.86 – 6.81 (2H, m, H12), 5.68 – 5.58 (1H, m, H5), 5.58 – 5.48 (1H, m, H4), 4.40 (1H, d, J = 15.5 Hz, 
H9a), 4.30 (1H, d, J = 15.5 Hz, H9b), 4.04 (1H, d, J = 8.4 Hz, H1a), 4.01 (1H, dd, J = 8.4, 0.8 Hz, H1b), 
3.79 (3H, s, H14), 2.32 – 2.14 (2H, m, H3a, H6a), 2.14 – 2.00 (1H, m, H6b), 2.00 – 1.90 (1H, m, 
H3b), 1.86 – 1.75 (1H, m, H7a), 1.58 – 1.50 (1H, m, H7b) ppm. 13C NMR (101 MHz, CDCl3) δ 159.1 
(C8), 158.5 (C13), 130.6 (C10), 129.1 (C11), 126.8 (C5), 123.8 (C4), 114.0 (C12), 73.0 (C1), 60.0 
(C2), 55.4 (C14), 43.8 (C9), 33.4 (C3), 30.6 (C7), 23.1 (C6) ppm. HRMS (ESI) calcd for 
[C16H19NO3Na]+: 296.1257, found 296.1247.  
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(5R*,7R*,8S*)-7,8-Dihydroxy-1-(4-methoxybenzyl)-3-oxa-1-azaspiro[4.5]decan-2-one 29a and 
(5R*,7S*,8R*)-7,8-dihydroxy-1-(4-methoxybenzyl)-3-oxa-1-azaspiro[4.5]-decan-2-one 29b 
 
To a solution of 28 (55 mg, 0.20 mmol) in THF (1.0 mL) was added 4-methylmorpholine N-oxide 
(47 mg, 0.40 mmol), citric acid (77 mg, 0.40 mmol), H2O (1.0 mL) and OsO4 (2.5 w/w % solution 
in tBuOH, 20 µL, 2.0 µmol) and the reaction stirred for 2 h at rt. The reaction mixture was 
quenched by Na2SO3 (sat. aq, 1.0 mL), stirred for 10 min, and then diluted with brine (1.0 mL) and 
extracted with EtOAc (3 × 3.0 mL). The combined organic layers were dried over MgSO4, filtered 
and concentrated in vacuo to yield a crude mixture of 29b and 29a (63 mg, 29b/29a = 1:2.5) as a 
transparent oil. The crude product was purified by flash column chromatography (silica gel, EtOAc 
to 5% MeOH in Et2O) to yield 29b (12.6 mg), 29a (33.2 mg) and a mixture of 29b and 29a (15 mg) 
all as white solids. Overall yield: 29b + 29a (60.8 mg, 0.198 mmol, 99%). 29b spontaneously 
crystallised from C6D6 and the co-crystals formed were used for the single crystal X-ray 
crystallography analysis. 
Analytical data for 29a:  
Rf = 0.13 (EtOAc). m.p. 120 – 121 °C (Et2O). IR (ATR) νMax 3422 (w, br, O-H), 3305 (w, br, O-H), 
2956 (w, C-H), 2898 (w, C-H), 1717 (s, C=O), 1613 (w, C=C), 1511 (s, C=C) cm-1. 1H NMR (400 MHz, 
CDCl3) δ 7.25 (2H, dt, J = 8.6, 2.5 Hz, H11), 6.83 (2H, dt, J = 8.6, 2.5 Hz, H12), .33 (2H, s, H9), 4.07 
(1H, d, J = 8.6 Hz, H1a), 4.05 (1H, d, J = 8.6 Hz, H1b), 3.92 – 3.88 (1H, m, H4), 3.78 (3H, s, H14), 
3.56 (1H, br d, J = 10.7 Hz, H5), 2.39 (1H, br s, C5OH), 2.31 (1H, br s, C4OH), 2.02 – 1.89 (3H, m, 
H3a, H6a, H7a), 1.57 (1H, ddd, J = 12.2, 4.4, 1.9 Hz, H3b), 1.43 – 1.23 (2H, m, H6b, H7b) ppm. 13C 
NMR (101 MHz, CDCl3) δ 159.1 (C13), 158.2 (C8), 130.3 (C10), 129.1 (C11), 114.1 (C12), 72.0 (C1), 
68.8 (C5), 67.1 (C4), 61.8 (C2), 55.4 (C14), 43.6 (C9), 36.2 (C3), 26.3 (C7), 26.0 (C6) ppm. HRMS 
(ESI) calcd for [C16H22NO5]+: 308.1498, found 308.1484. 
Analytical data for 29b:  
Rf = 0.20 (EtOAc). m.p. 122 – 123 °C (Et2O). IR (ATR) νMax 3434 (w, br, O-H), 3356 (w, br, O-H), 
2917 (w, C-H), 2851 (w, C-H), 1704 (s, C=O), 1611 (w, C=C), 1511 (s, C=C) cm-1. 1H NMR (500 MHz, 
CDCl3) δ 7.22 (2H, dt, J = 8.7, 2.5 Hz, H11), 6.84 (2H, dt, J = 8.7, 2.5 Hz, H12), 4.41 (1H, d, J = 
15.9 Hz, H9a), 4.33 (1H, dd, J = 9.4, 1.2 Hz, H1a), 4.26 (1H, d, J = 9.4 Hz, H1b), 4.21 (1H, d, J = 
15.9 Hz, H9b), 3.99 (1H, br s, H4), 3.79 (3H, s, H14), 3.61 – 3.54 (1H, m, H5), 2.30 (1H, br s, C4OH), 
1.91 – 1.82 (2H, m, H3), 1.79 – 1.66 (3H, m, H6, C5OH), 1.66 – 1.52 (2H, m, H7 + H2O) ppm. 13C 
NMR (126 MHz, CDCl3) δ 159.1 (C13), 158.6 (C8), 130.5 (C10), 128.8 (C11), 114.2 (C12), 73.4 (C1), 
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70.5 (C5), 69.5 (C4), 60.4 (C2), 55.4 (C14), 43.5 (C9), 37.9 (C3), 30.9 (C7), 25.1 (C6) ppm. HRMS 
(ESI) calcd for [C16H22NO5]+: 308.1498, found 308.1513. 
(5R*,7S*,8S*)-7,8-Dibromo-1-(4-methoxybenzyl)-3-oxa-1-azaspiro[4.5]decan-2-one 30a and 
(5R*,7R*,8R*)-7,8-dibromo-1-(4-methoxybenzyl)-3-oxa-1-azaspiro[4.5]-decan-2-one 30b 
 
To a solution of 28 (54.7 mg, 0.200 mmol) in CH2Cl2 (2.0 mL) at 0 °C was added PTAB (75.2 mg, 
0.200 mmol) and the reaction stirred at 0 °C for 2 h, then warmed to rt and stirred overnight. The 
reaction mixture was filtered and concentrated in vacuo, the residue was purified by flash column 
chromatography (silica gel, PE/Et2O 1:1 to 0:1) to yield 30a (76.0 mg), a mixture of 30a and 30b 
(3.7 mg, 30a/30b = 4.9:1) and 30b (3.4 mg) all as white amorphous solids. Overall yield: 30a + 
30b (83.1 mg, 0.192 mmol, 96%). 30a was crystallised from Et2O for the single crystal X-ray 
crystallography analysis. 
Analytical data for 30a:  
Rf = 0.49 (Et2O). m.p. 108 – 109 °C (Et2O). IR (ATR) νMax 2998 (w, C-H), 2960 (w, C-H), 2927 (w, C-
H), 2838 (w, C-H), 1737 (s, C=O), 1610 (w, C=C), 1509 (s, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 
7.28 (2H, br d, J = 8.7 Hz, H11), 6.85 (2H, br d, J = 8.7 Hz, H12), 4.62 – 4.54 (3H, m, H4, H5, H9a), 
4.38 (1H, d, J = 9.1 Hz, H1a), 4.33 (1H, dd, J = 9.1, 1.4 Hz, H1b), 4.20 (1H, d, J = 15.8 Hz, H9b), 3.80 
(3H, s, H14), 2.91 (1H, dd, J = 15.4, 3.9 Hz, H3a), 2.45 (1H, dddd, J = 15.4, 13.2, 3.4, 3.0 Hz, H6a), 
2.18 (1H, tdd, J = 13.6, 3.9, 1.2 Hz, H7a), 2.04 – 1.96 (1H, m, H6b), 1.89 – 1.82 (1H, m, H3b), 1.64 
– 1.57 (1H, m, H7b + H2O) ppm.13C NMR (101 MHz, CDCl3) δ 159.3 (C13), 158.0 (C8), 130.4 (C10), 
129.0 (C11), 114.3 (C12), 73.5 (C1), 60.7 (C2), 55.4 (C14), 51.2 (C5), 49.6 (C4), 43.8 (C9), 35.5 (C3), 
26.2 (C7), 25.4 (C6) ppm. HRMS (ESI) calcd for [C16H20NO379Br2]+: 431.9804, found 431.9800. 
Analytical data for 30b:  
Rf = 0.40 (Et2O). m.p. 68 – 69 °C (Et2O). IR (ATR) νMax 2932 (w, C-H), 1737 (s, C=O), 1611 (w, C=C), 
1512 (s, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.23 (2H, d, J = 8.7 Hz, H11), 6.86 (2H, d, J = 8.7 Hz, 
H12), 4.48 (1H, d, J = 15.8 Hz, H9a), 4.23 (1H, d, J = 15.8 Hz, H9b), 4.17 (1H, d, J = 8.7 Hz, H1a), 
4.10 (1H, d, J = 8.7 Hz, H1b), 3.95 – 3.77 (5H, m, H4, H5, H14), 2.47 – 2.33 (2H, m, CH2), 2.29 – 
2.13 (1H, m, CH2), 1.86 – 1.72 (1H, m, CH2), 1.64 (1H, td, J = 13.6, 3.5 Hz, CH2), 1.60 – 1.52 (1H, m, 
CH2 + H2O) ppm. 13C NMR (101 MHz, CDCl3) δ 159.4 (C13), 157.6 (C8), 129.7 (C10), 129.0 (C11), 
114.4 (C12), 71.0 (C1), 61.7 (C2), 55.5 (C14), 53.6 (C5), 51.4 (C4), 45.0 (C9), 44.0 (C3), 34.5 (C7), 
33.5 (C6) ppm. HRMS (ESI) calcd for [C16H20NO379Br223Na]+: 453.9624, found 453.9623. 
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(1R*,3S*,6S*)-3'-(4-Methoxybenzyl)-7-tosyl-7-azaspiro-[bicycle[4.1.0]heptane-3,4'-oxazolidin]-
2'-one 31a and (1R*,3R*,6S*)-3'-(4-methoxybenzyl)-7-tosyl-7-azaspiro[bicyclo[4.1.0]heptane-
3,4'-oxazolidin]-2'-one 31b 
 
To a solution of 28 (55 mg, 0.20 mmol) in MeCN (1.0 mL) was added chloramine T trihydrate 
(62 mg, 0.22 mmol) and PTAB (7.5 mg, 20 µmol) and the reaction stirred at rt over 4 Å molecular 
sieves overnight. The reaction mixture was filtered and concentrated in vacuo, the residue was 
purified by flash column chromatography (silica gel, Et2O) to yield 31a (34.5 mg, 78 µmol, 39%) 
and 31b (25.1 mg, 57 µmol, 28%) both as white amorphous solids. 31b was crystallised from Et2O 
for the single crystal X-ray crystallography analysis.  
Analytical data for 31a:  
Rf = 0.19 (Et2O). m.p. 177 – 178 °C (Et2O). IR (ATR) νMax 2952 (w, C-H), 2936 (w, C-H), 2921 (w, C-
H), 1729 (s, C=O), 1615 (w, C=C), 1513 (s, C=C) cm-1. 1H NMR (500 MHz, CDCl3) δ 7.75 (2H, dt, J = 
8.3, 1.7 Hz, H16), 7.34 (2H, br d, J = 8.3 Hz, H17), 7.19 (2H, dt, J = 8.7, 2.5 Hz, H11), 6.83 (2H, dt, J 
= 8.7, 2.5 Hz, H12), 4.37 (1H, d, J = 15.8 Hz, H9a), 4.19 (1H, d, J = 15.8 Hz, H9b), 4.06 (1H, d, J = 
9.4 Hz, H1a), 3.96 (1H, dd, J = 9.4, 0.7 Hz, H1b), 3.79 (3H, s, H14), 3.02 (1H, ddd, J = 6.9, 3.2, 1.7 Hz, 
H4), 2.95 (1H, t, J = 6.7 Hz, H5), 2.46 (3H, s, H19), 2.14 (1H, dtd, J = 15.9, 7.1, 1.8 Hz, H6a), 1.93 – 
1.77 (3H, m, H3, H6b), 1.50 (1H, td, J = 12.7, 7.7 Hz, H7a), 1.39 (1H, ddd, J = 13.4, 7.0, 1.8 Hz, 
H7b) ppm. 13C NMR (126 MHz, CDCl3) δ 159.3 (C13), 158.1 (C8), 145.0 (C15), 135.2 (C18), 130.2 
(C10), 130.1 (C17), 128.9 (C11), 127.7 (C16), 114.2 (C12), 72.3 (C1), 60.0 (C2), 55.4 (C14), 43.7 
(C9), 40.9 (C4), 36.7 (C5), 32.3 (C3), 28.2 (C7), 21.8 (C19), 20.2 (C6) ppm. HRMS (ESI) calcd for 
[C23H27N2O5S]+: 443.1641, found 443.1622. 
Analytical data for 31b:  
Rf = 0.12 (Et2O). m.p. 122 – 123 °C (Et2O). IR (ATR) νMax 2962 (w, C-H), 2934 (w, C-H), 1733 (s, 
C=O), 1615 (w, C=C), 1514 (s, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.77 (2H, br d, J = 8.2 Hz, 
H16), 7.35 (2H, br d, J = 8.2 Hz, H17), 7.18 (2H, dt, J = 8.6, 2.4 Hz, H11), 6.78 (2H, dt, J = 8.6, 2.4 Hz, 
H12), 4.34 (1H, d, J = 15.5 Hz, H9a), 4.10 (1H, d, J = 15.5 Hz, H9b), 4.00 (1H, d, J = 8.4 Hz, H1a), 
3.87 (1H, dd, J = 8.4, 1.4 Hz, H1b), 3.78 (3H, s, H14), 2.97 (1H, br d, J = 6.7 Hz, H5), 2.88 (1H, t, J = 
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6.7 Hz, H4), 2.47 (3H, s, H19), 2.10 – 2.02 (1H, m, H6a), 1.92 (1H, ddd, J = 15.2, 6.8, 2.0 Hz, H3a), 
1.81 – 1.71 (2H, m, H3b, H7a), 1.67 (1H, ddd, J = 14.5, 4.2, 2.9 Hz, H6b), 1.24 – 1.17 (1H, m, 
H7b) ppm. 13C NMR (101 MHz, CDCl3) δ 159.2 (C13), 157.9 (C8), 144.9 (C15), 135.1 (C18), 130.0 
(C17), 129.9 (C10), 129.3 (C11), 127.8 (C16), 114.1 (C12), 73.0 (C1), 58.8 (C2), 55.4 (C14), 43.7 
(C9), 38.4 (C5), 37.4 (C4), 29.5 (C3), 27.2 (C7), 21.8 (C19), 20.4 (C6) ppm. HRMS (ESI) calcd for 
[C23H27N2O5S]+: 443.1641, found 443.1629. 
(1R*,3R*,6S*)-7,7-Difluoro-3'-(4-methoxybenzyl)spiro-[bicycle[4.1.0]heptane-3,4'-oxazolidin]-
2'-one 32a and (1R*,3S*,6S*)-7,7-difluoro-3'-(4-methoxybenzyl)spiro[bicyclo[4.1.0]heptane-
3,4'-oxazolidin]-2'-one 32b 
 
To a solution of 28 (55 mg, 0.20 mmol) in THF (0.30 mL) was added anhydrous NaI (6.0 mg, 
40 µmol) and TMSCF3 (74 µL, 0.50 mmol) and the reaction stirred at 65 °C in a sealed tube. After 
6 h, the reaction was cooled to rt and opened to air, then more TMSCF3 (74 µL, 0.50 mmol) was 
added, the tube sealed and heated to 65 °C overnight. The reaction was then cooled to rt again 
and opened to air followed by the removal of solvent in vacuo. The residue was dissolved in Et2O 
(10 mL) and washed with H2O (10 mL), Na2SO3 (sat. aq, 10 mL), NaHCO3 (sat. aq, 10 mL) and H2O 
(10 mL), dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography (silica gel, PE/Et2O 1:1 to 1:4) to yield unreacted 28 (31.4 mg, 
0.115 mmol, 58%) as a white solid, 32b (0.8 mg, 2.5 µmol, 1%) as a transparent viscous oil and 
32a (16.2 mg, 50.1 µmol, 25%) as a white solid. Overall yield based on recovered starting 
material: 32b + 32a (17.0 mg, 52.6 µmol, 62%). 32a was crystallised from Et2O for the single 
crystal X-ray crystallography analysis. 
Analytical data for 32a:  
Rf = 0.04 (PE/Et2O 1:1). m.p. 90 – 91 °C (Et2O). IR (ATR) νMax 2931 (w, C-H), 1736 (s, C=O), 1614 (w, 
C=C), 1514 (s, C=C) cm-1. 1H NMR (500 MHz, CDCl3) δ 7.23 (2H, dt, J = 8.9, 2.5 Hz, H11), 6.85 (2H, 
dt, J = 8.9, 2.5 Hz, H12), 4.34 (1H, d, J = 15.6 Hz, H9a), 4.23 (1H, d, J = 15.6 Hz, H9b), 4.16 (1H, d, J 
= 8.5 Hz, H1a), 3.95 (1H, dd, J = 8.5, 1.7 Hz, H1b), 3.79 (3H, s, H14), 2.10 – 2.03 (1H, m, H6a), 1.87 
– 1.72 (2H, m, H3a, H6b), 1.68 – 1.55 (3H, m, H3a, H4, H7a), 1.53 – 1.44 (1H, m, H5), 1.33 – 1.26 
(1H, m, H7b) ppm. 13C NMR (126 MHz, CDCl3) δ 159.3 (s, C13), 158.1 (s, C8), 130.2 (s, C10), 129.4 
(s, C11), 114.1 (s, C12), 113.9 (dd, J = 287.3, 284.0 Hz, C15), 71.5 (d, J = 1.5 Hz, C1), 59.0 (d, J = 
3.6 Hz, C2), 55.4 (s, C14), 43.8 (s, C9), 29.0 (dd, J = 4.6, 1.0 Hz, C7), 23.2 (d, J = 3.1 Hz, C3), 16.2 (t, 
J = 11.3 Hz, C4/C5), 16.1 (t, J = 11.3 Hz, C4/C5), 15.5 (br s, C6) ppm. 19F NMR (376 MHz, CDCl3) δ -
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127.2 (1F, dtd, J = 157.7, 14.1, 1.2 Hz, Fa), -150.4 (1F, d, J = 157.7 Hz, Fb) ppm. HRMS (ESI) calcd 
for [C17H20NO3F2]+: 324.1411, found 324.1418. 
Analytical data for 32b:  
Rf = 0.06 (PE/Et2O 1:1). IR (ATR) νMax 2933 (w, C-H), 1738 (s, C=O), 1612 (w, C=C), 1512 (s, C=C) 
cm-1. 1H NMR (500 MHz, CDCl3) δ 7.23 (2H, br d, J = 8.7 Hz, H11), 6.85 (2H, br d, J = 8.7 Hz, H12), 
4.49 (1H, d, J = 15.9 Hz, H9a), 4.32 (1H, d, J = 15.9 Hz, H9b), 4.03 (1H, dd, J = 8.9, 1.3 Hz, H1a), 
3.94 (1H, d, J = 8.9 Hz, H1b), 3.80 (3H, s, H14), 2.06 – 1.97 (1H, m, H6a), 1.96 (1H, dd, J = 15.3, 
8.3 Hz, H3a), 1.73 (1H, d, J = 15.3 Hz, H3b), 1.68 – 1.50 (4H, m, H4, H5, H6b, H7a), 1.44 – 1.36 (1H, 
m, H7b) ppm. 13C NMR (126 MHz, CDCl3) δ 159.2 (s, C13), 158.4 (s, C8), 130.3 (s, C10), 128.6 (s, 
C11), 114.3 (s, C12), 114.1 (dd, J = 287.3, 284.2 Hz, C15), 73.8 (d, J = 11.5 Hz, C1), 59.1 (d, J = 
2.1 Hz, C2), 55.4 (s, C14), 44.2 (s, C9), 29.8 (dd, J = 2.6, 0.6 Hz, C7), 24.9 (dd, J = 2.0, 0.6 Hz, C3), 
18.0 (t, J = 11.7 Hz, C4), 16.9 (t, J = 11.5 Hz, C5), 13.8 (d, J = 3.2 Hz, C6) ppm. 19F NMR (376 MHz, 
CDCl3) δ -127.3 (1F, dt, J = 157.4, 13.8 Hz, Fa), -149.4 (1F, d, J = 157.4 Hz, Fb) ppm. HRMS (ESI) 




azaspiro[4.5]decan-2-one 34b and 8-hydroxy-1-(4-methoxybenzyl)-3-oxa-1-azaspiro[4.5]decan-
2-one 34c 
 
28 (109 mg, 0.400 mmol) was added to a solution of iron(II) acetylacetonate (20.4 mg, 80 µmol) 
and poly(methylhydrosiloxane) (272 µL) in tBuOH (4.0 mL) and the reaction stirred for 24 h at 50 
°C. The reaction mixture was then quenched by silica gel, stirred for 10 min, and concentrated in 
vacuo. The residue was purified by flash column chromatography (silica gel, PE/EtOAc, 9:1 to 0:1) 
to yield unreacted 28 (8.8 mg, 32 µmol, 8%), ketones 33a (32.5 mg, 0.112 mmol, 28%) and 33b 
(17.0 mg, 59 µmol, 15%) as white solids, and a mixture of alcohols 34a, 34b and 34c (38.5 mg, 
0.132 mmol, 33% combined) as a transparent viscous oil. The individual alcohol isomers were 
separated by preparative TLC (silica gel, eluting with either 5% MeOH in CH2Cl2 or EtOAc). 34a 
appeared as a transparent viscous oil, 34b and 34c as white amorphous solids. 34b was 
crystallised from Et2O for the single crystal X-ray crystallography analysis. 34a and 34c gave 
viscous oils or fibrous materials after each attempted crystallisation, that were not suitable for 
single crystal X-ray crystallography analysis, therefore their geometry could not be assigned.  
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Analytical data for 33a:  
m.p. 100 – 101 °C (Et2O). IR (ATR) νMax 2962 (w, C-H), 2930 (w, C-H), 1717 (s, C=O), 1615 (w, C=C), 
1514 (s, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.29 – 7.22 (2H, m, H11), 6.89 – 6.82 (2H, m, H12), 
4.43 (1H, d, J = 16.2 Hz, H9a), 4.42 (1H, d, J = 16.2 Hz, H9b), 3.98 (1H, d, J = 8.9 Hz, H1a), 3.96 (1H, 
d, J = 8.9 Hz, H1b), 3.80 (3H, s, H14), 2.49 (1H, d, J = 13.6 Hz, H3a), 2.39 – 2.29 (2H, m, H3b, H5a), 
2.20 (1H, td, J = 14.0, 6.1 Hz, H5b), 2.08 – 1.91 (2H, m, H6a, H7a), 1.81 – 1.72 (1H, m, H7b), 1.44 
(1H, qt, J = 13.5, 4.0 Hz, H6b) ppm. 13C NMR (101 MHz, CDCl3) δ 206.9 (C4), 159.4 (C8), 157.7 
(C13), 129.7 (C10), 129.1 (C11), 114.3 (C12), 71.7 (C1), 63.7 (C2), 55.4 (C14), 50.3 (C3), 44.0 (C9), 
40.2 (C5), 33.6 (C7), 20.0 (C6) ppm. HRMS (ESI) calcd for [C16H20NO4]+: 290.1392, found 290.1399. 
Analytical data for 33b:  
Rf = 0.44 (EtOAc). m.p. 121 – 122 °C (crystal decomposition), 136 – 137 °C (Et2O). IR (ATR) νMax 
2906 (w, C-H), 1732 (s, C=O), 1706 (s, C=O), 1616 (w, C=C), 1513 (s, C=C) cm-1. 1H NMR (500 MHz, 
CDCl3) δ 7.25 – 7.21 (2H, m, H9), 6.86 – 6.82 (2H, m, H10), 4.37 (2H, s, H7), 4.36 (2H, s, H1), 3.79 
(3H, s, H12), 2.43 – 2.29 (4H, m, H4), 2.04 (2H, td, J = 13.4, 5.5 Hz, H3a), 1.86 (2H, dqui, J = 13.8, 
3.0 Hz, H3b) ppm. 13C NMR (126 MHz, CDCl3) δ 207.3 (C5), 159.4 (C6), 157.9 (C11), 130.1 (C8), 
129.0 (C9), 114.3 (C10), 71.2 (C1), 60.4 (C2), 55.4 (C12), 44.0 (C7), 37.2 (C4), 33.0 (C3) ppm. HRMS 
(ESI) calcd for [C16H20NO4]+: 290.1392, found 290.1402. 
Analytical data for 34a:  
Rf = 0.29 (5% MeOH in CH2Cl2). IR (ATR) νMax 3358 (w, br, O-H), 2921 (w, C-H), 2852 (w, C-H), 1728 
(s, C=O), 1660 (w, C=C), 1513 (s, C=C) cm-1. 1H NMR (500 MHz, CDCl3) δ 7.28 (2H, dt, J = 8.7, 2.5 Hz, 
H9), 6.84 (2H, dt, J = 8.7, 2.5 Hz, H10), 4.37 (2H, s, H7), 4.10 (2H, s, H1), 4.02 (1H, sex, J = 2.5 Hz, 
H5), 3.79 (3H, s, H12), 2.07 (2H, td, J = 13.5, 4.0 Hz, H3a), 1.81 (2H, br d, J = 16.4 Hz, H4a), 1.47 
(2H, tdd, J = 14.3, 3.7, 2.6 Hz, H4b), 1.34 (2H, dqui, J = 13.1, 2.0 Hz, H3b), 1.17 (1H, d, J = 2.4 Hz, 
OH) ppm. 13C NMR (126 MHz, CDCl3) δ 159.1 (C11), 158.3 (C6), 130.8 (C8), 129.1 (C9), 114.0 (C10), 
71.6 (C1), 63.7 (C5), 61.4 (C2), 55.4 (C12), 43.6 (C7), 29.5 (C4), 27.7 (C3) ppm. HRMS (ESI) calcd 
for [C16H22NO4]+: 292.1549, found 292.1544. 
Analytical data for 34b:  
Rf = 0.23 (5% MeOH in CH2Cl2). m.p. 134 – 135 °C (Et2O). IR (ATR) νMax 3472 (w, br, O-H), 2921 (w, 
C-H), 2851 (w, C-H), 1728 (s, C=O), 1613 (w, C=C), 1510 (s, C=C) cm-1. 1H NMR (500 MHz, CDCl3) δ 
7.25 (2H, dt, J = 9.6, 2.5 Hz, H11), 6.84 (2H, dt, J = 9.6, 2.5 Hz, H12), 4.37 (1H, d, J = 15.9 Hz, H9a), 
4.33 (1H, d, J = 15.9 Hz, H9b), 4.05 (1H, d, J = 8.8 Hz, H1a), 4.04 (1H, d, J = 8.8 Hz, H1b), 3.79 (3H, 
s, H14), 3.58 – 3.48 (1H, m, H4), 1.97 – 1.92 (1H, m, H5a), 1.92 – 1.87 (1H, m, H3a), 1.79 – 1.73 
(1H, m, H6a), 1.55 – 1.47 (3H, m, H3b, H7a, OH), 1.45 – 1.37 (1H, m, H7b), 1.27 – 1.16 (1H, m, 
H6b), 1.14 – 1.04 (1H, m, H5b) ppm. 13C NMR (126 MHz, CDCl3) δ 159.2 (C13), 158.1 (C8), 130.4 
(C10), 129.0 (C11), 114.2 (C12), 72.1 (C1), 67.7 (C4), 62.1 (C2), 55.4 (C14), 43.7 (C9), 43.5 (C3), 
34.2 (C5), 33.0 (C7), 19.6 (C6) ppm. HRMS (ESI) calcd for [C16H22NO4]+: 292.1549, found 292.1553. 
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Analytical data for 34c:  
Rf = 0.23 (EtOAc). IR (ATR) νMax 3441 (w, br, O-H), 2940 (w, C-H), 2861 (w, C-H), 1720 (s, C=O), 
1612 (w, C=C), 1511 (s, C=C) cm-1. 1H NMR (400 MHz, CDCl3) δ 7.23 (2H, br d, J = 8.6 Hz, H9), 6.84 
(2H, br d, J = 8.6 Hz, H10), 4.32 (2H, s, H7), 4.13 (2H, s, H1), 3.79 (3H, s, H12), 3.59 – 3.48 (1H, m, 
H5), 1.99 – 1.90 (2H, m, H4a), 1.68 – 1.51 (5H, m, H3, OH), 1.32 – 1.19 (2H, m, H4b) ppm. 13C NMR 
(101 MHz, CDCl3) δ 159.1 (C11), 158.3 (C6), 130.5 (C8), 128.9 (C9), 114.1 (C10), 71.9 (C1), 69.0 
(C5), 60.9 (C2), 55.4 (C12), 43.7 (C7), 32.1 (C3), 31.8 (C4) ppm. HRMS (ESI) calcd for [C16H22NO4]+: 
292.1549, found 292.1545. 
(5R*,7S*,8S*)-7,8-Dibromo-3-oxa-1-azaspiro[4.5]decan-2-one 35 
 
Deprotection with TFA: 
A solution of 30a (10.8 mg, 25.0 µmol) in TFA (250 µL) was heated under reflux overnight, then 
cooled to rt and the reaction mixture was concentrated in vacuo. The residue was purified by 
flash column chromatography (silica gel, CH2Cl2/Et2O 9:1) to yield 35 (6.9 mg, 22.0 µmol, 88%) as 
a white amorphous solid. 35 was crystallised from Et2O for the single crystal X-ray crystallography 
analysis. 
Improved deprotection with CAN: 
To a solution of 30a (10.8 mg, 25 µmol) in MeCN (400 µL) and H2O (100 µL) was added CAN 
(41.1 mg, 75 µmol) and stirred for 1 h at rt. Upon completion, the reaction mixture was quenched 
with NaHCO3 (sat. aq, 3 mL), diluted with H2O (6 mL) and extracted with CH2Cl2 (4 × 10 mL). The 
combined organic layers were dried (MgSO4), then filtered through a short silica gel plug, washed 
with CH2Cl2 to remove the p-anisaldehyde by-product, then eluted with Et2O and concentrated 
in vacuo to yield 35 (7.5 mg, 24 µmol, 96%) as a white amorphous solid. 
Analytical data for 35 (recrystallised product obtained from reaction with TFA): 
Rf = 0.27 (CH2Cl2/Et2O 4:1). m.p. 173 – 174 °C (decomposition, Et2O). IR (ATR) νMax 3197 (w, N-H), 
3122 (w, C-H), 2954 (w, C-H), 1741 (s, C=O) cm-1. 1H NMR (400 MHz, CDCl3) δ 5.91 (1H, br s, NH), 
4.55 – 4.46 (1H, m, H4), 4.41 (1H, br s, H5), 4.35 (1H, d, J = 9.0 Hz, H1a), 4.31 (1H, d, J = 9.0 Hz, 
H1b), 2.78 (1H, dd, J = 14.8, 3.8 Hz, H3a), 2.55 – 2.44 (1H, m, H6a), 2.22 (1H, dd, J = 14.8, 5.7 Hz, 
H3b), 2.12 – 1.95 (2H, m, H6b, H7a), 1.92 – 1.81 (1H, m, H7b) ppm. 13C NMR (101 MHz, CDCl3) δ 
158.3 (C8), 75.1 (C1), 57.5 (C2), 51.8 (C5), 50.4 (C4), 41.0 (C3), 32.8 (C7), 28.4 (C6) ppm. HRMS 
(ESI) calcd for [C8H12NO279Br2]+: 311.9229, found 311.9219. 
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4.2.6 Syntheses of bis-amide linked compounds 
tert-Butyl (2-(5-bromo-1H-indole-3-carboxamido)ethyl)carbamate 47a 
 
To a suspension of 5-bromo-1H-indole-3-carboxilic acid 48 (200 mg, 0.834 mmol) in CH2Cl2 
(15 mL) was added DMF (6 µL, 80 µmol) and thionyl chloride (121 µL, 1.67 mmol) and heated 
under reflux overnight. The reaction mixture was concentrated under a flow of dry nitrogen to 
yield the crude acid chloride intermediate  49 as a pale pink/brown solid. The residue was 
dissolved in THF (10 mL) and the resultant solution added dropwise to a solution of tert-butyl (2-
aminoethyl)carbamate (264 µL, 1.67 mmol) and DIPEA (1.45 mL, 8.34 mmol) in THF (10 mL) at 
0 °C, the reaction mixture was warmed to rt and stirred for 2 h then concentrated in vacuo. The 
residue was purified by short silica gel plug filtration, washed with CH2Cl2, then eluted with EtOAc 
and concentrated in vacuo to yield 47a (250 mg, 0.654 mmol, 78%) as a pale yellow amorphous 
solid. 
Rf = 0.72 (acetone). IR (ATR) νMax 3361 (m, N-H), 3214 (m, N-H), 2931 (w, C-H), 1684 (s, C=O), 1612 
(s, C=O), 1545 (s, C=C), 1493 (m, C=C), 1426 (m, C=C) cm-1. 1H NMR (400 MHz, MeOD) δ 8.29 (1H, 
d, J = 1.9 Hz, H4), 7.88 (1H, s, H1), 7.34 (1H, dd, J = 8.6, 0.5 Hz, H7), 7.28 (1H, dd, J = 8.6, 1.9 Hz, 
H6), 3.45 (2H, t, J = 6.1 Hz, H10), 3.28 (2H, t, J = 6.1 Hz, H11), 1.41 (9H, s, H14) ppm. 13C NMR 
(101 MHz, MeOD) δ 168.1 (C9), 158.9 (C12), 136.7 (C8), 130.1 (C1), 128.9 (C3), 126.3 (C6), 124.5 
(C4), 115.3 (C5), 114.4 (C7), 111.6 (C2), 80.2 (C13), 41.2 (C11), 40.8 (C10), 28.7 (C14) ppm. HRMS 
(ESI) calcd for [C16H21N3O379Br]+: 382.0766, found 382.0753. 
tert-Butyl (3-(5-bromo-1H-indole-3-carboxamido)propyl)carbamate 47b 
 
To a solution of 5-bromo-1H-indole-3-carboxilic acid 48 (100 mg, 0.417 mmol) in DMF (5.0 mL) 
was added tert-butyl (3-aminopropyl)carbamate (109 mg, 0.626 mmol), EDC·HCl (120 mg, 
0.626 mmol), HOBt·xH2O (~80%, 110 mg, 0.626 mmol) and Et3N (87 µL, 0.626 mmol) at 0 °C. The 
reaction mixture was warmed to rt and stirred for 2 days, then concentrated in vacuo. The 
residue was purified by flash column chromatography (silica gel, PE/EtOAc 1:1 to 1:9) to yield 
impure 47b (92.5 mg, <0.232 mmol, <56%) as a yellow amorphous solid. Structure is tentatively 
assigned based on limited analytical data and analogy to 47a. 
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Rf = 0.75 (acetone). 1H NMR (400 MHz, MeOD) δ 8.30 (1H, s, H4), 7.89 (1H, s, H1), 7.35 (1H, d, J = 
8.6 Hz, H7), 7.28 (1H, d, J = 8.6 Hz, H6), 3.41 (2H, t, J = 6.5 Hz, H10), 3.16 (2H, t, J = 6.5 Hz, H12), 
1.76 (2H, qui, J = 6.5 Hz, H11), 1.44 (9H, s, H15) ppm.  
(2-(5-Bromo-1H-indole-3-carboxamido)ethan-1-aminium chloride 50a 
 
To a solution of 47a (55.0 mg, 0.144 mmol) in MeOH (10 mL) was added acetyl chloride (2 mL) 
dropwise at -40 °C. The reaction mixture was warmed to rt and stirred for 4 h, then concentrated 
in vacuo to yield crude amine hydrochloride 50a (51.6 mg) as a pale brown solid. The crude 
product 50a was taken on to the next steps without further purification, and its structure was 
tentatively assigned based on limited analytical data. 
IR (ATR) νMax 3161 (m, N-H), 2872 (m, C-H), 1574 (s, C=O), 1499 (m, C=C), 1444 (s, C=C) cm-1. HRMS 
(ESI) calcd for [C11H13N3O79Br]+: 282.0242, found 282.0234. 
3-(5-Bromo-1H-indole-3-carboxamido)propan-1-aminium chloride 50b 
 
To a solution of 47b (82.0 mg, 0.207 mmol) in MeOH (2.0 mL) was added HCl (4 M in dioxane, 
1.0 mL, 4.0 mmol) at rt and the reaction mixture was stirred overnight, then concentrated in 
vacuo to yield crude amine hydrochloride 50b (96.6 mg) as a pale brown solid. The crude product 
50b was taken on to the next step without further purification, and its structure was tentatively 
assigned based on limited analytical data. 
IR (ATR) νMax 2888 (m, br, N-H and C-H), 1582 (s, C=O), 1516 (m, C=C), 1438 (s, C=C) cm-1. HRMS 
(ESI) calcd for [C12H15N3O79Br]+: 296.0399, found 296.0389. 
4-((2-(5-Bromo-1H-indole-3-carboxamido)ethyl)amino)-4-oxobutanoic acid 51a 
 
To a suspension of crude 50a (17.0 mg, 46 µmol) in THF (6 mL) was added DIPEA (17.4 µL, 
0.100 mmol) followed by succinic anhydride (5.0 mg, 50 µmol) and stirred at rt for 2 days, then 
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concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 
MeCN/H2O 9:1) to yield 51a (15.0 mg, 39 µmol, 85%) as a white amorphous solid. 
Rf = 0.22 (MeCN/H2O 9:1). IR (ATR) νMax 3342 (w, N-H), 3191 (m, O-H), 2918 (w, C-H), 1660 (s, 
C=O), 1610 (s, C=O), 1545 (s, C=C), 1465 (m, C=C), 1437 (m, C=C), 1408 (m, C=C) cm-1. 1H NMR 
(400 MHz, MeOD) δ 8.28 (1H, dd, J = 1.9, 0.5 Hz, H4), 7.90 (1H, s, H1), 7.35 (1H, dd, J = 8.7, 0.5 Hz, 
H7), 7.28 (1H, dd, J = 8.7, 1.9 Hz, H6), 3.52 – 3.47 (2H, m, H10), 3.43 – 3.39 (2H, m, H11), 2.63 – 
2.58 (2H, m, H14), 2.51 – 2.46 (2H, m, H13) ppm. 13C NMR (101 MHz, MeOD) δ 176.8 (C15), 175.3 
(C12), 168.1 (C9), 136.6 (C8), 130.1 (C1), 128.9 (C3), 126.3 (C6), 124.5 (C4), 115.3 (C5), 114.4 (C7), 
111.4 (C2), 40.4 (C11), 40.1 (C10), 31.8 (C13), 30.6 (C14) ppm. HRMS (ESI) calcd for 
[C15H17N3O479Br]+: 382.0402, found 382.0383. 
5-((2-(5-Bromo-1H-indole-3-carboxamido)ethyl)amino)-5-oxopentanoic acid 51b 
 
To a suspension of crude 50a (5.5 mg, 15 µmol) in THF (2 mL) was added DIPEA (5.8 µL, 33 µmol) 
followed by succinic anhydride (1.8 mg, 18 µmol) and stirred at rt for 2 days, then concentrated 
in vacuo. The residue was purified by flash column chromatography (silica gel, MeCN/H2O 9:1) to 
yield 51b (1.9 mg, 4.9 µmol, 33%) as a white amorphous solid. The structure of 51b was 
tentatively assigned based on LCMS analysis and analogy to 51a. 
Rf = 0.24 (MeCN/H2O 9:1). LCMS (ESI) calcd for [C16H19N3O481Br]+: 398.1, found 398.2; calcd for 
[C16H17N3O481Br]-: 396.0, found 396.1. 
4-((3-(5-Bromo-1H-indole-3-carboxamido)propyl)amino)-4-oxobutanoic acid 51c 
 
To a suspension of crude 50b (6.7 mg, 14 µmol) in THF (2.0 mL) was added Et3N (9.8 µL, 70 µmol) 
followed by succinic anhydride (2.5 mg, 25 µmol) and stirred at rt overnight. The reaction mixture 
was diluted with HCl (conc. aq, 10 mL) and brine (10 mL), then extracted with EtOAc/iPrOH (9:1, 
5 × 20 mL), the combined organic layers were dried over Na2SO4, filtered and concentrated in 
vacuo to yield the crude product 51c (2.3 mg, <5.8  µmol, <41%) as a pale yellow amorphous 
solid. The crude 51c was tested for biological activity without further purification, and its 
structure was tentatively assigned based on crude 1H NMR and LCMS analyses and analogy to 
51a. 
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1H NMR (400 MHz, MeOD) δ 8.25 (1H, br s, H4), 7.96 (1H, s, H1), 7.38 (1H, br d, J = 8.7 Hz, H7), 
7.30 (1H, br d, J = 8.7 Hz, H6), 3.64 – 3.34 (4H, m, H10, H12), 2.72 – 2.50 (4H, m, H14, H15), 1.94 
– 1.79 (2H, m, H11) ppm. LCMS (ESI) calcd for [C16H19N3O481Br]+: 398.1, found 398.2; calcd for 
[C16H17N3O479Br]-: 394.0, found 394.1. 
Ethyl 4-((2-(5-Bromo-1H-indole-3-carboxamido)ethyl)amino)-4-oxobutanoate 52 
 
To a suspension of crude 50a (18.6 mg, 52 µmol) in THF (6 mL) was added DIPEA (20.9 µL, 
0.200 mmol) and mono-ethyl succinate (14.6 mg, 0.100 mmol) followed by HATU (21.0 mg, 
55 µmol) and stirred at rt overnight. The reaction mixture was purified by flash column 
chromatography (silica gel, EtOAc to EtOAc/acetone 4:1) to yield 52 (11.8 mg, 29 µmol, 56%) as 
a white amorphous solid. 
Rf = 0.58 (acetone). IR (ATR) νMax 3330 (w, N-H), 3223 (m, N-H), 2982 (w, C-H), 2934 (w, C-H), 1707 
(s, C=O, ester), 1652 (s, C=O, amide), 1610 (s, C=O, amide), 1556 (s, C=C), 1469 (m, C=C), 1444 
(m, C=C) cm-1. 1H NMR (400 MHz, acetone-d6) δ 8.46 (1H, dd, J = 2.0, 0.5 Hz, H4), 7.97 (1H, s, H1), 
7.51 (1H, br t, J = 5.0 Hz, NH), 7.47 (1H, br s, NH), 7.44 (1H, dd, J = 8.6, 0.5 Hz, H7), 7.29 (1H, dd, J 
= 8.6, 2.0 Hz, H6), 4.04 (2H, q, J = 7.1 Hz, H16), 3.51 – 3.45 (2H, m, H10), 3.43 – 3.37 (2H, m, H11), 
2.86 (1H, br s, NH), 2.60 – 2.55 (2H, m, H14), 2.50 – 2.45 (2H, m, H13), 1.17 (3H, t, J = 7.1 Hz, 
H17) ppm. 13C NMR (101 MHz, acetone-d6) δ 173.3 (C15), 172.7 (C12), 165.6 (C9), 136.0 (C8), 
129.1 (C3), 129.1 (C1), 125.8 (C6), 124.7 (C4), 114.6 (C5), 114.3 (C7), 112.2 (C2), 60.7 (C16), 40.3 
(C10/C11), 40.3 (C10/C11), 31.2 (C13), 30.0 (C14, under solvent peak), 14.5 (C17) ppm. HRMS 
(ESI) calcd for [C17H21N3O479Br]+: 410.0715, found 410.0702. 
4.2.7 Syntheses of further derivatives 
General procedure A 
To a solution of amine (1.00 mmol) in THF (5.0 mL) was added Et3N (280 µL, 2.00 mmol) followed 
by succinic anhydride (120 mg, 1.20 mmol) at 0 °C. The reaction mixture was warmed to rt and 
stirred overnight, then diluted with HCl (conc. aq, 10 mL) and brine (10 mL), and extracted with 
EtOAc (5 × 20 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated in vacuo to yield the crude product 53. The crude mixtures 53 were tested for 
biological activity without further purification, and their structures were tentatively assigned 
based on crude 1H NMR analysis.  
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4-oxo-4-(phenethylamino)butanoic acid 53a 
 
Synthesised according to general procedure A. 
1H NMR (400 MHz, CDCl3) δ 7.35 – 7.29 (2H, m, H9), 7.27 – 7.21 (1H, m, H10, CHCl3), 7.21 – 7.16 
(2H, m, H8), 5.71 (1H, br s, NH), 3.54 (2H, q, J = 6.6 Hz, H5), 2.82 (2H, t, J = 6.9 Hz, H6), 2.69 (2H, 
t, J = 6.6 Hz, H3), 2.46 (2H, t, J = 6.5 Hz, H2) ppm.  
These characterization data are in accordance with that previously reported in the literature.281 
4-oxo-4-((3-phenylpropyl)amino)butanoic acid 53b 
 
Synthesised according to general procedure A. 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.27 (2H, m, H10), 7.23 – 7.15 (3H, m, H9, H11), 5.64 (1H, br 
s, NH), 3.31 (2H, q, J = 6.6 Hz, H5), 2.71 – 2.62 (4H, m, H3, H7), 2.44 (2H, t, J = 6.4 Hz, H2), 1.86 
(2H, qui, J = 7.3 Hz, H2) ppm.  
4-oxo-4-((4-phenylbutyl)amino)butanoic acid 53c 
 
Synthesised according to general procedure A. 
1H NMR (400 MHz, CDCl3) δ 7.31 – 7.27 (2H, m, H11), 7.22 – 7.14 (3H, m, H10, H12), 5.68 (1H, br 
s, NH), 3.29 (2H, q, J = 6.6 Hz, H5), 2.69 (2H, t, J = 6.4 Hz, H3), 2.64 (2H, t, J = 7.4 Hz, H8), 2.49 (2H, 
t, J = 6.4 Hz, H2), 1.65 (2H, qui, J = 7.5 Hz, H6/H7), 1.54 (2H, qui, J = 7.2 Hz, H6/H7) ppm.  
4-((2-(1H-indol-3-yl)ethyl)amino)-4-oxobutanoic acid 53d 
 
Synthesised according to general procedure A. 
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1H NMR (400 MHz, MeOD) δ 7.55 (1H, d, J = 7.8 Hz, H9/H12), 7.32 (1H, d, J = 8.0 Hz, H9/H12), 
7.11 – 7.05 (2H, m, H10/H11, H14), 7.00 (1H, t, J = 7.4 Hz, H10/H11), 3.47 (2H, t, J = 7.3 Hz, H5), 
2.94 (2H, t, J = 7.3 Hz, H6), 2.61 – 2.54 (2H, m, H3), 2.49 – 2.42 (2H, m, H2) ppm. LCMS (ESI) calcd 
for [C14H17N2O3]+: 261.1, found 261.3; calcd for [C14H15N2O3]-: 259.1, found 259.2. 
tert-Butyl 5-bromo-3-(2-hydroxyethyl)-1H-indole-1-carboxylate 56 
 
Following a slightly modified version of a reported procedure,278 to a solution of 58 (1.36 g, 
3.00 mmol) in THF (30 mL) was added TBAF (1.0 M in THF, 4.5 mL, 4.5 mmol) at 0 °C. The reaction 
mixture was warmed to rt and stirred for 1 h, then filtered through a short silica plug, eluted with 
EtOAc and concentrated in vacuo. The crude product was purified by flash column 
chromatography (silica gel, 5 to 25% EtOAc in PE) to yield 56 (916 mg, 2.60 mmol, 87%) as a 
transparent viscous oil. 
Rf = 0.13 (PE/EtOAc 4:1). 1H NMR (400 MHz, DMSO-d6) δ 7.97 (1H, d, J = 8.8 Hz, H7), 7.81 (1H, d, 
J = 1.9 Hz, H4), 7.52 (1H, br s, H1), 7.45 (1H, dd, J = 8.8, 1.9 Hz, H6), 4.68 (1H, t, J = 5.3 Hz, OH), 
3.66 (2H, td, J = 6.5, 5.3 Hz, H10), 2.79 (2H, t, J = 6.5 Hz, H9), 1.61 (9H, s, H13) ppm. 13C NMR 
(101 MHz, CDCl3) δ 149.5 (C11), 134.5 (C8), 132.4 (C3), 127.4 (C6), 124.8 (C1), 121.9 (C4), 116.9 
(C7), 116.7 (C2), 116.0 (C5), 84.2 (C12), 62.0 (C10), 28.4 (C9), 28.3 (C13) ppm. 
These characterization data are in accordance with that previously reported in the literature.278 
5-Bromo-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-indole 57 
 
Following a slightly modified version of a reported procedure,278 to a solution of 
5-bromotryptophol 55 (960 mg, 4.00 mmol) and imidazole (599 mg, 8.80 mmol) in DMF (4.0 mL) 
was added TBSCl (663 mg, 4.40 mmol) at 0 °C. The reaction mixture was warmed to rt and stirred 
for 3 h, then diluted with EtOAc (20 mL), washed with water (20 mL), NH4Cl (5% aq, 3 × 20 mL), 
NaHCO3 (sat. aq, 20 mL) and brine (5 × 20 mL), dried over MgSO4, filtered and concentrated in 
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vacuo to yield the crude product 57 (1.40 g) as a yellow oil. The crude product 57 was taken on 
to the next step without further purification, and its structure was tentatively assigned based on 
the crude 1H NMR data that were in accordance with that previously reported in the literature278. 
Rf = 0.59 (CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 8.01 (1H, br s, NH), 7.74 (1H, d, J = 1.8 Hz, H4), 7.26 
(1H, dd, J = 8.6, 1.8 Hz, H6), 7.21 (1H, d, J = 8.6 Hz, H7), 7.04 (1H, d, J = 2.2 Hz, H1), 3.86 (2H, t, J 
= 7.0 Hz, H10), 2.93 (2H, t, J = 7.0 Hz, H9), 0.89 (9H, s, H13), 0.01 (6H, s, H11) ppm.  
tert-Butyl 5-bromo-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-indole-1-carboxylate 58 
 
Following a slightly modified version of a reported procedure,278 to a solution of crude 57 (1.40 g, 
~4.0 mmol) and DMAP (52.0 mg, 0.40 mmol) in CH2Cl2 (12.0 mL) was added Boc2O (1.31 g, 
6.00 mmol) and stirred for 3 days. The reaction mixture was then concentrated in vacuo, and the 
crude product was purified by flash column chromatography (silica gel, 0 to 3% EtOAc in PE) to 
yield 58 (1.69 g, 3.71 mmol, 93% over two steps) as a transparent viscous oil. 
Rf = 0.26 (5% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ 8.00 (1H, br d, J = 8.8 Hz, H7), 7.66 (1H, d, 
J = 1.8 Hz, H4), 7.42 (1H, br s, H1), 7.38 (1H, dd, J = 8.8, 1.8 Hz, H6), 3.86 (2H, t, J = 6.6 Hz, H10), 
2.85 (2H, t, J = 6.6 Hz, H9), 1.65 (9H, s, H16), 0.89 (9H, s, H13), 0.01 (6H, s, H11) ppm.  
These characterization data are in accordance with that previously reported in the literature.278 
tert-Butyl 6-(5-bromo-3-(2-((tert-butoxycarbonyl)oxy)ethyl)-1H-indole-1-yl)hexanoate 60 
 
To a solution of 56 (34.0 mg, 0.100 mmol) in DMF (1.0 mL) was added NaH (60 w/w % dispersion 
in mineral oil, 12.0 mg, 0.300 mmol) and NaI (15.0 mg, 0.100 mmol) and the reaction stirred at rt 
for 15 min, followed by the addition of tert-butyl 6-bromohexanoate (50.2 mg, 0.200 mmol) and 
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stirred for 2.5 h. The reaction mixture was quenched by NaHCO3 (sat. aq, 10 mL), stirred for 10 
min, then extracted with EtOAc (10 mL). The organic layer was washed with brine (6 × 10 mL), 
dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (silica gel, 5 to 15% EtOAc in PE) to yield 60 (38.0 mg, 74.4 µmol, 74%) 
as a transparent viscous oil. 
Rf = 0.20 (15% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ .71 (1H, dd, J = 1.9, 0.4 Hz, H4), 7.26 (1H, 
dd, J = 8.7, 1.9 Hz, H6, CHCl3), 7.15 (1H, dd, J = 8.7, 0.4 Hz, H7), 6.94 (1H, s, H1), 4.28 (2H, t, J = 
7.3 Hz, H10), 4.04 (2H, t, J = 7.1 Hz, H14), 3.05 (2H, td, J = 7.2, 0.5 Hz, H9), 2.18 (2H, t, J = 7.4 Hz, 
H18), 1.80 (2H, qui, J = 7.4 Hz, H15), 1.59 (2H, qui, J = 7.6 Hz, H17, H2O), 1.48 (9H, s, H13/H21), 
1.41 (9H, s, H13/H21), 1.34 – 1.24 (2H, m, H16) ppm. 13C NMR (101 MHz, CDCl3) δ 173.0 (C19), 
153.6 (C11), 135.0 (C8), 129.8 (C3), 127.2 (C1), 124.5 (C6), 121.8 (C4), 112.4 (C5), 110.9 (C7), 110.1 
(C2), 82.1 (C12/C20), 80.3 (C12/C20), 67.0 (C10), 46.3 (C14), 35.4 (C18), 30.1 (C15), 28.2 
(C13/C21), 27.9 (C13/C21), 26.5 (C16), 24.9 (C9), 24.7 (C17) ppm. 
5-Bromo-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-(4-methoxybenzyl)-1H-indole 61 
 
To a solution of crude 57 (700 mg, ~2.0 mmol) in DMF (10.0 mL) was added NaH (60 w/w % 
dispersion in mineral oil, 160 mg, 4.00 mmol) and the reaction stirred at rt for 10 min, followed 
by the addition of PMBCl (542 µL, 4.00 mmol) and stirred for 2 days. The reaction mixture was 
quenched by NaHCO3 (sat. aq, 10 mL), stirred for 10 min, then diluted with H2O (10 mL) and brine 
(30 mL), and extracted with EtOAc (50 mL). The organic layer was washed with brine (6 × 50 mL), 
dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (silica gel, 0 to 4% EtOAc in PE) to yield 61 (690 mg, 1.45 mmol, 73% 
over two steps) as a transparent viscous oil. 
Rf = 0.20 (5% EtOAc in PE). 1H NMR (400 MHz, CDCl3) δ 7.73 (1H, dd, J = 1.8, 0.4 Hz, H4), 7.22 (1H, 
dd, J = 8.7, 1.8 Hz, H6), 7.11 (1H, dd, J = 8.7, 0.4 Hz, H7), 7.04 (2H, dm, J = 8.8 Hz, H16), 6.94 (1H, 
s, H1), 6.83 (2H, dm, J = 8.8 Hz, H17), 5.17 (2H, s, H14), 3.84 (2H, t, J = 6.9 Hz, H10), 3.78 (3H, s, 
H19), 2.91 (2H, td, J = 6.9, 0.6 Hz, H9), 0.88 (9H, s, H13), 0.00 (6H, s, H11) ppm. 13C NMR (101 MHz, 
CDCl3) δ 159.3 (C18), 135.2 (C8), 130.3 (C3), 129.3 (C15), 128.3 (C16), 127.5 (C1), 124.4 (C6), 122.0 
(C4), 114.3 (C17), 112.4 (C2/C5), 112.3 (C2/C5), 111.2 (C7), 63.9 (C10), 55.4 (C19), 49.7 (C14), 28.9 
(C9), 26.1 (C13), 18.5 (C12), -5.2 (C11) ppm. 
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6.1 Computational Analysis 
Calculation of the energy minimised conformations for both libraries were performed with 
Molecular Operating Environment (MOE) software package version 2012.10 using the search 
settings summarised in Table 6.1. 
Table 6.1 Conformational search settings 
Force field MMFF94x 
Solvation Born 
Method LowModeMD 
Rejection Limit 100 
RMS Gradient 0.005 
Iteration Limit 10000 
MM Iteration Limit 500 
RMSD Limit 0.15 
Energy Window 3 
Conformation Limit 100 
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Structural and physicochemical parameters calculated using MOE 2018.0602 are summarised in 
Table 6.2. 
Table 6.2 Physicochemical parameters calculated by MOE. 
Parameter Description Propertya 
npr1 Normalised PMI ratio (1) (PMI1 / PMI3) - 
npr2 Normalised PMI ratio (2) (PMI2 / PMI3) - 
a_acc Number of hydrogen-bond acceptor atoms HBA 
a_aro Number of aromatic atoms - 
a_don Number of hydrogen-bond donor atoms HBD 
a_heavy Number of non-hydrogen heavy atoms - 
b_rotN Number of rotatable bonds RBC 
chiral Number of chiral centres chiral 
SlogP Log octanol/water partition coefficient SlogP 
TPSA Topological polar surface area (Å2) TPSA 
weight Molecular weight (Da) MW 
aas appear in Table 2.4 
The number of sp3 atoms (sp3-Atom) were calculated using Osiris Datawarrior version 4.7.3. 
Further properties calculated using Microsoft Excel 2010 are summarised in Table 6.3. 
Table 6.3 Physicochemical properties calculated by Excel. 
Parametera Description 
Fsp3 Fraction of sp3 atoms (sp3-Atom / a_heavy) 
Far Fraction of aromatic atoms (a_aro / a_heavy) 
npr1 + npr2 Sum of the normalised PMI ratios 
Fflat Fraction of molecules below the ‘flatland’ line (defined as: npr1 + npr2 ≤ 1.1) 
aas appear in Table 2.5 
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6.1.1 Spirocyclic library 
The spirocyclic library is based on the fragments described in 2.3.7. When applicable, protecting 
groups were removed yielding compounds numbered in general as X’. Normalised PMI ratios and 
molecular formulae of the library are summarised in Table 6.4, whereas distributions of the key 
physicochemical properties are displayed as histograms in Figure 6.1. 
Table 6.4 Normalised PMI ratios and molecular formulae of the spirocyclic library. 
Compound SMILES npr1 npr2 Formula 
8b O=C1[C@]2(NC(=O)C1)CC=CCC2 0.5336 0.9195 C9H11NO2 
21 O=C1OC[C@]2(N1)CC=CCC2 0.3346 0.9505 C8H11NO2 
37 O=C1OC[C@]2(NC1)CC=CCC2 0.2861 0.9367 C9H13NO2 
39 c1(C=2OC[C@]3(N=2)CC=CCC3)ccccc1 0.2010 0.9075 C14H15NO 
18 O=C1N[C@@]2(COC1)CC=CCC2 0.3961 0.8850 C9H13NO2 
38 NC=1OC[C@]2(N=1)CC=CCC2 0.3275 0.9491 C8H12N2O 
8a O=C1C2(NC(=O)C1)CC=CC2 0.3879 0.8086 C8H9NO2 
8c O=C1[C@]2(NC(=O)C1)CC=CCCC2 0.5826 0.9781 C10H13NO2 
43 O(C)c1ccc(C=2[C@]3(NC(=O)C=2)CC=CCC3)cc1 0.2737 0.8730 C16H17NO2 
44 O=C1N[C@@]2(C(O)C1)CC=CCC2 0.4161 0.8470 C9H13NO2 
40 O=C1OC[C@]2(N=C1)CC=CCC2 0.2499 0.8763 C9H11NO2 
41 O(CC)C=1[C@]2(NC(=O)C=1)CC=CCC2 0.4464 0.7134 C11H15NO2 
45 O=C1N[C@@]2(C=C1)CC=CCC2 0.3282 0.9689 C9H11NO 
33b' O=C1OCC2(N1)CCC(=O)CC2 0.2504 0.9771 C8H11NO3 
33a' O=C1OC[C@]2(N1)CC(=O)CCC2 0.2870 0.8968 C8H11NO3 
34b' O=C1OC[C@]2(N1)C[C@@H](O)CCC2 0.3619 0.9290 C8H13NO3 
34a' O=C1OCC2(N1)CCC(O)CC2 0.2614 0.9788 C8H13NO3 
34c' O=C1OCC2(N1)CCC(O)CC2 0.2614 0.9789 C8H13NO3 
29a' O=C1OC[C@]2(N1)C[C@@H](O)[C@@H](O)CC2 0.2965 0.9561 C8H13NO4 
29b' O=C1OC[C@]2(N1)C[C@H](O)[C@H](O)CC2 0.3059 0.9261 C8H13NO4 
35 Br[C@@H]1[C@@H](Br)CC[C@@]2(NC(=O)OC2)C1 0.3131 0.7957 C8H11NO2Br2 
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30b' Br[C@H]1[C@H](Br)CC[C@@]2(NC(=O)OC2)C1 0.3871 0.7196 C8H11NO2Br2 
27a O=C1OC[C@]2(N1)C[C@H]1O[C@H]1CC2 0.3455 0.9534 C8H11NO3 
32a' FC1(F)[C@H]2[C@@H]1CC[C@@]1(NC(=O)OC1)C2 0.3173 0.8961 C9H11NO2F2 
27b O=C1OC[C@]2(N1)C[C@@H]1O[C@@H]1CC2 0.4577 0.9443 C8H11NO3 
32b' FC1(F)[C@@H]2[C@H]1CC[C@@]1(NC(=O)OC1)C2 0.3725 0.9335 C9H11NO2F2 
31a' O=C1OC[C@]2(N1)C[C@H]1N[C@H]1CC2 0.2416 0.9675 C8H12N2O2 
31b' O=C1OC[C@]2(N1)C[C@@H]1N[C@@H]1CC2 0.4516 0.9439 C8H12N2O2 
 
   
   
   
Figure 6.1 Distribution of key physicochemical properties of the spirocyclic library. 
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6.1.2 Maybridge core fragment collection 
This library is based on the core 1000-member collection within the Maybridge Fragment library. 
Details of the library (including SMILES and SDF) are available from 
‘http://www.maybridge.com/’ under the ‘Ro3 Fragment library section. More details can be 
found at: 
‘http://www.maybridge.com/images/pdfs/MB_Ro3_fragment_flyer_2011_EUR_v7.pdf’ 
The best-matched fragments were chosen based on heavy atom and hetero atom counts 
compared to the spirocyclic library. For heteroatom counts of 2 and 3, only exact heavy atom 
matches (i.e. same number of N and O atoms) were used, whereas for heteroatom counts of 4 
and 5 no exact matches were found and therefore only the total heteroatom counts were used. 
Normalised PMI ratios and molecular formulae of the Maybridge best-matched fragments are 
summarised in Table 6.5. 
Table 6.5 Normalised PMI ratios and formulae of the Maybridge best-matched fragments. 
SMILES npr1 npr2 Formula 
OCCNCc1ccccc1 0.1566 0.9438 C9H13NO 
Oc1c2c(nccc2)ccc1 0.3618 0.6382 C9H7NO 
O=C(C)c1cc(C#N)ccc1 0.2475 0.7561 C9H7NO 
O=C1Nc2c(cccc2)CC1 0.2480 0.7704 C9H9NO 
OC[C@H](N)Cc1ccccc1 0.2401 0.9471 C9H13NO 
Oc1cc2ncccc2cc1 0.2253 0.7747 C9H7NO 
O(C)c1cc(CC#N)ccc1 0.2339 0.8611 C9H9NO 
O(C)c1cc2c([nH]cc2)cc1 0.2076 0.7963 C9H9NO 
NCc1cc2c(OCC2)cc1 0.2047 0.8484 C9H11NO 
N#Cc1cc2c(occ2)cc1 0.1741 0.8259 C9H5NO 
Oc1c(C)cc(C#N)cc1C 0.3298 0.6775 C9H9NO 
c1(-c2ccccc2)ocnc1 0.1600 0.8400 C9H7NO 
OCCc1ccc(C#N)cc1 0.1608 0.9466 C9H9NO 
O=C(N)c1c(C)c(C)ccc1 0.3472 0.7208 C9H11NO 
O=C(N)c1cc(C)c(C)cc1 0.2338 0.7872 C9H11NO 
OC[C@H]1[C@@H](NCc2ccccc2)CCCC1 0.1717 0.9024 C14H21NO 
O[C@@H]([C@@H](N)c1ccccc1)c1ccccc1 0.4721 0.7911 C14H15NO 
O(c1c(CNC)cccc1)c1ccccc1 0.3960 0.7590 C14H15NO 
O(c1ccc(CNC)cc1)c1ccccc1 0.1063 0.9808 C14H15NO 
O(Cc1cc(CN)ccc1)c1ccccc1 0.1368 0.9586 C14H15NO 
O=C1CC2N(Cc3ccccc3)C(C1)CC2 0.2342 0.9468 C14H17NO 
O=C(OCc1ccccc1)N 0.1520 0.9775 C8H9NO2 
O=C(N)c1ccc(OC)cc1 0.1434 0.8704 C8H9NO2 
O=C1NC(=O)[C@@H]2[C@H]1CC=CC2 0.3972 0.8514 C8H9NO2 
O=C(OCC)[C@H]1[C@@H](N)CCC1 0.2814 0.8759 C8H15NO2 
O=C(C)c1c(O)cc(N)cc1 0.2658 0.7756 C8H9NO2 
O=C1OCc2c1cc(N)cc2 0.2879 0.7163 C8H7NO2 
O=C(N(C)C)C1CCOCC1 0.3110 0.9079 C8H15NO2 
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O=C(N)Cc1ccc(O)cc1 0.1807 0.9326 C8H9NO2 
Nc1cc2c(OCOC2)cc1 0.2340 0.7841 C8H9NO2 
N#Cc1cc2OCOc2cc1 0.1844 0.8194 C8H5NO2 
O=C(OC)c1c(C)[nH]c(C)c1 0.2785 0.7317 C8H11NO2 
O=C(N)COc1ccccc1 0.1227 0.8802 C8H9NO2 
O=C(OC)c1cc(N)ccc1 0.2016 0.8018 C8H9NO2 
O=C(O)c1c(N)cc(C)cc1 0.2578 0.7459 C8H9NO2 
O(C)c1cc2nc[nH]c2cc1 0.2120 0.7920 C8H8N2O 
O=C1N(C)N=C(C(C)(C)C)C1 0.2896 0.8515 C8H14N2O 
Oc1nc(C(C)C)nc(C)c1 0.4024 0.7353 C8H12N2O 
OCC1=Cn2c(ncc2)C=C1 0.1881 0.8499 C8H8N2O 
OCc1cc2nc[nH]c2cc1 0.2025 0.8439 C8H8N2O 
O=C1NN=Cc2c1cccc2 0.3495 0.6505 C8H6N2O 
N#CCCNCC1OCCC1 0.0719 0.9648 C8H14N2O 
OC1(C#N)C2CCN(C1)CC2 0.5090 0.8849 C8H12N2O 
Oc1c(C#N)c(C)cc(C)n1 0.3510 0.6569 C8H8N2O 
OCc1nc(CCCC)[nH]c1 0.1723 0.8988 C8H14N2O 
O=C(CC#N)N1CCCCC1 0.1898 0.8750 C8H12N2O 
O=C(NCc1cnccc1)C 0.2305 0.9262 C8H10N2O 
O=C(O)c1cc2c([nH]cc2)cc1 0.1798 0.8202 C9H7NO2 
O=C(OCC)c1ccc(N)cc1 0.1503 0.8545 C9H11NO2 
O=C(Nc1ccc(OC)cc1)C 0.1073 0.8974 C9H11NO2 
O=C(OCC)[C@H]1[C@H](N)CC=CC1 0.3119 0.8862 C9H15NO2 
O=C(OCC)c1c(C)cc(C)[nH]1 0.2959 0.7147 C9H13NO2 
O(C(C)(C)C)C(=O)N1CC=CC1 0.2214 0.8897 C9H15NO2 
O=C(OCc1ccccc1)CN 0.1301 0.9955 C9H11NO2 
O=C(OC)c1cc(N)c(C)cc1 0.1827 0.8227 C9H11NO2 
O=C1C(CCC#N)C(=O)CCC1 0.3067 0.7990 C9H11NO2 
O=C(C)N1CCC(C(=O)C)CC1 0.2330 0.8951 C9H15NO2 
O=C(OC)c1cc(CN)ccc1 0.2111 0.8248 C9H11NO2 
O=C(OC)c1cc(C#N)ccc1 0.2563 0.7466 C9H7NO2 
O=C(OCC)c1c(C)[nH]c(C)c1 0.2602 0.7501 C9H13NO2 
O=C(OC)c1c(C#N)cccc1 0.3960 0.6518 C9H7NO2 
O=Nc1c(O)ccc2c1cccc2 0.3216 0.6978 C10H7NO2 
O=C(Oc1c2c([nH]c1)cccc2)C 0.2915 0.7757 C10H9NO2 
O=C1O[C@H]([C@@H](C)N1)c1ccccc1 0.2327 0.9131 C10H11NO2 
O=C(OC)c1cc2c([nH]cc2)cc1 0.1679 0.8345 C10H9NO2 
O=C1Oc2c(C(C)=C1)ccc(N)c2 0.2982 0.7046 C10H9NO2 
NCc1c2OCCCOc2ccc1 0.4024 0.6688 C10H13NO2 
NCc1cc2OCCCOc2cc1 0.2122 0.8505 C10H13NO2 
OCc1noc(-c2ccccc2)c1 0.1157 0.9080 C10H9NO2 
OCc1onc(-c2ccccc2)c1 0.1294 0.9000 C10H9NO2 
OCC1N(Cc2occc2)CCC1 0.2605 0.8751 C10H15NO2 
O=C1OC[C@H](Cc2ccccc2)N1 0.1333 0.9562 C10H11NO2 
OCCN(CCO)c1ccccc1 0.4901 0.7449 C10H15NO2 
O(C)c1c(OC)cc2c(c1)CNCC2 0.3130 0.7029 C11H15NO2 
O=C1OC(C)(C)[C@@H](c2ccccc2)N1 0.2965 0.8657 C11H13NO2 
O=C(NCC(=O)C)Cc1ccccc1 0.2460 0.8973 C11H13NO2 
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O=C(OC)c1ncc2c(c1)cccc2 0.1409 0.8612 C11H9NO2 
O=C(C)c1c(N)c(CCC)c(O)cc1 0.3040 0.7637 C11H15NO2 
O=C(O)CC1(CN(C)C)CCCCC1 0.4960 0.7257 C11H21NO2 
OCc1c(C)onc1-c1ccccc1 0.2664 0.7941 C11H11NO2 
O(CCN(C)C)c1c(CO)cccc1 0.1946 0.8300 C11H17NO2 
O(C(C)(C)C)C(=O)c1cc(N)ccc1 0.1824 0.8858 C11H15NO2 
O=C(Nc1ccc(OCC=C)cc1)C 0.0702 0.9422 C11H13NO2 
O=C(Nc1cc2c(C(=O)CC2)cc1)C 0.1551 0.8506 C11H11NO2 
O=C(N(C)C)c1c-2c(C(=O)c3c-2cccc3)ccc1 0.4483 0.6742 C16H13NO2 
O(C)c1ccc(CNCc2ccc(OC)cc2)cc1 0.1178 0.9595 C16H19NO2 
O=C(CC12CC3CC(C1)CC(C2)C3)N1CCOCC1 0.1592 0.9586 C16H25NO2 
FC(F)(F)c1ccc(CO)cc1 0.1638 0.9439 C8H7OF3 
Clc1cc(OCC(=O)O)ccc1 0.1310 0.8709 C8H7O3Cl 
Fc1cc2C(=O)C(=O)Nc2cc1 0.2277 0.7723 C8H4NO2F 
Fc1c(NC(=O)C)ccc(F)c1 0.2136 0.7891 C8H7NOF2 
Clc1c(NC(=O)C)c(F)ccc1 0.4058 0.6018 C8H7NOClF 
Fc1c(OC(=O)C)ccc(F)c1 0.2273 0.8861 C8H6O2F2 
S(CC)c1c(C(=O)O)cccn1 0.3754 0.6717 C8H9NO2S 
ClC1=NNC(=O)c2c1cccc2 0.4180 0.5820 C8H5N2OCl 
O=C(O)c1sc2ncccc2c1 0.1817 0.8183 C8H5NO2S 
NCc1nc(-c2sccc2)sc1 0.2239 0.7930 C8H8N2S2 
OCc1noc(-c2sccc2)c1 0.1229 0.9019 C8H7NO2S 
O=C(O)c1n(C)c2c(scc2)c1 0.2212 0.7815 C8H7NO2S 
OCc1n[nH]c(-c2sccc2)c1 0.1134 0.8956 C8H8N2OS 
N(Cc1scc2OCCOc12)C 0.3228 0.7224 C8H11NO2S 
S(=O)(=O)(C)c1ccc(C#N)cc1 0.1549 0.9370 C8H7NO2S 
S(C)c1sc2c(n1)ccc(N)c2 0.1548 0.8474 C8H8N2S2 
S=C1NCN(C2CCCC2)CN1 0.1229 0.9184 C8H15N3S 
Clc1nc(-c2occc2)ccn1 0.1873 0.8127 C8H5N2OCl 
Clc1sc(C2=NN(C)CC2)cc1 0.1058 0.9037 C8H9N2ClS 
Clc1c(Cl)ccc(NC(=O)C)c1 0.1982 0.8037 C8H7NOCl2 
Clc1ccc(SCC(=O)O)cc1 0.0971 0.9480 C8H7O2ClS 
Clc1c(C)c(C#N)c(O)nc1C 0.3474 0.6582 C8H7N2OCl 
Clc1cc(C(=O)OC)c(O)cc1 0.2323 0.7701 C8H7O3Cl 
Fc1ccc(CNC(=O)N)cc1 0.1160 0.9905 C8H9N2OF 
FC(F)(F)c1c(CO)cccc1 0.4573 0.6836 C8H7OF3 
Clc1c(CO)nc(CCCC)[nH]1 0.2479 0.8232 C8H13N2OCl 
S=C(NN)NC1C2C=CC(C1)C2 0.3102 0.8552 C8H13N3S 
Clc1cc(Cl)cc(OCC#N)c1 0.3151 0.6866 C8H5NOCl2 
S(CC#N)c1c(F)cc(F)cc1 0.1607 0.9087 C8H5NF2S 
S=C(Nc1c(OC)cccc1)N 0.2920 0.7332 C8H10N2OS 
Clc1c(C(=O)OC)ccc(F)c1 0.3007 0.7813 C8H6O2ClF 
O=C1NN=C(c2sccc2)CC1 0.1465 0.8724 C8H8N2OS 
FC(F)(F)c1cc(N)c(OC)cc1 0.2119 0.8552 C8H8NOF3 
Fc1cc(F)cc(C(O)C(=O)O)c1 0.3356 0.8586 C8H6O3F2 
FC(F)(F)c1nc(C)c(C#N)cc1 0.1955 0.8740 C8H5N2F3 
Clc1ccc(CNS(=O)(=O)C)cc1 0.0957 0.9716 C8H10NO2ClS 
O=C(O)c1nc(-c2sccc2)sc1 0.1809 0.8191 C8H5NO2S2 
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S(=O)(=O)(N)c1cc2c(cc1)COC2 0.1890 0.8939 C8H9NO3S 
Clc1sc(C(OC(C)(C)C)=O)cn1 0.1276 0.9275 C8H10NO2ClS 
ClC=1C(=O)C(Cl)=CN(CCC#N)C=1 0.3168 0.7079 C8H6N2OCl2 
Clc1cc(NC(=S)N)c(OC)cc1 0.3658 0.6540 C8H9N2OClS 
FC(F)(F)c1cnc(N(C)C)cc1 0.1554 0.9094 C8H9N2F3 
FC(F)(F)Oc1ccc(CO)cc1 0.1400 0.9484 C8H7O2F3 
FC(F)(F)Oc1ccc(CC#N)cc1 0.1403 0.9705 C9H6NOF3 
Fc1c(NC(=O)C)c(C#N)cc(F)c1 0.3497 0.6673 C9H6N2OF2 
Fc1c(F)ccc(-c2nc(N)sc2)c1 0.1461 0.8637 C9H6N2F2S 
O=C(O)c1sc(-c2nc(C)sc2)cc1 0.1087 0.8927 C9H7NO2S2 
Fc1c(N(C)C)c(F)cc(C(=O)N)c1 0.2561 0.7567 C9H10N2OF2 
Clc1c(F)ccc(NC(=O)CSC)c1 0.1720 0.8946 C9H9NOClFS 
O=S1(=O)CCN(Cc2sccc2)CC1 0.1538 0.9913 C9H13NO2S2 
S(C)c1c(C(=O)C)c(C)c(C(=O)O)s1 0.3663 0.7309 C9H10O3S2 
Clc1c(F)ccc(N2C(=O)C=CS2)c1 0.2071 0.7929 C9H5NOClFS 
Clc1c(F)c(N2C(=O)C=CS2)ccc1 0.2380 0.7645 C9H5NOClFS 
Clc1sc([SH0](=O)C)c2C(=O)CCCc12 0.4492 0.6241 C9H9O2ClS2 
Clc1c(Cl)cccc1NC(=O)N(C)C 0.2101 0.8023 C9H10N2OCl2 
Clc1ccc(CCNC(=S)NN)cc1 0.1770 0.9074 C9H12N3ClS 
Clc1cc2C(=O)CCS(=O)(=O)c2cc1 0.2936 0.7708 C9H7O3ClS 
Clc1ccc(S(=O)(=O)CCC#N)cc1 0.1325 0.9591 C9H8NO2ClS 
Fc1cc2C(=O)CCS(=O)(=O)c2cc1 0.3716 0.7099 C9H7O3FS 
FC(F)(F)c1cc(OCC#N)ccc1 0.1718 0.8767 C9H6NOF3 
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Identification code DS_B1_0022 CCDC 1912287 
Empirical formula C16H21NO4 Formula weight (Da) 291.34 
Temperature (K) 180(2) Wavelength (Å) 1.54178 
Crystal system Monoclinic Space group P 21/c 
Unit cell lengths (Å) a = 9.1715(2) 
b = 6.6200(2) 
c = 23.5770(6) 
Unit cell angles (°) α = 90 
β = 92.5461(12) 
γ = 90 
Volume (Å3) 1430.07 Z 4 
Density calculated (gcm-3) 1.353 Absorption coefficient (mm-1) 0.795 
F(000) 624 Crystal size (mm3) 0.220 × 0.100 × 0.040 
θ range for data coll. (°) 3.753 – 67.040 Completeness to θ = 67.040° 99.7% 
Reflections collected 15488 Independent reflections 2545 
Index ranges –10 ≤ h ≤ 10 
–7 ≤ k ≤ 7 
–28 ≤ l ≤ 28 
Refinement method Full-matrix least-
squares on F2 
Absorption correction Multi-scan Max/min. transmission 0.969/0.845 
Data/restraints/parameters 2545/2/204   
Goodness of fit F2 1.306 Largest diff. peak/hole (eÅ-3) 0.245/-0.286 
Final R indices [I > 2σ(I)] R1 = 0.0654 
wR2 = 0.1474 
R indices (all data) R1 = 0.0692 






Identification code DS_B1_0015 CCDC 1912286 
Empirical formula C22H21D6NO5 Formula weight (Da) 391.48 
Temperature (K) 180(2) Wavelength (Å) 1.54178 
Crystal system Triclinic Space group P 1" 
Unit cell lengths (Å) a = 6.2880(2) 
b = 7.9649(3) 
c = 20.1941(8) 
Unit cell angles (°) α = 82.118(3) 
β = 87.204(2) 
γ = 82.302(2) 
Volume (Å3) 992.33(6) Z 2 
Density calculated (gcm-3) 1.310 Absorption coefficient (mm-1) 0.743 
F(000) 412 Crystal size (mm3) 0.120 × 0.120 × 0.020 
θ range for data coll. (°) 2.210 – 66.855 Completeness to θ = 66.855° 99.5% 
Reflections collected 13031 Independent reflections 3530 
Index ranges –7 ≤ h ≤ 7 
–9 ≤ k ≤ 9 
–23 ≤ l ≤ 24 
Refinement method Full-matrix least-
squares on F2 
Absorption correction Multi-scan Max/min. transmission 0.985/0.916 
Data/restraints/parameters 3530/0/261   
Goodness of fit F2 1.037 Largest diff. peak/hole (eÅ-3) 0.234/-0.181 
Final R indices [I > 2σ(I)] R1 = 0.0434 
wR2 = 0.0890 
R indices (all data) R1 = 0.0681 







Identification code DS_B1_0018 CCDC 1912284 
Empirical formula C17H19F2NO3 Formula weight (Da) 323.33 
Temperature (K) 180(2) Wavelength (Å) 1.54178 
Crystal system Monoclinic Space group P 21/c 
Unit cell lengths (Å) a = 13.5002(5) 
b = 12.3831(5) 
c = 9.9272(4) 
Unit cell angles (°) α = 90 
β = 110.910(2) 
γ = 90 
Volume (Å3) 1550.28(11) Z 4 
Density calculated (gcm-3) 1.385 Absorption coefficient (mm-1) 0.934 
F(000) 680 Crystal size (mm3) 0.300 × 0.180 × 0.120 
θ range for data coll. (°) 3.505 – 66.845 Completeness to θ = 66.845° 99.6% 
Reflections collected 11811 Independent reflections 2739 
Index ranges –16 ≤ h ≤ 16 
–14 ≤ k ≤ 10 
–11 ≤ l ≤ 11 
Refinement method Full-matrix least-squares 
on F2 
Absorption correction Multi-scan Max/min. transmission 0.896/0.767 
Data/restraints/parameters 2739/0/228   
Goodness of fit F2 1.112 Largest diff. peak/hole (eÅ-3) 0.239/-0.193 
Final R indices [I > 2σ(I)] R1 = 0.0416 
wR2 = 0.0990 
R indices (all data) R1 = 0.0453 







Identification code DS_B1_0014 CCDC 1912283 
Empirical formula C23H26N2O5S Formula weight (Da) 442.52 
Temperature (K) 180(2) Wavelength (Å) 1.54178 
Crystal system Triclinic Space group P 1" 
Unit cell lengths (Å) a = 7.0012(2) 
b = 12.6065(4) 
c = 12.9625(4) 
Unit cell angles (°) α = 80.1740(10) 
β = 75.6130(10) 
γ = 76.4970(10) 
Volume (Å3) 1069.83(6) Z 2 
Density calculated (gcm-3) 1.374 Absorption coefficient (mm-1) 1.668 
F(000) 468 Crystal size (mm3) 0.250 × 0.200 × 0.150 
θ range for data coll. (°) 3.545 – 66.774 Completeness to θ = 66.774° 98.7% 
Reflections collected 8306 Independent reflections 3741 
Index ranges –7 ≤ h ≤ 8 
–15 ≤ k ≤ 13 
–14 ≤ l ≤ 15 
Refinement method Full-matrix least-
squares on F2 
Absorption correction Multi-scan Max/min. transmission 0.7886/0.681 
Data/restraints/parameters 3741/0/282   
Goodness of fit F2 1.038 Largest diff. peak/hole (eÅ-3) 0.308/-0.418 
Final R indices [I > 2σ(I)] R1 = 0.0353 
wR2 = 0.0894 
R indices (all data) R1 = 0.0403 






Identification code DS_B1_0021 CCDC 1912289 
Empirical formula C8H11NO3 Formula weight (Da) 169.18 
Temperature (K) 180(2) Wavelength (Å) 1.54178 
Crystal system Monoclinic Space group P 21/n 
Unit cell lengths (Å) a = 5.7530(2) 
b = 12.8809(4) 
c = 10.6497(3) 
Unit cell angles (°) α = 90 
β = 92.918(2) 
γ = 90 
Volume (Å3) 788.16(4) Z 4 
Density calculated (gcm-3) 1.426 Absorption coefficient (mm-1) 0.919 
F(000) 360 Crystal size (mm3) 0.250 × 0.080 × 0.070 
θ range for data coll. (°) 5.393 – 66.842 Completeness to θ = 66.842° 99.6% 
Reflections collected 5783 Independent reflections 1394 
Index ranges –7 ≤ h ≤ 8 
–15 ≤ k ≤ 13 
–14 ≤ l ≤ 15 
Refinement method Full-matrix least-
squares on F2 
Absorption correction Multi-scan Max/min. transmission 0.7886/0.681 
Data/restraints/parameters 1394/18/132   
Goodness of fit F2 1.137 Largest diff. peak/hole (eÅ-3) 0.187/-0.199 
Final R indices [I > 2σ(I)] R1 = 0.0415 
wR2 = 0.1001 
R indices (all data) R1 = 0.0477 






Identification code DS_B1_0019 CCDC 1912285 
Empirical formula C16H19Br2NO3 Formula weight (Da) 433.14 
Temperature (K) 180(2) Wavelength (Å) 1.54178 
Crystal system Monoclinic Space group P 21/n 
Unit cell lengths (Å) a = 6.4606(2) 
b = 12.5480(3) 
c = 20.3610(6) 
Unit cell angles (°) α = 90 
β = 98.4700(10) 
γ = 90 
Volume (Å3) 1632.61(8) Z 4 
Density calculated (gcm-3) 1.762 Absorption coefficient (mm-1) 6.403 
F(000) 864 Crystal size (mm3) 0.140 × 0.140 × 0.140 
θ range for data coll. (°) 4.151 – 66.735 Completeness to θ = 66.735° 99.5% 
Reflections collected 17954 Independent reflections 2886 
Index ranges –7 ≤ h ≤ 6 
–14 ≤ k ≤ 13 
–21 ≤ l ≤ 24 
Refinement method Full-matrix least-
squares on F2 
Absorption correction Multi-scan Max/min. transmission 0.468/0.468 
Data/restraints/parameters 2886/0/201   
Goodness of fit F2 1.092 Largest diff. peak/hole (eÅ-3) 0.546/-0.461 
Final R indices [I > 2σ(I)] R1 = 0.0243 
wR2 = 0.0573 
R indices (all data) R1 = 0.0264 






Identification code DS_B1_0026 CCDC 1912288 
Empirical formula C8H11Br2NO2 Formula weight (Da) 313.00 
Temperature (K) 180(2) Wavelength (Å) 1.54178 
Crystal system Monoclinic Space group P 21/c 
Unit cell lengths (Å) a = 13.0067(12) 
b = 6.2766(6) 
c = 12.8006(10) 
Unit cell angles (°) α = 90 
β = 103.002(6) 
γ = 90 
Volume (Å3) 1018.22(16) Z 4 
Density calculated (gcm-3) 2.042 Absorption coefficient (mm-1) 9.863 
F(000) 608 Crystal size (mm3) 0.300 × 0.040 × 
0.010 
θ range for data coll. (°) 3.486 – 66.672 Completeness to θ = 66.672° 99.7% 
Reflections collected 13072 Independent reflections 1806 
Index ranges –15 ≤ h ≤ 15 
–7 ≤ k ≤ 6 
–14 ≤ l ≤ 15 
Refinement method Full-matrix least-
squares on F2 
Absorption correction Multi-scan Max/min. transmission 0.908/0.156 
Data/restraints/parameters 1806/0/118   
Goodness of fit F2 1.046 Largest diff. peak/hole (eÅ-3) 0.945/-0.788 
Final R indices [I > 2σ(I)] R1 = 0.0528 
wR2 = 0.1174 
R indices (all data) R1 = 0.0884 
wR2 = 0.1336 
 
158  
6.3 NMR Spectra 
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